



NPR

Clerodane Diterpenes: Sources, Structures, and Biological Activities

Journal:	<i>Natural Product Reports</i>
Manuscript ID	NP-REV-11-2015-000137.R2
Article Type:	Review Article
Date Submitted by the Author:	25-May-2016
Complete List of Authors:	Li, Rongtao; Kunming University of Science and Technology, Faculty of Life Science and Technology Morris-Natschke, Susan L ; University of North Carolina, UNC Eshelman School of Pharmacy Lee, Kuo-Hsiung; University of North Carolina at Chapel Hill,

SCHOLARONE™
Manuscripts

Clerodane Diterpenes: Sources, Structures, and Biological Activities

Rongtao Li^{a,b}, Susan L. Morris-Natschke^b, and Kuo-Hsiung Lee^{b,c*}*

^a *Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, Yunnan, People's Republic of China*

^b *Natural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina 27599-7568, US*

^c *Chinese Medicine Research and Development Center, China Medical University and Hospital, Taichung, Taiwan*

* To whom correspondence should be addressed. K. H. Lee Tel: (919) 962-0066. Fax: (919) 966-3893. E-mail: khlee@unc.edu; R. T. Li Tel: (86) 871-65920569. Fax: (86) 871-65920570. E-mail: lrt512@163.com

1. Background and Introduction

- 1.1. The sources of clerodane diterpenes
- 1.2. The basic structures of clerodane diterpenes
- 1.3. The biological activities of clerodane diterpenes

2. Structure Classifications and Sources of Clerodane Diterpenes

- 2.1. Type I with an acyclic side chain at C-9
- 2.2. Type II with a 2-ethylfuran-based side chain at C-9
- 2.3. Type III with a 3-ethyl-2-butenolide-based side chain at C-9
- 2.4. Type IV with a 5-(3-furyl)- δ -valerolactone-based side chain at C-9
- 2.5. Type V with an α -spiro-attached 4-(3-furyl)- γ -butyrolactone-based side chain at C-9
- 2.6. Type VI with a furofuran-based side chain at C-9
- 2.7. Type VII with a 13-spiro-15,16- γ -lactone moiety
- 2.8. Clerodane-type diterpene glycosides
- 2.9. Clerodane derivatives
- 2.10. NMR Features of Clerodane Diterpenes
- 2.11. Abbreviation of functional groups

3. Biological Activities

- 3.1. Insect antifeedant activities
- 3.2. Opioid receptor agonists
- 3.3. NGF-potentiating activities
- 3.4. Anti-ulcer activities
- 3.5. Cytotoxic activities
- 3.6. Anti-inflammatory activities
- 3.7. Antiparasitic/Antiprotozoal activities
- 3.8. Antifungal and antibacterial activities
- 3.9. Other bioactivities
- 3.10. Toxicity

4. Conclusion

5. Acknowledgements

6. Supplementary Material Listing

7. References

Abstract

The clerodane diterpenoids are a widespread class of secondary metabolites and have been found in several hundreds of plant species from various families and in organisms from other taxonomic groups. These substances have attracted interest in recent years due to their notable biological activities, particularly insect antifeedant properties. In addition, the major active clerodanes of *Salvia divinorum* can be used as novel opioid receptor probes, allowing greater insight into opioid receptor-mediated phenomena, as well as opening additional areas for chemical investigation.

This article provides extensive coverage of naturally occurring clerodane diterpenes discovered from 1990 until 2015, and follows up on the 1992 review by Merritt and Ley in this same journal. The distribution, chemotaxonomic significance, chemical structures, and biological activities of clerodane diterpenes are summarized. In the cases where sufficient information is available, structure activity relationship (SAR) correlations and mode of action of active clerodanes have been presented.

1. Background and Introduction

1.1. The Sources of Clerodane Diterpenes

Clerodane diterpenes are a large group of naturally occurring secondary metabolites found in several hundreds of plant species from various families and in organisms from other taxonomic groups, such as fungi, bacteria, and marine sponges. **Table 1** illustrates the occurrence of clerodane diterpenes in the plant kingdom and marine animals.

Table 1. The occurrence of clerodane diterpenes in the plant kingdom and marine animals

Division	Class	Family	Genus	Number of Species
Magnoliophyta (flowering plants)	Dicotyledon	Lamiaceae	<i>Ajuga, Ballota, Elsholtzia, Glossocarya, Gomphostemma, Kinostemon, Nepeta, Otostegia, Plectranthus, Salvia, Scutellaria, Teucrium,</i>	81


		Verbanaceae→ Lamiaceae	<i>Callicarpa, Clerodendrum, Cornutia, Premna, Vitex</i>	7
		Euphorbiaceae	<i>Aparisthium, Cleidion, Croton, Macaranga</i>	27
		Compositae or Asteraceae	<i>Aster, Baccharis, Conyza, Haplopappus, Microglossa, Nannoglottis, Pulicaria</i>	18
		Flacourtiaceae→ Salicaceae	<i>Casearia, Laetia, Zuelania</i>	16
		Menispermaceae	<i>Burasaia, Fibraurea, Tinospora</i>	10
		Annonaceae	<i>Polyalthia</i>	7
		Portulacaceae	<i>Portulaca</i>	3
		Caesalpiniaceae	<i>Detarium, Hymenaea</i>	2
		Meliaceae	<i>Amoora</i>	2
		Araliaceae	<i>Cussonia</i>	1
		Chrysobalanaceae	<i>Licania</i>	1
		Combretaceae	<i>Bucida</i>	1
		Loganiaceae→ Stilbaceae	<i>Nuxia</i>	1
		Mimosaceae	<i>Entada</i>	1
		Rutaceae	<i>Clausena</i>	1
	Monocotyledon	Dioscoreaceae	<i>Dioscorea</i>	2
		Alismataceae	<i>Echinodorus</i>	1
		Hydrocharitaceae	<i>Halophila</i>	1
	Pteridophyta (ferns)	Gleicheniaceae	<i>Dicranopteris</i>	5
	Marchantiophyta (liverworts)	Geocalycaceae	<i>Heteroscyphus</i>	2
		Jungermanniaceae	<i>Jamesoniella</i>	2
		Scapaniaceae	<i>Scapania</i>	2
		Adelanthaceae	<i>Adelanthus</i>	1
		Lejeuneaceae	<i>Thysananthus</i>	1
	Marine animals	Marine Sponge	<i>Agelas</i>	3
		Marine Mollusk	<i>Syphonota</i>	1

Clerodane diterpenes have attracted interest in recent years as a result of their noteworthy biological activities, particularly as agents modifying the feeding behavior of many economically important insect phytophagous pests. Various genera from the plant family Lamiaceae have been identified as rich sources of antifeedant clerodanes, with species of the genus *Scutellaria* producing some of the most potent clerodane antifeedants known so far. In addition, the major active clerodanes of *Salvia divinorum* can serve as opioid receptor probes, enabling better understanding of opioid

receptor-mediated phenomena, as well as providing additional areas for chemical investigation.

1.2. The Basic Structures of Clerodane Diterpenes

Clerodane diterpenes are bicyclic diterpenoids. The basic skeleton is divided into two fragments: a fused ring decalin moiety (C-1–C-10) and a six-carbon side chain at C-9 (C-11–C-16, with C-16 attached at C-13, i.e., 3-methylpentyl). The remaining four carbons (C-17–C-20) are attached at C-8, C-4, C-5, and C-9, respectively, on the decalin system as illustrated below.



Approximately 25% of clerodanes have a 5:10 *cis* ring fusion as represented by columbin (1). This diterpenoid furanolactone has been isolated from several plants, including *Sphenocentrum jollyanum* Pierre (Menispermaceae) and *Jateorhiza columba* Miers (Menispermaceae). It is sold in a crude drug preparation called *Calumbae Radix* or *Tinosporae Radix*. Columbin exhibited dose dependent anti-inflammatory activity as well as chemopreventative activity against colorectal cancer.¹⁻³ The remaining 75% of clerodanes have a 5:10 *trans* ring fusion as exemplified by clerodin (2). This compound was originally isolated from *Clerodendrum infortunatum* L. (Lamiaceae) and has potential as a natural pesticide due to its insect antifeedant activity.⁴ Clerodanes with a 5:10 *trans* ring junction are characteristic of the Lamiaceae family and to a lesser extent the Compositae (Asteraceae) family, while clerodanes with a 5:10 *cis* ring junction are more commonly found in the Euphorbiaceae, Flacourtiaceae (Saliaceae), and Memispermaceae families.

In addition to the relative configuration of the *trans* or *cis* junction of the fused rings, clerodanes are further classified by their relative configurations at C-8 and C-9. Consequently, as shown in **Figure 1**, four types of clerodane skeletons are defined with respect to the configuration at the ring fusion and of the substituents at C-8 and C-9: *trans-cis* (TC), *trans-trans* (TT), *cis-cis* (CC), and *cis-trans* (CT).⁵ In the majority of clerodanes, the C-17 and C-20 substituents on C-8 and C-9 are *cis*.⁵







Figure 1 Stereochemical variety in clerodane diterpenoids

In their 1992 review, Merritt and Ley noted that confusion exists in the literature over the absolute stereochemistry of the clerodanes.⁶ The absolute stereochemistry of clerodin (**2**), the first member of the clerodane series, was revised leading to the following terminology. *neo*-Clerodanes (formerly *ent*-clerodanes) have the same absolute stereochemistry as clerodin, while *ent-neo*-clerodanes are enantiomeric to clerodin.^{6,7} The former compounds predominate in number over the latter compounds.⁵ We have used *neo*-clerodane in this paper, except for compound names already given with the *ent*-clerodane terminology.



Biosynthetically, the clerodanes likely arise from geranylgeranylpyrophosphate (**3**) as shown in **Scheme 1**. However, this overall biogenetic route is simplified as many parallel pathways are needed to yield the multiplicity of clerodane natural products.⁸ Initially, plant cyclases catalyze a proton-initiated cationic cycloisomerization of **3** to

generate a labdane-type precursor skeleton, such as **4** [one of four possible structures ('normal', 'ent', 'syn-normal', 'syn-ent'), depending on the conformation of **3**].^{8b} Subsequently, this intermediate can undergo either a concerted or stepwise migration process of methyl and hydride shifts. A concerted process, with a C-4 α to C-5 α methyl group migration⁹ gives clerodane-type intermediate **5** and results in only *trans* clerodanes. A stepwise process 'pauses' at a halimane-type intermediate (**6**) that retains both *gem*-dimethyl groups on C-4. Intermediate **6** can then progress to either *cis* or *trans* clerodanes. The general scheme without specific stereochemistry is also shown. Examples to support this proposed biosynthetic pathway include the isolation of the partially rearranged labdane compounds chettaphanin (**7**) from *Adenochlaena siamensis* (Compositae)¹⁰ and salmantic acid (**8**) from *Cistus laurifolius* (Cistaceae).¹¹



1.3. The Biological Activities of Clerodane Diterpenes

The most important biological activities of clerodanes are insect antifeedant effects¹² and action as novel opioid receptor probes.¹³


1.3.1. Insect Antifeedant Activity

Clerodane diterpenes are best-known and most extensively studied for their insect antifeeding and related insecticidal properties, with an emphasis placed on the safety aspects of such natural insect antifeedants in relation to mammalian and piscial life. To date, over 400 natural and semi-synthetic clerodanes have been examined in laboratory assays, yielding several compounds with potent antifeedant activity against various insect species.¹²

1.3.2. Probes in Opioid Pharmacology

In 2002, opioid receptors were implicated in the actions of the psychoactive mint *Salvia divinorum*.¹³ The main active constituent isolated from the leaves of *S. divinorum* is the neoclerodane diterpene salvinorin A (**9**). This molecule is interesting to pharmacologists, because it is a non-serotonergic hallucinogen that lacks a basic nitrogen and is a potent and selective agonist for κ opioid receptors. Synthetic organic chemists also find it an attractive target because of its unique structure containing seven chiral centers and a diterpene scaffold.

Opioid agonists based on **9** have the potential to treat pain, cough, diarrhea, stimulant dependence, and mood disorders. Antagonists derived from **9** have potential use in treating several medical conditions, including drug dependence, depression, opioid-induced constipation, and obesity. Thus, analogues of **9** may prove to be excellent research tools and provide greater insight into opioid receptor-mediated phenomena.



salvinorin A (9)

1.3.3. Other Bioactivities

Besides insect antifeedant activity and opioid receptor agonist effects, clerodane diterpenes can exhibit other pharmacological activities, including antitumor,¹⁴ antifungal, NGF-potentiating, antibiotic, anti-peptic ulcer, antiplasmodial, as well as hypoglycemic, hypolipidemic, and anti-thrombin inhibitory activity.

This review provides extensive coverage of naturally occurring clerodane diterpenes discovered in the last 25 years (1990–2015) along with their various bioactivities. The distribution, chemotaxonomic significance, chemical structures, and biological activities of clerodane diterpenes are summarized. In the cases where sufficient information is available, the structure activity relationship (SAR) correlations and mode of action of active clerodanes have been presented.

2. Structure Classifications and Sources of Clerodane Diterpenes

During the last 25 years, over 1,300 diterpenoids and *nor*-diterpenoids with the clerodane carbon skeleton have been isolated. For clarity and the purposes of this review, they have been grouped together by particular structural features as described below.

Firstly, the C-11–C-16 fragment can be acyclic or occur as several different bi- and mono-cyclic substructures (**Figure 2**). Substructures **a–c** contain a bicyclic furofuran system, either tetrahydro (**a**) or hexahydro (**b** and **c**). Moreover, the two latter systems can have oxygen moieties present on C-13 and C-14 (**b**) or C-15 (**c**), forming a hemiacetal or acetal. Furthermore, when OR is methoxy or ethoxy in substructure **c**, the compound could be an artifact resulting from the use of methanol or ethanol using the

isolation procedure. Substructure **d** possesses one furan ring (C-11–C-13, C-16) and a two-carbon open chain system (C-14–C-15), formally arising from the opening of the acetal moiety and subsequent reduction of the C-15 aldehyde to a primary alcohol. Alternatively, carbons C-11 and C-12 are present as a two-carbon ethyl chain, while carbons C-13–C-16 form an attached single ring, either an α,β -unsaturated- γ -lactone (**e**) or lactol (**f**). Sometimes, $\Delta^{11,12}$ unsaturation is present or carbons C-11 and C-12 can bear oxygenated groups. Finally, bicyclic spiro substructures can be found. The tetrahydropyran incorporates C-8 and C-9, as well as C-11–C-13, and the γ -lactone (C-13–C-16) can assume both possible configurations (**g**, **h**) at C-13.


C₁₁-C₁₆ moiety

Figure 2 C₁₁-C₁₆ moiety of clerodane diterpenoids

Secondly, the decalin moiety contains some consistent functional features. The decalin junction is mostly *trans*, and the two groups (C-17 and C-20) on positions C-8 and C-9, respectively, are primarily *cis*, as well as α -oriented (Type TC *neo*-clerodanes in **Section 1.2**). Six classifications (**A–F**) have been made based on the formal oxidation number of carbon C-18 in the decalin moiety (**Figure 3**). Groups **A** and **B** contain a C-4 α /C-18 epoxide, while C-18 is present as a hydroxymethyl in group **C**. Furthermore, in Groups **A** and **B**, carbon C-19 is often hydroxylated, either esterified (**A**) or forming a hemiacetal or acetal bridge with the α -hydroxy group on carbon C-2 (**B**). In a few cases, carbon C-19 is a methyl or a carboxylic group. In substructure **D**, C-4 and C-18 form an exocyclic

double bond. In this case, carbon C-19 is always a methyl. When C-18 is a methyl, C-19 is also always a methyl. Finally, carbon C-18 can have a higher oxidation number as in an aldehyde (**E**) or acetal (**F**). Again, in this case, carbon C-19 is always a methyl.




Figure 3 The decalin moiety of clerodane diterpenoids

Finally, all of the natural *neo*-clerodanes have been classified into seven different groups on the basis of their two fragments, the C-11–C-16 moiety (**a-h**) and the decalin moiety (**A-F**). Unless otherwise indicated, the diterpenes possess the *neo*-clerodane absolute stereochemistry (**I-VII**, **Figure 4**).




Figure 4 Basic skeletal classifications of clerodane diterpene

2.1. Type I with an Acyclic Side Chain at C-9

Type I clerodane diterpenoids are characterized firstly by having an acyclic side chain at C-9, and then are further divided into three subtypes related to the decalin system. The first subtype has an *O*-containing five-membered cyclic ring attached to the decalin ring A (18,19-oxide), the second subtype has a double bond between C-3 and C-4 or at another (or no) position of either decalin ring (without an 18,19-oxide), and the third subtype has an epoxy ring in the decalin system.

2.1.1. Type I Subtype I with an *O*-Containing Five-membered Ring at C-18 and C-19

In this subtype, most of the representative compounds are based on two derivations of the 18,19-oxide clerodane nucleus – zuelanin (double bonds at C-12/C-13 and C-14/C-15) and isozuelanin (double bonds at C-13/C-16 and C-14/C-15) (**Figure 5**). Various substituents are found at C-2, C-6, C-7, C-18 and C-19, as well as sometimes at C-12, in the isozuelanin subtype, and the decalin system can be saturated. Compounds with other skeletons also exist.





Figure 5 Zuelanin and isozuelanin skeletons


2.1.1.1. Type I Subtype Ia with the Isozuelanin Skeleton¹⁵⁻³³ (Table 2 – compounds 10–86 found in Supplementary Material)

The new clerodanes from Type I Subtype Ia are all 5:10 *cis* and 17:20 *trans*, mostly isolated from genera *Casearia* and *Zuelania* in the family Salicaceae. The structures of zuelaguidins A–D (**17–20**) from *Z. guidonia* are typical of this subtype.¹⁶ Corymbulosins A–C (**25–27**) from *Laetia corymbulosa* were elucidated as clerodane diterpenes unsaturated at C-3, C-13(16), and C-14.¹⁸ Corymbulosin A (**25**) has a decadienoate ester

at C-2, while corymbulosins B and C (**26–27**) have a saturated decanoate ester at C-6. The latter two compounds are identical except for the configuration at C-2. As based on coupling constant and NOE data, H-2 is equatorial in the former and axial in the latter. However, the study was unable to assign the absolute or relative stereochemistry of the three compounds. Corymbulosin A was the most cytotoxic with IC₅₀ values of 0.6 μM against SF539 human CNS tumor cells and 8 μM against the LOX melanoma cell line in two-day cytotoxicity tests.¹⁸




- 17** R₁ = α-OH, R₂ = OCin, R₃ = H
18 R₁ = β-OCin, R₂ = OH, R₃ = H
19 R₁ = α-OH, R₂ = X₁₃, R₃ = H
20 R₁ = α-OH, R₂ = X₁₃, R₃ = α-OH




- 25** R₁ = X₁, R₂ = OH
26 R₁ = OH, R₂ = ODC
27 R₁ = OH, R₂ = ODC


Two other compounds in this structural subtype, intrapetacins A (**35**) and B (**36**) from *Licania intrapetiolaris*, with a *p*-hydroxybenzoate group at C-2, displayed moderate cytotoxicity against KB cells, with IC₅₀ values of 2.0 and 0.8 μg/mL.²⁰ Caseanigrescens A–D (**37–40**) from *C. nigrescens* showed moderate cytotoxicity against the A2780 human ovarian cancer cell line, with an IC₅₀ range of 0.83–1.4 μM.²¹ Unlike most compounds in this subtype, compounds **37–39** are substituted at C-12 (**37**, acetoxy; **38–39**, hydroxy). When **37–40** were stored in CDCl₃ for varying times during NMR analysis, their hemiacetal resonances disappeared and aldehyde resonances appeared. This result indicated that all four compounds slowly hydrolyzed to corresponding unstable dialdehydes. The hydrolysis was likely caused by traces of acid in the specific CDCl₃ used, and did not occur when the compounds were allowed to stand in a fresh sample of CDCl₃.²¹ Argutins F–H (**41–43**) with a unique hydroperoxide moiety at C-12 were isolated from *C. arguta*.²²



It should be noted that the clerodane absolute stereochemistry was not determined in every structural characterization study. For example, esculentin A (**76**) has been reported in both *ent-neo*¹⁶ and *neo*³² configurations. In addition, while caseargrewiin A (**74**) was shown as a *neo*-clerodane, caseargrewiins B–D (**1256–1258**, structures in Section 3.5) co-isolated from *C. grewiifolia* were shown as *ent-neo*-clerodanes. The absolute configuration of C-2 in **1258** established as *R* by a modified Mosher's method, and the absolute stereochemistry in the rest of the molecule based on NMR coupling constants and NOESY correlations.³¹ Generally, this review has focused on relative configurations only.




Caseabalansin A and 18-epicaseabalansin A (**85–86**) are the first examples of clerodane diterpenoids with an oxygen bridge between C-2 and C-19.³³ They were initially isolated as an inseparable 1.3:1 isomeric mixture from *C. balansae* and identified based on NMR spectroscopy. Conversion to the 18-acetates allowed separation of the two compounds by HPLC.




2.1.1.2. Type I Subtype Ib with the Zuelanin Skeleton ^{14,22,23,25,28,34-40} (Table 3 – compounds 87–135 found in Supplementary Material)

The newly reported Type I Subtype Ib compounds are also 5:10 *cis* and 17:20 *trans*, mostly isolated from the family Salicaceae. They are structurally similar to Type I Subtype Ia compounds, but with a different double bond pattern in the C-11–C-16 acyclic side chain. Casearvestrins A–C (**87–89**) from *Casearia sylvestris* show the typical zuelanin skeleton, with acetoxy groups at both C-18 and C-19, in addition to a 18,19-oxide. In these three compounds, C-2 and C-6 are also substituted with various four to six carbon esters and a hydroxy group, respectively. Compounds **87–89** displayed promising bioactivity in cytotoxicity assays against a panel of tumor cell lines and antifungal assays against *Aspergillus niger* in a disk diffusion assay.³⁴ Argutins A–E (**90–94**) from *C. arguta* contain the same cyclic ether with varying combinations of decadienoyloxy, hydroxy, and hydrogen at C-2, C-6, and C-7. Among them, argutin B (**91**) showed the highest degree of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitization. Furthermore, the synergistic effect of **91** and TRAIL together was three-fold greater than that of **91** alone.²² Like the Type I Subtype Ia compounds **35–36** mentioned above, Type I Subtype Ib casearborins A–E (**96–100**) from *C. arborea* contain structurally novel aromatic esters, either at C-2 or C-6. When evaluated against LOX and SF539 cell lines using a two-day cytotoxicity assay, compounds **96–100**

exhibited IC₅₀ values ranging from 0.29 to 9.7 μM.³⁵



Caseobliquins A (**127**) and B (**128**) from *C. obliqua* have different substituents at C-6, a *p*-hydroxybenzoate moiety in **127** and a cinnamoate moiety in **128**.³⁹ Meanwhile, the acetoxy groups on C-18 and C-19 are *trans*, rather than *cis* as in the above-mentioned compounds.




127 R₁ = α-OAc, R₂ = Z₁
128 R₁ = β-OAc, R₂ = OCin


2.1.1.3. Type I Subtype Ic with Other Skeletons^{16,41,42} (Table 4 – compounds 136–155 found in Supplementary Material)

Type I Subtype Ic includes compounds with acyclic side chains different from 3-methylenepent-4-ene or (*E*)-3-methylpenta-2,4-diene, which are found in Subtypes Ia and Ib, respectively. Most of the Type I Subtype Ic compounds contain a 18,19-lactone ring. Compounds **136–138** from the aerial parts of *Olearia teretijdia* contain a Δ^{13E} double bond, while this position is saturated in **139–149**. The terminal carbon in the side

chain is generally hydroxymethyl, malonyloxymethyl, or carboxy rather than methyl. Compound **149** also has a Δ^2 rather than Δ^3 double bond.⁴¹



Baccharis linearis was the source of three new clerodanes: baclinal (**150**) with a 3-formyl-3E-pentenyl side chain and epimeric baclinepoxides (**151–152**) with an interesting 13,16 spiro-oxirane in the C-9 side chain.⁴² Zuelaguidins E, G, and H (**153–155**), isolated from *Zuelania guidonia* (family Salicaceae), were the first reported diterpenoids containing a 3,6-dihydro-1,2-dioxin moiety. This endoperoxide may result from a Diels-Alder reaction between zuelaguidin A (**17**, see Section 2.1.1.1), also found in *Z. guidonia*, and molecular oxygen.¹⁶ Compounds **153–155** are 5:10 *cis* and 17:20 *trans*. The remaining compounds in Type I Subtype Ic are 5:10 *trans* and 17:20 *cis*, as typical of clerodanes isolated from the family Asteraceae.




2.1.2. Type I Subtype II with a Double Bond between C-3 and C-4 or another Position


2.1.2.1. Type I Subtype IIa with a Double Bond between C-3 and C-4^{14,15,18,26,41,43-88}

(Table 5 – compounds **156–253** found in Supplementary Material)

Type I Subtype IIa compounds contain many of the same acyclic side chains as Type I Subtype Ia–Ic compounds. For instance, both 3-methylenepent-4-ene (**156–158**) and 3-methylpenta-2,4-diene (**164–167**) side chains are found in Type I Subtype IIa. Interestingly, compounds **164–166** with a Δ^{12Z} double bond were isolated from both *Schistochila acuminata* and *Heteroscyphus planus*,⁴⁵⁻⁴⁷ while heteroscyphol (**167**) with an assigned Δ^{12E} double bond was found only in *Heteroscyphus planus*.⁴⁷




Terpenetetraene (**159**) was produced from a transformant of *Streptomyces lividans* and postulated to be a probable biosynthetic intermediate of terpentecin (**160**), a diterpenoid antibiotic previously isolated from the bacterium *Streptomyces griseosporus*.⁴³ This study was the first to report a bacterial diterpene cyclase. Compound **159** was also isolated together with **161** from *Jungermannia infusca*. These two compounds have the same planar structure but different stereochemical structures. Both are 5:10 *trans*, but the former compound is 17:20 *trans*,⁴³ while the latter is 17:20 *cis*.⁴⁴




Compounds **193** and **194** have a *neo*-clerodane skeleton with a $\Delta^{3,4}$ C=C bond and a C=O group at C-2.⁶³ Compounds **197** (2-oxokolavenic acid) and **198**, isolated from different plant species, are identical, except for the orientation of the C-20 methyl group, β in the former compound and α in the latter compound.^{65,66} The *cis*-decalin (5α Me, 10α H) and

trans orientation of C-8 and C-9 (17 α Me, 20 β Me) in **197** were confirmed by X-ray crystallographic analysis. Furthermore, 2-oxokolavenic acid with a *trans*-decalin (5 β Me, 10 α H) and *cis* orientation of C-8 and C-9 (17 β Me, 20 β Me) was co-isolated at the same time from the fruits of *Detarium microcarpum*, as well as previously from the bark and leaves of the same plant.⁶⁵




Portulene acetal (**199**) with a caged hemiacetal [6.6]-ring was isolated as a minor constituent from *Portulaca grandiflora*.⁶⁷ The structures of **200** and **201** were quite similar, except for a tigloyl group in **200** and an angeloyl group in **201**.⁶⁸ Seven new clerodanes, exemplified by **207**, were obtained from *Baccharis trinervis*.⁷² Although no double bond is present between C-13/C-14, the stereochemistry of C-13 in these compounds and their analogue **214** from *B. gaudichaudiana*⁷³ could not be deduced spectroscopically.




The four new clerodanes (**227–230**) isolated from *Nuxia sphaerocephala* were assigned to the *ent*-series (now *neo*-series) based on optical rotation values, plus the absolute configuration of C-13 in **227** was established as *S* based on its phenylglycine methyl ester (PGME) amide derivatives.⁷⁸ In addition to having a free carboxylic acid rather than ethyl

ester at the side chain terminus, compounds **231** and **232** have a formyloxy group and an acetyloxy group, respectively, on C-2 compared with the hydrogen in **233**.⁷⁹ All three compounds were isolated from *Clausena dunniana*.



Compounds **240–242** were established as hydroxy and peroxy derivatives of the 2-oxo group **239**, based on X-ray and CD analysis.⁸¹ Compounds **249–252**, isolated as 3:1 or 4:1 mixtures from *Linaria saxatilis*, are the (12*E*)- and (12*Z*)-stereoisomers of the Δ^3 -endocyclic analogues.⁸⁷




2.1.2.2. Type I Subtype IIb with a Double Bond at Another (or No) Position

36,55,63,65,74,75,79,82,83,88-102 (Table 6 – compounds **254–289** found in

Supplementary Material)

The decalin double bonds in Type I Subtype IIb compounds can be either endocyclic at C-1/C-2 (e.g., **277**), C-2/C-3 (**276**), or C-7/C-8 (**272**) or exocyclic at C-4/C-18 (**281**) or C-8/C-17 (**258**). Alternatively, some compounds in this subtype do not have a decalin double bond, but instead often have dihydroxy substitution (e.g., **266–267**). Like in Type I Subtype IIa, various acyclic side chains are present.




Leojaponin A (**276**), characterized by a C4-C7 oxa-bridge and a double bond between C-2 and C-3, is the first clerodane diterpenoid obtained from *Leonurus japonicus*.⁹⁶ Palmadorins A and B (**288–289**), from the Antarctic nudibranch *Austrodoris kerguelensis*, were the first two of a new series of clerodane diterpene glycerides.⁸⁸

2.1.3. Type I Subtype III with an Epoxy Ring^{46,65,90,99,103-105} (Table 7 – compounds 290–296 found in Supplementary Material)


Among all compounds with an acyclic side chain, seven compounds are classified as Type I Subtype III with an epoxy ring either at C-3/C-4 (**290–294**)^{90,65,46,103,104} or C-4/C-18 (**295–296**).^{99,105} The β -orientations of the four methyl groups (C17–C20), as well as H-10, in **291** from *Detarium microcarpum* are shown as reported.⁶⁵ The assignments were based on NOE correlations, but seem uncommon from a biogenetic viewpoint. Compound **292** from *Heteroscyphus planus* is a possible intermediate in the biosynthesis of diterpenes that have a spiro- γ -lactone group at the C-9 position.⁴⁶ Compounds **293** from *Jungermannia paroica* and **294** from *Stachys glutinosa* have almost identical structures with a hydroxy group at C-13, but a hydrogen and α -hydroxy group, respectively, at C-2.^{103,104} The orientation of the epoxy methylene H₂-18 in **295** from *Polyalthia*

longifolia was deduced to be β , based on comparison of the chemical shifts and coupling constants with those of similar structures in the literature.⁹⁹ Highly oxygenated compound **296** from *Ajuga decumbens* inhibited lipopolysaccharide (LPS)-induced nitric oxide production in RAW 264.7 macrophages.¹⁰⁵



2.2. Type II with a 2-Ethylfuran-based Side Chain at C-9

Type II clerodane diterpenoids are characterized initially by a 2-ethylfuran-based, rather than acyclic, side chain at C-9. When viewed simplistically as shown below, an oxygen atom has been inserted between C-15 and C-16 of a 3-methylenepent-4-ene side chain.




Type II compounds then are further split into various subtypes. Subtypes Ia and Ib generally have more complex or multiple *O*-containing rings at various positions of the decalin moiety, as compared with Subtype Ic with only one simple epoxy ring on the decalin moiety. Subtypes IIa and IIb do not have an *O*-containing ring, but instead have one or more double bonds in the decalin moiety (IIa) or saturated decalin or oxodecalin moiety (IIb). Finally, Subtype III compounds have a distinctive tetrahydrofuran rather than furan in the C-9 side chain, along with various decalin moieties.


2.2.1. Type II with Various *O*-Containing Rings

2.2.1.1. Type II Subtype Ia with Various *O*-Containing Rings^{75,106-127} (Table 8 – compounds 297–323 found in Supplementary Material)

Nasimalun A (**297**) from *Barringtonia racemosa* illustrates a Type II Subtype Ia clerodane with a C-18/C-19 γ -lactone ring,¹⁰⁶ while teumassilenin B (**302**) from *Teucrium massiliense* is a Type II Subtype Ia with a similar γ -lactol ring.¹¹¹ *T. massiliense* also yielded new clerodane diterpenes from two additional Type II subtypes: teumassilenin C (**336**) (Type II Subtype Ib with an oxetane ring, see Section 2.2.1.2) and teumassilenin A (**423**) (Type II Subtype IIb with an oxodecalin, see Section 2.2.2.2; the first example of an 18 β -aldehyde from *Teucrium* species).¹¹¹




A furan ring is present between C-18 and C-6 in clerodanes **314–316**,^{122,123} while plaunol E (**306**) has a γ -lactone ring at this same position, as well as a δ -lactol ring between C-20 and C-19.¹¹⁵ Compound **306** significantly inhibited LPS-induced NO production with an IC₅₀ value of 2.79 μ M.¹¹⁵




Other new clerodanes in this subtype also had oxygenated rings incorporating C-20. Sacacarin (**318**) from *Croton cajucara* has a C-19/C-20 δ -lactone ring. Compound **319** from *Salvia miniata* has an oxygenated structure containing C-19/C-20 and C-7/C-20 acetalic bridges.¹⁰⁸ The C-20/C-19 δ -lactone in **321**¹¹⁶ from *Teucrium oxylepis* and the

C-20/C-6 δ -lactol ring in **323**⁷⁵ from *Pteronia eenii* are also accompanied by C-4/C-18 and C-3/C-4 epoxide rings, respectively.




2.2.1.2. Type II Subtype Ib with Other *O*-Containing Rings^{84,111,128–140} (Table 9 – compounds **324–355** found in Supplementary Material)

Clerodane diterpenoids with an axial oxyfunction at the C-7 position are rare, but a few examples, such as **326–329**, have been reported. The structure of **326** from *Teucrium cossonii* distinctly contained a 4,18 spiro-oxirane compared with those of **327–329** from *Ptychopetalum olacoides*.^{129,130} Methyl dodonates A–C (**330–332**), three new modified clerodanes containing a tricyclo [5.4.0.0^{1,3}]undecane ring system, were isolated from *Dodonaea viscosa*.¹³¹ They have been proposed as putative intermediates in the biogenetic pathway to diterpenes possessing a bicyclo[5.4.0]undecane or bicyclo[5.3.0]decane ring system.




Teucrolin E (**335**) from *Teucrium oliverianum* contains an oxo group (C=O) at C-7.^{133,134} Its originally proposed structure also contained an oxetane ring with the oxygen connecting C-4 to C-10, leaving C-18 as a hydroxymethyl group.¹³³ However, additional NMR analysis of the diacetate, including NOE studies, indicated that C-18 is instead part of a tetrahydrofuran ring that includes C-10 and a tertiary OH group is present at C-4.¹³⁴

As mentioned previously, teumassilenin C (**336**) from *Teucrium massiliense* does possess an oxetane ring; however, the oxygen bridges C-4 α and C-19.¹¹¹ Anastreptin (**337**) from *Adelanthus lindenbergianus* contains a cyclic ketal moiety with oxygen bridges from C-12 to C-7 and C-12 to C-8 of the decalin moiety.⁸⁴ Three Type II Subtype Ib clerodanes (bafoudiosbulbins A, D, and E; **339–341**) were isolated from *Dioscorea bulbifera*.^{135,136} Compound **339** is a stereoisomer of **340**; both compounds contain a lactone bridge (OC=O) between C-2 and C-5, as well as between C-6 and C-8.^{135,136} Compound **341** is identical to **340**, but also contains a 3 α ,4 α -epoxide.¹³⁶




Scaparvin A (**343**), a novel caged *cis*-clerodane diterpenoid with an unprecedented C-6/C-11 bond and a ketal ring, were isolated together with scaparvins B–E (**344–346**, **350**), without the C-6/C-11 bond, from the Chinese liverwort *Scapania parva*.¹³⁸ Their absolute structures were elucidated by analysis of NMR and CD data coupled with electronic circular dichroism (ECD) calculations. The authors proposed an enzymatic intramolecular aldol reaction as the key step in the biogenetic pathway of **343**.¹³⁸ Parvitexins A–C (**347–349**) from *S. parvitexta* are the first natural products identified with an unusual 2,8-dioxobicyclo[3.2.1]octane moiety.¹³⁹



2.2.1.3. Type II Subtype Ic with a Simple Epoxy Ring ^{123,129,139,141-148} (Table 10–compounds 356–376 found in Supplementary Material)

Clerodane diterpenes in this subtype generally have either a 3,4 epoxide (e.g., **357** from *Scapania parvitexta*,¹³⁹ **359** from *Croton eluteria*,¹⁴² **364** from *Thysanathus spathulistipus*¹⁴³) or a 4,18 spiro-oxirane (e.g., **369** from *Teucrium oliverianum*,¹⁴⁶ **375** from *T. fruticans*¹²³). Their structural differences are mainly in the linkages between the carbocyclic and heterocyclic moieties and the functionalization of the decalin core. However, the β -oriented epoxide of phlomeic acid (**376**) from *Phlomis bracteosa* is uniquely at C-1/C-10.¹⁴⁸




2.2.2. Type II with or without a C=C Double Bond in the Decalin Moiety


2.2.2.1. Type II Subtype IIa with One or More Decalin C=C Double Bonds ^{74,106,110,130,149-168} (Table 11 – compounds 377–419 found in Supplementary Material)

Vishautriwatic acid (**377**) from *Dodonaea viscosa* was identified with different stereochemistry at C-5 and C-9 from the known *neo*-clerodane hautriwatic acid (**378**)

found in *Eremocarpus setigerus*.^{149,150} The *cis*-relationship of H-10 and Me-20 in **377** is uncommon compared with the *trans*-relationship found in **378**. Crotonolide G (**404**, *Croton laui*, with a unique 2,5-dihydrofuran rather than furan in the C-9 side chain, displayed significant antibacterial activity with an MIC value of 43.4 μM against four strains of gram-positive bacteria, including *Staphylococcus aureus* ATCC 25923, *Staphylococcus epidermidis* ATCC 12228, *Micrococcus luteus* ATCC 9341, and *Bacillus subtilis* CMCC 63501.¹⁶⁵ Crotomembranafuran (**414**, *Croton membranaceus*), which has a less common ethanone rather than ethyl or ethylene linkage between the decalin and furan ring systems, had an IC_{50} value of 10.6 μM against PC-3 cells.¹⁶⁸



In addition to the C-3/C-4 double bond, compounds **415** and **418** found in *Conyza hypoleuca* also contain a second double bond (C-1/C-2 in **415**¹⁵⁵; C-1/C-10 plus C-2 oxo in **418**¹⁶⁹). Finally, eluterin B (**419**) from *Croton eluteria* contains an exocyclic C-4/C-18 double bond.¹⁴²




2.2.2.2. Type II Subtype IIb without a Decalin C=C Double Bond^{89,111,142,151,165,170-172}

(Table 12 – compounds 420–428 found in Supplementary Material)


Crolechinic acid (**422**) is representative of Type II Subtype IIb compounds and was found

as a minor constituent in *Croton lechleri* based on TLC profiles and NMR spectra.⁸⁹ Eluterin A (**425**) differs structurally from eluterin B (**419**) only in the functionalities at C-3, C-4, and C-18: oxo and β -methyl in the former, but α -hydroxy and exocyclic double bond in the latter.¹⁴² Four new tricyclic clerodane type diterpene aldehydes (**423** and **426–428**) were characterized through modern spectroscopic techniques and comparison with literature data.^{111,170-172} 20 α -Aldehydes are present in **426** and **427** from *C. hovarum*.^{170,171} Compounds **423** and **428** both contain a 18-aldehyde and the same relative stereochemistry, but the former was reported as a *neo*-clerodane from *Teucrium massiliense* and the latter as an *ent-neo*-clerodane from *Nepeta juncea*.^{111,172}




2.2.3. Type II Subtype III with a Tetrahydrofuran Ring^{72,89,149,173-179} (Table 13 – compounds **429–445** found in Supplementary Material)

Compounds **429** and **430** from *Baccharis trinervis* were determined as trinerolide and 15-*epi*-trinerolide, respectively, based on the number of split peaks and coupling constant of the acetal H at C-15.⁷² Compound **434** was a possible artifact from *B. articulata*, with the true natural product being its hemiacetal analogue.¹⁷³ Two new *neo*-clerodane diterpenoids with multiple O-containing rings, compounds **439** and **440**, were isolated from an acetone extract of the aerial parts of *Scutellaria galericulata*.^{176,177}



2.3. Type III with a 3-Ethyl-2-butenolide-based Side Chain at C-9

Type III clerodane diterpenoids bear a 3-ethyl-2-butenolide-based side chain at C-9, with various *O*-containing rings or double bonds at different positions. Comparison of the Type II and Type III general structures shows that the furan ring in the former has been replaced by a furan-2(5*H*)-one (or 2-butenolide) in the latter.




2.3.1. Type III Subtype I with *O*-Containing Rings

2.3.1.1. Type III Subtype Ia with Five-Membered Cyclic *O*-Containing Rings


^{84,173,180-191} (Table 14 – compounds 446–480 found in Supplementary Material)

Amphiacrolides A–E, I, J, L, and M (**446–454**), isolated from *Amphiachyris dracunculoides*, have an ethyl butenolide side chain attached at C-9, as supported by characteristic MS fragments (*m/z* 111, 98, and 97) and ¹H- and ¹³C-NMR peaks.¹⁸⁰⁻¹⁸² The stereochemistries of the amphiacrolides were established from the chemical correlation of these compounds to gutierolide, a compound with absolute stereochemistry


determined by X-ray analysis.¹⁸⁰⁻¹⁸²



The planar structures of **460** and **461**, isolated from different *Baccharis* species are identical, but the compounds are epimeric at C-8.^{173,186} The absolute stereochemistry (*neo*-series, 5:10 *trans*, 17:20 *trans*) of gaudichanolide A (**461**) from *B. gaudichaudiana* was established by X-ray crystallographic analysis.¹⁸⁶




Several new clerodanes, exemplified by **463** from *Cephaloziella kiaeri*, have a unique unsaturated γ-lactone moiety incorporating C-18 and C-6.^{84,182,187-191} Three 1:1 mixtures (**470–475**) of epimeric clerodane diterpenes with a C-8/C-12 ether bridge were isolated from *Adelanthus lindenbergianus*.⁸⁴ Structures **474–476** contain a second ether bridge between C-12 and C-7 forming a cyclic ketal at C-12.⁸⁴ A C-1/C-12 ether bridge is present in **477** also from *A. lindenbergianus*,⁸⁴ while a C-10/C-12 ether bridge is found in **478–480** from *Scapania ciliata*.¹⁹¹




2.3.1.2 Type III Subtype Ib with Other *O*-Containing Rings^{52,181,192-214} (Table 15 – compounds 481–527 found in Supplementary Material)

Many compounds in this subtype contain the typical functional groups of *neo*-clerodane diterpenoids, including a C-4/C-18 (e.g., **505**) or C-3/C-4 epoxide (e.g. **515**, **516**) and *cis* C-17 α and C-20 α methyl groups.¹⁹²⁻²⁰⁹ Among them, hastifolin A (**505**) from *Scutellaria hastifolia* showed significant antifeedant activity against larvae of *Spodoptera littoralis* at a concentration of 100 ppm; its feeding index was 60 ± 15.2 and FI₅₀ concentration was 45 ppm.²⁰⁴ Seguinilactones A and B (**515**–**516**) from *Colquhounia seguinii* differ structurally only in where the butenolide ring is connected to C-12. This connection is at the β position of the butenolide ring in the former compound and at the α position in the latter compound.²⁰⁹ Thus, the carbonyl moiety of the lactone ring is at C-15 (a 15,16-olide) in **515** and at C-16 (a 16,15-olide) in **516**. A β -substituted α,β -unsaturated γ -lactone functionality was found to be crucial for the strong antifeedant activity of this compound class, and **515** was approximately 17-fold more potent than commercial neem oil insecticide against the generalist plant-feeding insect *Spodoptera exigua*.^{208,209}




The C-2/C-19 ether bridges of amphiacrolide K (**518**; *Amphiachyris dracunculoides*) and conyzalactone (**519**; *Conyza blinii*) have opposite relative configurations, and these two compounds are also the two *ent-neo-clerodane* exceptions in this subtype.^{181,210} *Neo-clerodane*-type diterpenoid **520** from *Ajuga decumbens* has a C-1/C-19 ether bridge.²¹¹ Compounds **521–525** contain a C-20/C-7 γ -lactone/lactol bridge,^{52,212} compounds **526** has a C-18/C-7 δ -lactone bridge,²¹³ and finally, microdon B (**527**) possesses a C-17/C-12 δ -lactone bridge.²¹⁴




2.3.2.1. Type III Subtype IIa with C3/C4 Double Bond^{58,70,72,155,163,164,175,183,189,213,}

215-228 (Table 16 – compounds 530–575 found in Supplementary Material)


A wide range of substituents are found on the decalin and butaenolide moieties in Type III Subtype IIa compounds. With CO₂H at the decalin C-4 position and OMe or H, respectively, at the butenolide C-4 position, limbatolides B (**533**) and C (**534**) from *Otostegia limbata* inhibited acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzymes in a concentration-dependent manner with IC₅₀ values of 47.2, 103.7 and 17.5, 14.2 μM, respectively.¹⁸⁹ Polylongifoliaon B (**543**) from *Polyalthia longifolia* is one of a few Type III Subtype IIa compounds with an α,β-unsaturated ketone in the decalin ring A.²²⁰ This compound improved the viability of human neuroblastoma cells (SK-N-MC cells) under Aβ-induced neurotoxicity with an IC₅₀ value of 3.75 μM.²²⁰



The H-10 of compounds **558–571** has the more unusual α-orientation (*ent-neo-clerodane*).^{163,164,183,213,226} Both *cis-trans* (e.g., **558–564**), *trans-cis* (e.g., **566**), and *cis-cis* (e.g., **571**) configurations of the decalin ring junction and C-17/C-20 orientation, respectively, are found. Solidagoic acids C–I (**558–564**) from *Solidago virgaurea* contain a carboxylic acid at C-19, a motif that is relatively uncommon among the clerodanes.¹⁸³ Compared with the standard drug deoxynojirimycin (425.6 ± 8.1 μM), compound **566** from *Duranta repens* showed significant α-glucosidase inhibitory activity (IC₅₀ 577.7 ± 19.0 μM).²²⁶ Structurally, it has a 6β-OH and opposite stereochemistry at C-8 to C-10 compared with **534** mentioned above.



Scutebata A (**574**), as well as scutebatas B and C (**994** and **995**; see Section 2.9.1), from *Scutellaria barbata* possess a rare hydroxy group at the α -position of the α,β -unsaturated lactone ring. Scutebata A showed weak cytotoxic activity against SK-BR-3 cells with an IC₅₀ value of 15.2 μ M.²²⁸ Compound **575** from *Baccharis trinervis* has a saturated, rather than unsaturated, γ -lactone in its side chain.⁷²




2.3.2.2. Type III Subtype IIb with Double Bonds in Other Positions


117,194,205,206,208,217,229-248 (Tables 17 and 18 – compounds **576**–**614** found in Supplementary Material)

Compounds **577**–**579**, **584**, and **888** (see Section 2.7) from *Scutellaria barbata* showed significant cytotoxic activities against three human cancer lines, HONE-1 nasopharyngeal, KB oral epidermoid carcinoma, and HT29 colorectal carcinoma, with IC₅₀ values in the range of 2.0–8.1 μ M.^{229,230,232} Compound **584** has a 2,3-epoxy-2-isopropyl-*n*-propoxy moiety attached at C-6, and its possible biosynthesis was proposed.²³⁰ Salvidivins C (**587**) and D (**588**) from *Salvia divinorum* are unique *neo*-clerodane diterpenes that possess a

γ -hydroxy- α,β -unsaturated γ -lactone moiety, and are geometrical isomers at the γ -lactone moiety.²³⁵




Several compounds in this subtype have a 4,18-*exo*-methylene group (e.g., **589**, **597**, **598–600**),^{217,231,236-242} while compounds **612–614** have a unique α -oriented cyclopropane ring formed from C-4, C-5, and C-19.^{247,248} The latter three compounds were isolated from two different marine organisms, an Okinawa tunicate *Cystodytes* sp and a Formosan gorgonian coral *Echinomuricea* sp. Echinoclerodane A (**614**) was found to be the C-8 epimer of dytesinin A (**612**), and the chiral carbons in **614** were assigned as 4S*, 5S*, 8S*, 9S* and 10R*.²⁴⁸



2.4. Type IV with a 5-(3-Furyl)- δ -valerolactone-based Side Chain at C-9


Compounds in this group are characterized by a 5-(3-furyl)- δ -valerolactone-based side chain at C-9, together with lactone and epoxy rings, hydroxy and acetoxy groups, as well as double bonds. Both Type II and Type IV compounds contain a furan ring in the C-9


side chain but differ by the presence of a 17,12- δ -lactone ring in the latter class. Thus, as seen below, position 17 is generally a free methyl group in Type II compounds, while it is incorporated into the δ -lactone ring as the carbonyl group in Type IV compounds.




2.4.1. Type IV Subtype I with O-Containing Rings ^{108,109,113,120,249-262} (Table 19 – compounds 615–655 found in Supplementary Material)


In addition to the 17,12- δ -lactone ring characteristic of Type IV clerodanes, many new Subtype I compounds from *Salvia* species have a 18,19- γ -lactone ring. Their decalin moieties also contain various numbers and locations of double bonds (see **615**, **617**, **622–624**) and oxygenated groups. The 1 β ,10 β -epoxy group of **627–630** from *Salvia herbacea* was deduced by analysis of spectroscopic data.²⁴⁹ Tehuanin G (**630**) exhibited anti-inflammatory activity (IC₅₀ 0.24 μ M/ear) comparable to that of indomethacin, the reference compound.²⁴⁹ In contrast, the C-1(2)-epoxy group of **632–634** from *S. reptans* has an α -orientation.^{252,253} Except for the stereochemistry of the C-18–C-19 lactone ring fusion (*trans* in **632**, *cis* in **633**), compounds **632** and **633** have identical structures with both A/B and B/C *cis* ring fusions, as established by X-ray analysis.^{252,253} Furthermore, tehuanins A–C (**635–637**) from *S. herbacea* contain a 1,8-oxygen bridge; this unusual structural feature was confirmed by X-ray diffraction of **635**.²⁴⁹






In addition to the C-12–C-17 δ -lactone ring found in the Type IV class, compounds **638–640** from *Jamesoniella autumnalis* have a second lactone ring at C-18/C-6,¹²⁰ while fibrauretin A (**641**) from *Fibraurea tinctoria* has a second lactone ring at C-1/C-18 as well as an epoxide ring at C-2/C-3.²⁵⁴ Compound **647**, a stereoisomer of 8-hydroxycolumbin at the C-12 position, contains the same C-1(18)-lactone ring as **641** rather than the C-2(18)-lactone ring of compounds **648** and **649**.²⁵⁸ Compounds **650–653** are novel furano-clerodanes from *Dioscorea antaly* and *D. bulbifera* with a second δ -lactone ring bridging carbonyl C-19 to C-2.^{259,260}






2.4.2. Type IV Subtype II Other Compounds ^{84,108,132,157,165,214,235,257,263-274} (Table 20) – compounds 656–691 found in Supplementary Material)

Compound **665** from *Salvia divinorum* is a C-17 epimeric mixture of the hemiacetal salvinorin J, and is an example of a *neo*-clerodane hemiacetal (lactol) susceptible to mutarotation with the formation of an equilibrium mixture of C-17 epimers.²⁶⁶ Salvinicins A (**684**) and B (**685**) from the same plant are unique *neo*-clerodanes with a 3,4-dihydroxy-2,5-dimethoxytetrahydrofuran ring.²⁷³ Their absolute stereochemistry (*neo*-series, A/B ring *trans*, B/C ring *trans*) was based on X-ray crystallographic analysis. Interestingly, salvinicin A (**684**) exhibited partial κ agonist activity with an EC₅₀ value of $4.1 \pm 0.6 \mu\text{M}$ ($E_{\text{max}} = 80\%$ relative to (–)-U50, 488H), while salvinicin B (**685**) exhibited antagonist activity at μ receptors with a K_i of $>1.9 \mu\text{M}$. This report provided a new lead in the development of opioid receptor antagonists.²⁷³ Salvidivins A (**686**) and B (**687**) are a pair of geometrical isomers of the γ -hydroxy- α,β -unsaturated γ -lactone, differing from each other in the linkage position to C-12. It appears that **686** and **687** are important precursors of **684** (a partial agonist of the κ -opioid receptor) and **685** (the first μ -opioid antagonist with a *neo*-clerodane skeleton).²³⁵




Compounds **688–691** are Type IV Subtype II compounds with variations on the δ -lactone structure.^{84,108,274} Compound **688** from *Cornutia grandifolia* and **689** from *Adelanthus lindenbergianus* are distinguished by a unique ether linkage between C-1 and C-12.^{84,274} Remarkably, the structures of orcadensin (**690**) also from *A. lindenbergianus*, as well as salvianduline D (**691**) from *Salvia miniata*, contain cyclic ketal functions with two oxygen bridges from C-12 to different positions of the decalin moiety.^{84,108}




2.5 Type V with an α -Spiro-attached 4-(3-Furyl)- γ -butyrolactone-based Side Chain at C-9

Clerodane diterpenoids of this group contain an unusual C-9 spiro- γ -lactone substituted at C-12 with a furan ring or are compounds arising from rearrangements of this structure. As contrasted in the below figure, the γ -lactone ring of Type V compounds includes C-20 (C=O), C-9 (as the one carbon link to the decalin system), C-11, and C-12, while the δ -lactone ring of Type IV compounds incorporates C-17 (C=O), C-8, C-9, C-11, and C-12. Type V compounds have a free Me-17, while Type IV compounds have a free Me-20.




2.5.1. Type V Subtype I with Various *O*-Containing Rings^{75,108,113,165,187,275-281} (Table 21 – compounds 692–719 found in Supplementary Material)


Compound **692** from *Salvia fulgens* exemplifies a variation on the basic Type V structure. In it, C-20 is connected to C-7 as well as C-12 by oxygen atoms, forming two tetrahydrofuran rings joined at the C-20 acetal. This interesting structure was confirmed by X-ray crystallographic analysis as a dihydro derivative of the known salvifaricin, which has a double bond at C-1/C-2, as well as C-3/C-4.²⁷⁵ Like salvifaricin, salvifolin (**695**; *S. tiliaefolia*)²⁷⁶ and dugesin F (**696**; *S. dugesii*),¹¹³ also have two double bonds in the decalin A-ring. However, unlike salvifaricin and **692**, the second ether bridge from C-20 to C-7 is missing in **695** and **696**, and instead a cyclic hemiacetal (spiro- γ -lactol) and C-7 oxo groups are present. An A/B *cis* ring fusion was elucidated in **695**, in comparison with linearolactone whose structure was established by X-ray diffraction analysis, while the structurally similar **696** has a *trans* decalin ring fusion. Dugesin F (**696**) exhibited an inhibitory effect on influenza virus FM1, a strain that causes a cytopathic effect (CPE) in MDCK cells.¹¹³ The results [TC₅₀ 45.67 μ g/mL, IC₅₀ 9.43 μ g/mL, therapeutic index (TI) 4.84] implied that **696** is a non-toxic antiviral compound against influenza virus FM1.



Teusandrins A–D (**708–711**) isolated from *Teucrium sandrasicum* contain a non-rearranged C-9 spiro- γ -lactone. Notably, such diterpenoids containing an oxetane ring involving positions $4\alpha,19$ (e.g., **708** and **709**) and $4\beta,10\beta$ (e.g., **710** and **711**), as well as $4\beta,6\beta$ (not illustrated) of the *neo*-clerodane skeleton are relatively frequent among the constituents of *Teucrium* plants.²⁸¹




Several new clerodane diterpenoids, crotonolides A–D (**713–714**, **716**, **718**) and isocrotonolides B–D (**715**, **717**, **719**), were isolated from the aerial parts of *Croton laui*.¹⁶⁵ They contain a variation on the C-9 spiro- γ -lactone with the two oxygen atoms on C-20 incorporated into both a tetrahydrofuran ring through C-12 and a six-membered lactone/lactol ring between C-19 and C-20. Crotonolide A (**713**) also contains a $\Delta^{3,4}$ double bond, a $\Delta^{8,17}$ exocyclic double bond, and a 18,6- γ -lactone. In **714–719**, the latter lactone ring is absent, and also C-19 is hydroxylated rather than present as an oxo group. Compounds **714/715**, **716/717**, and **718/719** are epimeric pairs at C-19 and were obtained as 3:1 interconverting mixtures.




2.5.2. Type V Subtype II with 4,18-; 3,4-; or 8,17-Oxirane Moieties

75,123,126,128,142,144,145,262,280-294 (Table 22 – compounds 720–767 found in Supplementary Material)


Most of the new compounds in this subtype have a C-12 furan, a spiro-20,12-hemiacetal function involving the C-9, C-11, C-12, and C-20 carbons, a 4 α ,18-oxirane, and a *trans* decalin ring junction. Teumassin (**720**) from *Teucrium massiliense* contains the rare feature of a C-2 hydroxy group.²⁸² The diterpenes **729–732** isolated from *T. polium* possess the same absolute configuration, and belong to the *neo*-clerodane series.²⁸⁵ In this clerodane subtype, the C-12 stereocenter can have an *R*-configuration (e.g., **743** from *T. maghrebinum*), as well as an *S*-configuration (e.g., **729**).^{126,144,280} New C-10 oxygenated Type V Subtype III *neo*-clerodane derivatives, sandrasin A (**744**) and 6-deacetylsandrasin A (**745**) were isolated from the aerial parts of *T. sandrasicum*.²⁸⁹ Analysis of spectroscopic data revealed ether linkages between both C4 α ,C18 and C19 α ,C20 α in **750** obtained from *T. abutiloides*.²⁸⁷




The investigation of different *Pteronia* species afforded 28 new diterpenes, including five *cis*-clerodanes in this subtype (**751–753**, **758–759**).⁷⁵ Compounds **751–753** have a 8,17-oxirane and C-10 is hydroxylated. Compounds **758–759** have a 3,4-oxirane and C-10 bears a hydrogen. An extract of the aerial parts of *Microglossa pyrhopappa* afforded *cis*-clerodanes **760–763** as well as **767** with a Δ 1,10 double bond.¹²⁸



Cascarilla, the bitter bark of the South American tree *Croton eluteria*, is a commercially available and inexpensive source of polyfunctionalized clerodane diterpenoids. In addition to the bitter triol cascarillin, ten additional new diterpenoids, including eluterins J and I (**756–757**) in this subtype, were isolated and characterized.¹⁴² The structural differences among cascarilla clerodanes mainly involve the linkage between the carbocyclic and the heterocyclic moieties and the functional groups on C-3, C-4, and C-6. Although cascarillin was previously reported to be a γ -hydroxyaldehyde, this study showed that it is actually a mixture of interconverting γ -lactols.¹⁴² Compound **756** is set apart by the oxygenation of C-11, a very unusual feature in furoclerodanes.¹⁴²




Crotonpene A (**764**), which has a rare 2,3-dihydrofuran ring with a spiro-carbon at C-9 and an oxygen connecting C-12 and C-20, may be formed by oxidation or enzyme catalysis of crotonpene B (**765**). Both compounds are found in *Croton yanhuui*.²⁹⁴



2.5.3. Type V Subtype III with a C-9-Spiro- γ -lactone/lactol Moiety and Opened Furan Ring^{47,61} (Table 23 – compounds 768–773 found in Supplementary Material)


Clerodane-type diterpenoids (**768–773**) with a C-9-spiro- γ -lactone/lactol moiety bearing an opened furan ring (2-hydroxy-3-buten-2-yl) at C-12 are rare and found only in *Heteroscyphus* plants. In the decalin portion, compounds **768** and **769** possess a 3,4-epoxide, **770** contains a 3,4-epoxy and 2-oxo groups, and compounds **771–773** have a 3,4-double bond and 2-oxo moiety.^{47,61}



2.5.4. Type V Subtype IV Other Compounds^{75,142,277,289,292,295-299} (Table 24 – compounds 774–793 found in Supplementary Material)


Compounds in this subtype possess the furanyl substituted C-9-spiro- γ -lactone/lactol together with various substituents and unsaturation (Δ 3,4 **777**;²⁹⁷ Δ 4,18 **778**;²⁹⁷ Δ 1,10 **779**;⁷⁵ Δ 1,2 **780**;²⁷⁷ saturated **781**²⁹⁷) in the decalin system. A small coupling constant

between H-6 and H-7 proved that these protons were in α,α -equatorial positions in **777**, which consequently contains a *cis*-6 β ,7 β -diol. Teulolin B (**778**) is the first *neo*-clerodane diterpene with an exocyclic double bond at C-4/C-18 isolated from *Teucrium* species.²⁹⁷ In sandrasin B (**781**), C-4 bears α -OH and β -CH₂OH groups, rather than being involved in a spiro-oxirane with C-18 as found in **744** and **745**, which are Type V Subtype III compounds co-isolated from *T. sandrasicum*.²⁸⁹



2.6. Type VI with a Furofuran-based Side Chain at C-9


Type VI compounds contain a bicyclic furofuran system, either hexahydro or tetrahydro, attached at C-9. As contrasted below, an oxygen bridge between C-11 and C-16 differentiates the bicyclic Type IV from the monocyclic Type II compounds.




2.6.1. Type VI Subtype I with a Hexahydrofurofuran-based Side Chain at C-9 176,193,195,207,300-319 (Table 25 – compounds 794–845 found in Supplementary Material)

Most *neo*-clerodanes in this group possess a hexahydrofurofuran side chain at C-9 and a 4 α ,18-spiro-oxirane group, while some compounds also contain an additional C-19,2 α -hemiacetal function (compare the structures of **815** and **834** obtained from *Scutellaria discolor*).³¹¹ Interestingly, compound **819**, isolated from *S. columnae*, was the


first *neo*-clerodane diterpene reported to have a hexahydrofurofuran moiety with an 11*R*-configuration.³¹³



Generally, clerodin hemiacetal derivatives are found as C-15 epimeric mixtures. Scupolin K (**811**) from *S. polyodon* was found as a mixture of the C-15 epimers of the 14,15-dihydro-15-hydroxy derivative of scupolin J,³¹⁰ and scutalsin (**818**) from *S. altissima* was also a 1:1 epimeric mixture of the C-15 hemiacetal function.³¹² Compounds **812–814** and **832–833**, which have ethoxy acetal groups, are considered to be artifacts from *Scutellaria discolor* formed in the course of extraction or separation using ethanol.³¹¹ Compounds **824** and **825** from *Ajuga salicifolia* are the C-15 epimers of the 14,15-dihydro-15-hydroxy derivative of **826**.³¹⁶ Compound **831** from *Clerodendrum inerme* was assigned as a mixture of C-15 epimers of 14,15-dihydro-15-hydroxy-3-epicaryoptin.³¹⁹ Two pairs of diastereomeric hemiacetals, scutecyprols A (**838**) and B (**810**), were detected in the aerial parts of *S. cypria*. After oxidation, they were isolated as their γ -lactone derivatives.³⁰⁹



Compound **837** from *S. alpine* contains an isobutyroyloxy group at C-19, while a rarer propanoyloxy substituent is present in **836** from *S. barbata*; however, their absolute configurations were not ascertained.^{195,321} Scupontins C, D, and F (**839–841**) from *S. pontica* possess unusual [(3'*S*,3''*S*)-3'-[(3'''-acetoxybutyryl)oxy]butyryloxy and [(3'*S*,3''*S*,3'''*S*)-3'-[[3'''-[(3''''-hydroxybutyryl)oxy]butyryl]oxy]butyryl]oxy substituents, respectively, attached to the C-19 position of the *neo*-clerodane nucleus.³²² Scutalpin M (**842**) also from *S. alpine* is the first 14-oxidized hexahydrofuro-furan-*neo*-clerodane derivative isolated from natural sources.¹⁹³ Compound **843** from *A. lupulina* has a C-4/18 exocyclic double bond, which is unusual in this type of clerodane diterpenes.³¹⁵ Inermes A (**844**) and B (**845**) from *C. inerme* are dimeric *neo*-clerodanes with the two hexahydrofurofuran rings joined through an ether linkage at C-15, the latter compound contains a C-1 methoxy group not found in the former compound.³¹⁹




2.6.2. Type VI Subtype II with a Tetrahydrofurofuran-based Side Chain at C-9

207,300-302,306,310,311,320,322-328

(Table 26 – compounds 846–874 found in Supplementary Material)


The tetrahydrofurofuran system with a 14,15 double bond is the same in compounds of this subtype, and their clerodendrin skeletons also contain a 4 α ,18-spiro-oxirane. They differ in other substitutions on the decalin system. Certain compounds [e.g., jodrellins A and B (**860–861**) from *Scutellaria* species] also contain an additional C-19,2 α -hemiacetal function,^{306,310-312,326-328} as found in the Type VI Subtype I compounds mentioned in the prior section. The spectroscopic differences observed between **853** and **854** found in *S. lateriflora* suggested the presence of an acetoxy substituent in the former and a 2-methylbutanoyloxy group in the latter.³²⁰ *Clerodendrum trichotomum* yielded clerodendrins I, E, F, G (**868–871**) all having a double bond at C-7/C-8 in their decalin skeleton are substituted with 2 α -hydroxy, 4 α ,18-epoxy, 6 α ,19-diacetoxy, 7,8-ene and 11,12,13,16-tetrahydrofurofuran functions, but with different 3 β -acyloxy groups.^{325,328} Like **839–841**, scupontins A, B, and E (**872–874**) from *S. pontica* are esterified at C-19 with di- and tri-esters of 3-hydroxybutanoic acid.³²²




2.7 Type VII with a 13-Spiro-15,16- γ -lactone Moiety^{192,193,201,204,208,329-338} **(Table 27 – compounds 875–902 found in Supplementary Material)**

The defining structural characteristics of Type VII *neo*-clerodane structures are a 8,13-ether bridge creating a tetrahydropyran that incorporates C-8 and C-9, as well as C-11–C-13, and a 13-spiro-15,16- γ -lactone moiety. Both possible configurations are

found at the spiro C-13. A comparison with Type III compounds is shown below.




Scutorientalin C (**876**) is the first *neo*-clerodane with a free C-11 axial hydroxy group in ring C (tetrahydropyran) to be isolated from a *Scutellaria* species.¹⁹² The observed spectroscopic differences between **877** and **878** were consistent with the presence of a C-6 α isobutyric ester in the former compound rather than the tigloyloxy group found in the latter.^{201,329} From a chemotaxonomic point of view, compound **879** is the first 8 β ,13*S*-epoxy-*neo*-clerodan-15,16-olide derivative found in European *Scutellaria* species, although these structural features are shown by several *neo*-clerodanes isolated from Asian *Scutellaria* species.³³⁰



Opposite absolute configurations have been found at C-13 (e.g., 13*S* and 13*R* in **884** and **898**, respectively).^{208,337} The aerial parts of *Scutellaria hastifolia* yielded several clerodanes similar structurally to the known scuteparvin, but distinguished by being *trans*-cinnamoyl derivatives. Some of these compounds are epimeric at C-13, and it was not possible to separate the 4:1 mixture of hastifolin G (**886**) and hastifolin F (**894**).²⁰⁴ Likewise, barbatellarine E (**888**) is a C-13 epimer of barbatellarine F (**892**), as confirmed by NOESY and optical rotation data.^{333,334} Comparison of spectroscopic data for **896** and **897** indicated the presence of C-6 α and C-7 β equatorial isobutyryloxy groups and a free C-19 hydroxy group in the former compound instead of C-6 α tiglate and C-7 β and C-19


acetates in the latter compound.^{332,336}




2.8. Clerodane Diterpene Glycosides^{62,102,254,255,257,268,339-361} (Table 28 – compounds 903–981 found in Supplementary Material)

The clerodane diterpene glycosides come from many of the above types but have been placed into a separate category based on the presence of one or more sugar groups at various positions on both the decalin and C-9 side chain. *Gleichenia japonica* and *Dicranopteris pedata* yielded new glycosylated Type I clerodane diterpenes with an acyclic C-9 side chain (**903–904** and **905–906**, **910–913**, respectively).^{339,340} The only structural difference between **903** and **904** is the presence of only glucopyranosyl at C-6 in the former, but glucopyranosyl linked to rhamnopyranosyl in the latter. However, compound **903** inhibited the growth of lettuce, whereas **904** accelerated growth.³³⁹ The related glycoside **905** with sugars on both C-6 and C-13 also accelerated lettuce stem growth, but inhibited root growth.³⁴⁰ Compounds **907–909** are the first clerodane diterpenes with L-arabinoside at C-13 isolated from the family Compositae (species *Nannoglottis carpesioides*).³⁴¹ Compounds **910–913** are monodesmosidic clerodane diterpene glycosides containing two monosaccharides, glucopyranosyl and rhamnopyranosyl.³⁴² Compounds **918–922** possess a 1,4-dihydroxy-2-buten-2-yl-ethyl group at C-9, which is characteristic of the diterpenoids found in *Portulaca* and *Salvia*

plants.^{62,102,344}




Examples of glycosylated clerodanes with Type II structures are **924–925** from *Elsholtzia bodinieri*, **926** from *Salvia amarissima*, and **927–928** from *Tinospora tuberculata*.³⁴⁵⁻³⁴⁷ Amarisolide (**926**) was the first reorted diterpene glucoside found in *Salvia* species.³⁴⁶




Compounds **930** and **931**, both found in *Baccharis sagittalis*, were separated and characterized as C-18 β -D-glucopyranosyl peracetylated derivatives.³⁴⁹ The former compound can be classed as a Type I clerodane glycoside, while the latter compound is a


Type III clerodane glycoside with a 3-ethyl-2-butenolide side chain.




Clerodane diterpene glycosides with various five-membered *O*-containing rings attached at C-12 were isolated from three *Tinospora* species.³⁵⁰⁻³⁵² Compounds **934** and **935** with an unsubstituted butenolide ring exhibited moderate anti-settling activity against the sea barnacle *Balanus amphitrite*, and are the first clerodane diterpenes to be reported with antifouling activity.³⁵⁰ Rumphiosides A and B (**936** and **937**) contain hydroxy- and methoxy-butenolide rings, while the tetrahydrofuran rings attached to C-12 in the epimeric **939** and **940** were possibly artifacts formed from a dialdehyde during the extraction of the plant material with methanol.³⁵¹ Compounds **941** and **942** have a 17,6- γ -lactone,³⁵¹ while compounds **936–937**, **939–940**, and **943–944** contain a 17,12- δ -lactone as well as an 18 β ,1 β - δ -lactone. In cordifolides B and C (**943** and **944**) the butenolide ring located on C-12 is rotated nearly 180° from the C-12/C-13 bond, resulting in different orientations.³⁵² Their structures were determined on the basis of spectroscopic data interpretation.³⁵²



In addition to cordifolides B and C, *Tinospora cordifolia* also yielded a novel unique sulfur-containing Type IV clerodane furanoditerpene glycoside, cordifolide A (**948**).³⁵² Its structure and configurations at chiral centers were confirmed by single-crystal X-ray crystallographic analysis. Cordioside (**949**) is a 19-*nor*-clerodane furanoditerpene glycoside with a C-3/C-4 double bond, and hence, no C-19 carbon.³⁵⁴ Phytochemical investigations on the aerial parts of *Tinospora crispa* led to the isolation of several new *cis*-clerodane Type IV furanoditerpene glycosides (e.g., **950**, **966**, **967**). In addition, spectroscopic assignments of a previously reported compound, borapetoside A (**947**), were revised on the basis of HMQC and HMBC correlations.³⁵³ Type IV glycoside **968** adopted a unique all boat conformation of its tricyclic ring system, as also indicated by energy calculations.²⁵⁵




Compounds **970** and **973** are Type IV 18-*nor*-clerodane glucosides, whereas **971** and **972** are 18,19-dinor-clerodane-type diterpene glucosides.^{254,357} Compounds **970–972**, isolated from *Tinospora sinensis*, were subjected to an α -glucosidase inhibition assay, and exhibited IC_{50} values of 2.9, 3.8, 3.3, and 1.9 mM, respectively. Meanwhile, the positive control, acarbose, demonstrated an IC_{50} value of 0.84 mM.³⁵⁷ Compounds **974–976** are three new Type V 19-*nor*-*neo*-clerodane diterpene glucosides.³⁵⁸



Compounds **978–981** are described by a novel macrocyclic skeleton containing an *neo*-clerodane diterpenoid moiety, one or two D-glucose units, and a 3-hydroxy-3-methylglutaric residue.^{360,361} Two long nine-atom extended strands are connected by two “cyclohexane-chairlike” two atom junctions to create a unique three-dimensional construction. The structure and the absolute stereochemistry of **978** were elucidated through a combination of spectroscopic techniques, degradation reactions,


and conformational analysis methods. Compound **978** inhibited high density induced apoptosis in several human and murine carcinoma cell lines.



2.9. Clerodane Derivatives

2.9.1. *N* (or *S* or *Cl*)-Containing Derivatives ^{218,228,230,232-234,333,338,362-379} (Table 29 – compounds 982–1054 found in Supplementary Material)


Compounds **982** and **983** from *Polyalthia longifolia* contain a succinic diamide moiety attached at C-12; the former compound also has a double bond between C-13 and C-14.³⁶² Other *N*-containing clerodane diterpenes have a heterocyclic group attached at the terminal carbon (C-15) of a 3-methyl-3-pentenyl side chain. For example, when the marine sponge *Agelas axifera* was investigated for cancer cell growth inhibitory constituents, pyrimidine diterpenes (e.g., **986**) were isolated.³⁶⁴ Other compounds from *Agelas* species possess both a 9-*N*-methyladenine moiety at C-15 as well as a 2-carboxy-4-bromopyrrole linked through an ester at C-18 (e.g., **990**), whereas compound **991** with a C4/C18 exocyclic methylene has only the former moiety.³⁶⁵




Scutellaria barbata is a major source of *neo*-clerodane diterpenoid

alkaloids.^{228,232,233,338,366-372} Nicotinic acid (also known as niacin or vitamin B3) is a

frequent *N*-containing component of ester groups found at various positions on the decalin, as shown in the following examples: **994–995** (mentioned in Section 2.3.2.1.), **998, 1008, 1012**.




Two similar *N*-containing clerodanes (**1013** and **1014**) were isolated from *P. longifolia*.³⁶² The former compound has a molecular weight two units greater than the latter, consistent with a pyrrolidine-15,16-dione in **1013** and a 1*H*-pyrrole-15,16-dione attached at C-12 in **1014**. New clerodanes **1015–1021** (with either a dihydro-2*H*-pyrrol-15-one, dihydro-2*H*-pyrrol-16-one, or 1*H*-pyrrole-15,16-dione) at C-12 were isolated from *Echinodorus macrophyllus* and *Casearia sylvestris*.^{218,373,374}





Compounds **1022–1024** isolated from the twigs and leaves of *Cleidion brevipetiolatum* have a type IV clerodane skeleton with an infrequent methylsulfinyl group present at C-3.³⁷⁵ Rare Cl-containing clerodanes **1025** and **1026** were isolated from *Teucrium pernyi* and *T. racemosum*, respectively.^{376,377} The Cl is part of a chlorohydrin in both compounds, with the CH₂Cl at C-17 in **1025** and at C-18 in **1026**. Because they were present in acetone extracts of the plant material, these two compounds were not regarded as artifacts

of the isolation procedure.



Other compounds with nicotinoyl esters were isolated from *S. barbara* as described below. Compound **1031**, with an α -configuration of the ethoxy group, is the epimer of **1030**.³⁷⁰ Compared with **1033**, compound **1032** lacks a 13-spiro-15,16- γ -lactone moiety, as the result of oxidative cleavage between C-13 and C-14.³⁶⁸ NMR spectroscopy confirmed the presence of hydroxy and hydroxymethyl groups at C-13 in **1032**, as well as the absence of carbon signals for C-14 and C-15. The originally reported structures of **1036–1043** were revised.³⁶⁶ The absolute stereochemistry $1R,5R,6R,7S,8R,9R,10R,13S$ was assigned to compounds **1045 (1048)** and **1049**, whereas compound **1050** has the same $5R,6R,7S,8R,9R,10R,11S,13R$ absolute configuration as **1051**.³⁷⁹ Barbatine A (**1050**) also showed significant capability to protect cells against H_2O_2 with an ED_{50} value of $16.8 \mu M$.³⁷⁹ Barbatellarine C (**1053**) is a C-13 epimer of barbatellarine D (**1054**), as confirmed by a NOE difference experiment and the respective NOESY spectra.³³³







2.9.2. Degraded Derivatives ^{44,79,92,98,132,133,146,158,163,170,191,219,227,258,277,278,280,293,342,380-392}


(Table 30 – compounds 1055–1097 found in Supplementary Material)

Compounds in this subtype have fewer than the normal 20 carbons of the basic clerodane skeleton. Firstly, in pentandranoic acid B (**1055**) from *Callicarpa pentandra*, a new contracted ring-A (cyclopentanone rather than cyclohexanone) is present.⁹⁸ Secondly, various one-carbon substituents can be absent, primarily, but not exclusively, C-18 or C-19. Compounds **1056–1061** are rare 18-*nor*-clerodane diterpenoids with a C-4 oxo or hydroxy group.^{258,293,380,381}




19-*nor*-Clerodanes constitute the majority of the degraded clerodanes, and the following examples come primarily from *Croton* and *Teucrium* species. One of the simplest 19-*nor*-clerodanes is cajucarin B (**1062**) isolated from *Croton cajucara*.¹⁵⁸ The 19-*nor*-clerodane **1063** with a C-5/C-10 double bond could be formed by a retro Diels-Alder reaction.¹⁷⁰ Except for an opened 17,12- γ -lactone ring and C-12 oxidation, compound **1064** from *C. euryphyllus* is quite structurally similar to **1070** and **1071**, which have a butenolide moiety spanning C-19 to C-6, from *Teucrium viscidum*.^{278,382} Crassifolin H (**1073**) from *C. crassifolius* has a similar structure except for the presence of a C-5/C-10 rather than C-4/C-5 double bond.³⁸⁷ It demonstrated anti-angiogenic activity by reducing vessel formation to 59.3% of the control value at a concentration of 15 $\mu\text{g/mL}$. Notably, the bioactive Type V 19-*nor*-clerodane-type diterpenoid *trans*-dehydrocrotonin (**1076**), with a cyclohexenone decalin ring A, is one of the most investigated clerodanes in the current literature.³⁸⁹ Two of the three hydroxy groups in sypiresin A (**1078**) from *T. chamaedrys* are replaced by hydrogen (C-2) and a methoxy group (C-6) in teupolin IX (**1079**) from *T. polium*.^{92,277} Crotoeurin A (**1084**) from *C. euryphyllus* was the first *nor*-clerodane diterpenoid dimer connected through a unique cyclobutane ring via a [2+2] cycloaddition; its structure was confirmed by single-crystal X-ray diffraction analysis.³⁸²






Compound **1085** is a 14,15,16-trinor-clerodane isolated from *Sindora sumatrana*.¹⁶³ Isolated from several different plant species, compounds **1086–1089** are unusual 14,15-bisnor clerodanes with a C-4/C-5 double bond,^{44,79,219,391} and compounds **1090–1096** are 13,14,15,16-tetranor-clerodanes. Among the latter tetranor-clerodanes, C-12 is present as a free carboxylic acid (e.g., **1090–1092**)^{227,342} or as part of a lactone ring. Croinsulactone (**1093**) from *C. insularis* contains a 12,13- γ -lactone with a spiro-carbon at C-9,¹³² while ciliatolide A (**1094**) from *Scapania ciliata* contains a 12,10- γ -lactone as well as a 14,6- γ -lactone (the latter ring is comparable with a 18,6- γ -lactone in a non-degraded clerodane).¹⁹¹ Teucrolin D (**1095**) and teucrolivin F (**1096**) from *T. oliverianum* also contain a 12,10- γ -lactone as well as a 4,14 spiro-oxirane (identical to a 4,18 spiro-oxirane in a non-degraded clerodane).^{133,146} Compound **1097** from *Jamesoniella colorata* is a degraded clerodane (rearranged drimane)-type sesquiterpenoid.³⁹²



2.9.3 Ring-*seco* Derivatives ^{75,108,119,121,128,131,144,155,187,250,252,263,270,393-398} (Table 31 – compounds 1098–1145 found in Supplementary Material)


Seco-derivatives have an opened ring at some point in the structure, creating multiple interesting compounds, depending on which bond is broken and what additional rearrangements are present. The first examples are 9,10-*seco*-clerodane diterpenoids.^{119,128,393-395} Although the configuration of the C-8/C-9 epoxide in jamesoniellide F (**1098**) from the liverwort *Jamiesoniella autumnalis* could not be determined absolutely by NMR, this 9,10-*seco*-clerodane likely is a biogenetic product of *cis*-clerodane **1110** found in the same plant.¹¹⁹ Salvianduline A (**1102**) and pyrrophappolide (**1104**) from *Salvia lavanduloides* and *Microglossa pyrrophappa*, respectively, are both 9,10-*seco*-clerodanes, but contain a 17,12- δ -lactone and a 20,12- γ -lactone, respectively. Compound **1111** is a 9,10-*seco*-clerodane with a fully saturated benzofuran rather than decalin bicyclic skeleton.¹⁰⁸ A C-7/C-10 ether bridge plus a hydroxyl on C-10 forms a hemiketal. Other 9,10-*seco*-clerodanes contain a C-8/C-10 ether bridge.^{119,187,393} Among several compounds of this type from *Cephaloziella kiaeri*, cephaloziellins H and I (**1115**–**1116**) are C-8/C-10 hemiketals, while one additional degree of unsaturation in cephaloziellin J (**1117**) was indicative of a

second ether bridge between the C-10 ketal carbon and the C-11 oxygenated methine.¹⁸⁷ Furthermore, in cephaloziellin K (**1118**), the hemiketal bridge found in **1115** and **1116** is absent.¹⁸⁷ Both jamesoniellides B (**1121**) and A (**1120**), from *J. autumnalis*, have a C-8/C-10 ether bridge; however, the B-ring in the former compound is opened between C-9 and C-10, while that in the latter compound is fragmented between C-8 and C-9.¹²¹




In various 5,10-*seco-neo-clerodanes*,^{131,155,250,263,270} the unsaturated patterns of the “opened” decalins include 2,4,10(1)-triene (cyclodeca-1,3,5-triene) (e.g. **1122**),²⁵⁰ 10-oxo-2,4-diene (cyclodeca-3,5-dien-1-one) (e.g., **1123**),²⁵⁰ and 1,3,5(19)-triene (5-methylenecyclodeca-1,3-diene) (e.g., **1124**)⁷⁵ conjugated systems. Salvimicrophyllin A (**1122**) from *S. microphylla* was unstable in solution and decomposed on exposure to light and heat.²⁵⁰ The relative configuration of salvimicrophyllin B (**1123**) was confirmed by single-crystal X-ray diffraction crystallography.²⁵⁰ The epimeric hemiacetals **1125/1126** and acetals **1127/1128** could not be separated when isolated from *Conyza welwitschii*.²⁶³ Compounds **1132** and **1135** from *Conyza* and *Dodonaea* species, respectively, have the same ethylfuran side chain at C-9 but different double bond patterns in the cyclodecane ring, 1,3,5(19) and 2,4,10(1), respectively.^{131,155} Tonalensin (**1136**) from *S. tonalensis* is an interesting 5,10-*seco-neo-clerodane* containing an acetal at C-20 with oxygens from C-7 and C-11 forming two fused tetrahydrofuran rings. Its


trans,cis,cis-cyclodecatriene ring adopts a boat-chair conformation in which the $\Delta^{1,3,5}$ -triene system is no longer coplanar.³⁹⁶



Tinosporafuranol (**1137**) and tinosporafuranadiol (**1138**), obtained from the stem bark of *Tinospora cordifolia*, are 4,5-*seco*-clerodane-type diterpenoids.³⁹⁷ The single-crystal X-ray diffraction analysis of 5,6-*seco*-compound **1139** established a 5α -configuration for the C-19 acetoxymethylene group, as well as the absolute stereochemistry. In the crystalline state, the substituted cyclohexane ring of **1139** is in a chair conformation, with a mean torsion angle of 57° .¹⁴⁴ Both rhyacophiline (**1140**) and salvireptanolide (**1141**) from *S. rhyacophila* and *S. reptans*, respectively, have novel skeletons characterized by cleavage of the C-5/C-6 bond and aromatization of the A-ring.^{252,398} Compound **1140**'s structure was fully established by spectroscopic and X-ray diffraction analyses.³⁹⁸ Jamesoniellide J (**1142**) from *J. autumnalis* is a *seco*-clerodane diterpenoid cleaved between C-8 and C-9.^{187,393}




1137 R = H
1138 R = OH





2.9.4. Rearranged Derivatives ^{55,75,81,98,113,128,164,187,219,220,240,271,276,290,392,399-415} (Table 32 – compounds 1146–1224 found in Supplementary Material)

The clerodanes in this group have a vast scope of ring numbers, sizes, and fusions. The “usual” decalin systems are especially affected, but rearranged C-9 side chains also occur. In various abeoclerodane diterpenes with a (4→2) rearranged ring A moiety, C-3 is generally an aldehyde (e.g., **1149**) or carboxylic acid (e.g., **1152**) attached to the five-membered ring A. ^{55,81,98,219,220,240,399} However, compound **1146** from *Solidago altissima* is also a homoditerpene with 21 carbons [a methyl (C-21) is attached to a C-3 oxo group] and could have resulted from reaction of a C-3 aldehyde with diazomethane used to esterify the extract.⁵⁵ In addition to the rare contracted ring A, pentandranoic acid A (**1153**) from *Callicarpa pentandra* also contains an 12-oxo-13(16)-methylene in a C-9 pentanoic acid side chain rather than the C-9 ethyl- α,β -unsaturated- γ -lactone of pentandralactone (**1154**), also found in the same plant.⁹⁸ Compound **1155** was isolated from *Polyalthia viridis* as a 1:1 mixture of C-16 epimers.²¹⁹




Compounds **1157**–**1160** contain an expanded seven-membered A-ring where C-19 is inserted between C-4 and C-5.^{164,400,401} In **1157** from *Portulaca pilosa*, this novel bicyclo[5.4.0]undecane *trans*-clerodane skeleton also has an ether bridge at C-3→C-5 in the A-ring.⁴⁰⁰ Scapanialide B (**1160**) from *Scapania parva* is the first *cis*-clerodane diterpenoid with a bicyclo[5.4.0]undecane skeleton isolated from liverworts.¹⁶⁴ Compounds **1161**–**1163** from two *Salvia* species⁴⁰²⁻⁴⁰⁴ also contain a seven-membered A-ring; however, this ring includes C-6, rather than C-19. In addition, C-11 has been inserted between C-8 and C-9, creating a phenyl B-ring fused to a γ -lactone, in a tricyclic skeleton.






Notably, compounds **1164–1166** from three different *Salvia* species have a novel rearranged A/B ring spiro-fused neoclerodane skeleton with the spirocyclic junction at C-10.^{113,402,405} The structure of spiroleucantholide (**1164**) might be derived biogenetically by a ring contraction of the seven-membered ring in a precursor benzocycloheptatriene skeleton to form a spiro-fused junction. This report was the first to identify a spiro-6/6 A/B ring diterpenoid derived from a neoclerodane skeleton.⁴⁰²




Compounds **1167–1171**, also from various *Salvia* species, contain a salvigenane skeleton with a seven-membered B-ring, which contains C-11 inserted between C-8 and C-9.^{113,403,404,406,407} Like in **1161–1163**, a fused γ -lactone is also present. However, the A/B ring sizes are 7/6 in **1161–1163**, but 6/7 in **1167–1171**.





X-ray crystal structure determination of blepharolide A (**1172**) showed a 5,6-unsaturated octahydro-1*H*-cyclopropa[α]naphthalene derivative, which presented a new rearranged

clerodane structure with a C6-C6-C3 ring system. This new skeleton was named isosalvigenane. The isolation of salvigenane (blepharolide B, **1167**) and isosalvigenane (blepharolide A, **1172**) diterpenoids from *Salvia blepharophylla* suggested a botanical chemotaxonomic relation between sections Fulgentes, Albolanatae and Brandegeia of subgenus Calosphaea.⁴⁰⁶ Tilifodiolide (**1173**) from *Salvia dugesii* was the first natural product with a substituted tetralin skeleton; its unusual structure was confirmed by X-ray diffraction analysis.²⁷⁶ A biogenetic derivation of both **1173** and the co-isolated **1161** from a clerodane precursor was postulated.




The rearranged clerodane diterpenes baenzigerides A (**1174**) and B (**1176**) and the related open-ring glucosides, baenzigerosides A (**1175**) and B (**1177**), were isolated from the stems of *Tinospora baenzigeri*.^{408,409} The novel skeleton of baenzigeride A (**1174**) could be produced from the *cis-ent*-neoclerodane epoxide (A) (**Scheme 2**). Rearrangement with ring-A contraction through migration of either the 1–2 or 3–4 bond would give the aldehyde (B). Reduction of B should give the primary alcohol (C), which could lactonize to **1174**. Although epoxides such as (A) have not been found as natural products, the known clerodane 2,3-epoxides, e.g., jateorin, do have a 1,18-lactone group.⁴⁰⁸






Scheme 2. Possible biogenesis of baenzigeride A (**1174**).

The vapor and condensed solid resulting from heating salvinorin A (**9**) to 245 °C for 10 min were combined as a chloroform extract, from which two new rearranged clerodanes (**1178–1179**), were isolated. The major structural changes to **9** were epimerizations at C-2 and C-8, eliminations of acetoxy and methyl ester groups, and carbon-carbon rearrangements at C-1, C-2, and C-10. Compounds **1178** and **1179** are unique salvinorin derivatives with interlocking five-membered cyclopentane and six-membered anhydride rings; the 3-oxabicyclo[3.2.1]octane-2,4-dione system was confirmed by X-ray analysis.²⁷¹




Microphyllandiolid (**1180**) from *Salvia microphylla* represents the first example of a new framework with a 9/3 bicyclic ring system (microphyllane skeleton). A plausible

biogenetic pathway to this new skeleton arises from proposed transformations of other *neo*-clerodane diterpenes isolated from *Salvia* species, involving pericyclic reactions. As shown in **Scheme 3**, an electrocyclic opening of the decalin ring of the diene (**a**) would give the triene (**b**). Cyclopropanation of (**b**) would give (**c**), and finally, allylic oxidation of (**c**) would provide the C-3 hydroxy group of **1180**.⁴¹⁰




Scheme 3. A Plausible Biogenetic Pathway to **1180**.

Compound **1181** from *Teucrium betonicum* is a biogenetically unexpected diterpenoid with a new 7β -homo-19(5 \rightarrow 18)*abeo*-*neo*-clerodane skeleton.⁴¹¹ Its structure was established by spectroscopic means, including an X-ray diffraction analysis.




Both *Microglossa pyrhopappa* (e.g., **1182**, **1186**) and *Pteronia divaricata* (e.g., **1190**) provided rearranged clerodanes with a 2-oxabicyclo[2.2.1]heptan-3-one system most likely formed by Wagner-Meerwein rearrangement; compound **1182** also has a 7,8-epoxide.^{75,128} Ring-A of **1194** (*M. pyrhopappa*) and **1195** (*P. incana*) is a cyclopentene ring substituted with hydroxymethyl (C-3), and the former compound has an additional hydroxy group at C-6.^{75,128} Pteroniatriolactone (**1198**) from *P. eeni* has the same rearranged carbon skeleton as **1186** with the addition of a third lactone between C-2

and C-19 (OC=O). An inseparable mixture of related 3:1 epimeric hemiacetals 19- α - and 19- β -hydroxypteronia dilactone (**1196**, **1197**) was also isolated.⁷⁵ Eeniolide (**1199**), also from *P. eeni*, was probably formed biogenetically from an 8,10-dihydroxyclerodane diterpenoid, with cleavage of the C-9/C-10 bond and formation of a C-9/C-8 double bond, followed by ring-A/B reclosure at C-17/C-10.⁷⁵




Jamesoniellide C (**1200**) with the same side chain (furanyl-methylene-dihydrofuranone) as **1199** but a 5/6 rather than 6/6 skeleton was isolated from the liverwort *Jamesoniella autumnale* along with the interesting 8,9 and 9,10-*seco*-clerodanes **1200** and **1201** (see Section 2.9.3).⁴¹² Compounds **1201–1206** with a novel rearranged tetrahydrobenzofuran fused to the decalin through a C₈-C₁₆ bond were isolated from *Teucrium alyssifolium*.^{413,414} Although **1205** and **1206** were structurally quite similar to **1201–1204**, the presence of a C-7/C-19 hemiketal bridge in the former compounds was the main difference between these two related groups.^{413,414} Salvilanguiduline A (**1207**) from *Salvia languidula* illustrates a rearranged clerodane skeleton containing an epoxy spiro γ -lactone function and a C₁-C₁₃ bond.⁴¹⁵ The structure of the rearranged clerodane cephaloziellin O (**1215**) isolated from the Chinese liverwort *Cephaloziella kiaeri* was confirmed by single-crystal

X-ray diffraction analyses, and the absolute configurations of 16 new clerodane diterpenoids, cephaloziellins A–P, were established by comparing experimental and calculated electronic circular dichroism spectra.¹⁸⁷




Teucrium brevifolium yielded several clerodanes containing an unusual rearranged skeleton with an eight-membered ring carbocycle (e.g., **1217**, **1219**, **1221**).²⁹⁰ The ring conformation in each compound was established by exhaustive NMR spectroscopic studies as well as X-ray data on **1221**. A biogenetic pathway from teubrevin D (**747**) was postulated to explain the formation of the 5,10-*seco*-9(8→19)*abeo*-*neo*-clerodane skeleton (**1219**, **1221**) and the 7,8,17-trinor derivatives (**1217**).²⁹⁰



The leaves of *Salvia xalapensis* yielded two new clerodane-type diterpenoids with an opened (C₅–C₆) unsaturated ring-B skeleton, salvixalapadiene (**1223**) and isosalvixalapadiene (**1224**).⁴⁰⁷ Both compounds have a phenyl A-ring and two double bonds in the opened B-ring at C₆₋₇/C₈₋₁₁ and C₇₋₈/C₉₋₁₁, respectively. Their unprecedented rearranged skeleton may be derived biogenetically from a salvigenane precursor.

Salvixalapoxide (**1222**) with a languidulane skeleton was also isolated at the same time.⁴⁰⁷



2.10. NMR Features of Clerodane Diterpenes


NMR spectroscopy, especially ^{13}C NMR analysis, has been widely employed for the characterization of the different skeletons of clerodane diterpenes. The assignments of carbon signals of a new clerodane diterpene by comparison with the data of known compounds require the ^{13}C data of appropriate model compounds. It would appear to be of value to provide an easy access to an extensive list of ^{13}C data of these diterpenes. Inspection of the chemical shifts of different types of clerodanes revealed that the main differences among the seven structural types (I–VII) are related to the number of methyl groups (C-17 or C-20 are absent, in the IV and V structural types, respectively), and chemical shifts of C-8, C-12, C-17, and C-20. The characteristic spectroscopic features associated with these seven different structural types I–VII are summarized in Table 33.

Table 33. Characteristic ^{13}C NMR chemical shifts of Types I–VII (δ_{C} , ppm)

	I	II	III	IV	V	VI	VII
C-5	37→40	35→55					
C-8	31→38	31→45		46→52	35→47		79
C-9			38→40		51→54		37
C-10	10 β -H: 46 10 α -H: 50	10 β -H: 42→50	48→52				
C-11						84→87	
C-12	32→38	17→27		70→73	68→75		
C-13		123→129	168→176	120→125	125→130	40→42	75→77
C-14		108→111	112→117	108→110	108→117		
C-15		136→146	172→175	144→146	138→145	68	173→176
C-16		137→148	70→74	138→140	138→145	102→108	76→80

C-17	16→18	13→18	169→177	14→20
C-20	18	16→18	14→26	172→178
		$\Delta^{5,10}$: 140	$\Delta^{7,8}$: 170,100	

Clerodanes that possess a furan ring at C-12 show carbon resonances between δ_C 123→132 (C-13), δ_C 107→114 (C-14), δ_C 138→146 (C-15), and δ_C 137→148 (C-16). In clerodane diterpenes containing a Δ^3 double bond (C-3: δ_C 120→130; C-4: δ_C 130→145), the chemical shifts of these carbons are affected by the presence of the substituents at C-18. When this carbon contains a carboxyl or carboxymethyl group, C-3 (ca. δ_C 133) and C-4 (ca. δ_C 149), are deshielded. However, when C-18 is an aldehyde group, C-3 (δ_C 152.4) and C-4 (δ_C 151.7) are more deshielded. On the other hand, in clerodane diterpenes containing a $\Delta^{1,3}$ double bond and a carboxymethyl group at C-18, resonances occur between δ_C 133→134 (C-1), δ_C 123→125 (C-2), δ_C 132→136 (C-3), and δ_C 134→137 (C-4). In the structural type **IV** containing a Δ^7 double bond, carbon resonances appear at δ_C 172 (C-7) and δ_C 100 (C-8). For compounds having a Δ^4 double bond and C-18 as a methyl group, C-4 and C-5 resonate at δ_C 125.7 and 134, respectively. If C-18 is part of a lactone ring, these carbons are deshielded [δ_C 127.6 (C-4) and 162 (C-5)]. An epoxy ring at C-4 and C-18 leads to carbon signals at δ_C 63→67 (C-4) and δ_C 43→51 (C-18).



3. Biological Activities


Clerodane secondary metabolites may benefit a plant species by acting as a chemical defense mechanism against phytophagous animals or diseases. Apart from insect antifeedant properties, several clerodane diterpenes display other effects against insects. Insecticidal activity has been reported for ajugarins I and IV.^{416,417} Ajugarin IV also displays insect growth regulating activity, as do 3-*epi*-caryoptin⁴¹⁸ and the 19-*nor*-clerodanes *cis*- and *trans*-dehydrocrotonin.⁴¹⁹ Fungicidal activity against plant pathogenic fungi has been reported for clerodin and the related jodrellins A and B.³²⁶

Besides insect antifeedant and antifungal activities, many clerodane diterpenes possess various pharmacological activities beneficial to humans, including action as opioid receptor probes, as well as NGF-potentiating, anti-ulcer, cytotoxic, anti-inflammatory, antiparasitic, and antibacterial activities.

3.1. Insect Antifeedant Activities


3.1.1. Insect Antifeedant and Related Plant Protective Activities of Clerodane Diterpenes

Clerodane-type secondary metabolites have attracted considerable attention as insect antifeedants, which is by far the most extensively studied bioactivity of these diterpenes. Clerodane diterpenoids have been found in several hundreds of plant species from various families and in organisms from other taxonomic groups, such as fungi, bacteria, and marine sponges.⁴²⁰⁻⁴²² Especially, various genera from the plant families Lamiaceae have been identified as rich sources of antifeedant clerodanes, with species of the genus *Scutellaria* producing some of the most potent clerodane antifeedants known so far.^{306,330,423-426} The most active compounds from these species against larvae of *Spodoptera littoralis* (cotton leafworm) were scutalpin C (**497**), scutecyprol B (**810**), jodrellin A (**860**), jodrellin B (**861**), and dihydroclerodin (**1225**), with corresponding Feeding Index (FI) values of 92 ± 8 , 100 ± 0 , 95 ± 16 , 100 ± 0 , and 97 ± 1 , respectively. In addition, **810** showed potent activity against several other species of Lepidoptera.⁴²⁶




Ajubractins A–E (**855–856**, **795–797**) and 15-epi-lupulin B (**821**) were isolated from a dichloromethane extract of *Ajuga bracteosa*.³⁰¹ Among them, **795–797** and **821** showed moderately high antifeedant activities (FR = 0.14–0.15). Data analysis from the behavioral responses of *S. littoralis* exposed to the clerodane diterpenoids hativenes A–C (**827–829**), from *Ajuga pseudoiva*, showed that all of the compounds tested had strong antifeedant activity at 100, 10, and 1 mg⁻¹, which began to dissipate at 0.1 mg⁻¹.³¹⁷ Comparison of the antifeedant index at the latter two concentrations also indicated that a change in the relative configuration of carbons C-12 and C-15 did not modify the activity


considerably. 14,15-Dehydroajugareptansin (**859**), from *Ajuga reptans*, had significant activity against sixth stadium larvae of *Spodoptera littoralis*.²⁰⁷ Overall, these data, compared to those of other clerodanes isolated from *Ajuga* and *Salvia* species, helped to clarify different authors' suggestions and conclusions, which related the antifeedant activity of clerodanes to the presence of a perhydrofuranofuran moiety, a *trans* decalin ring system bearing an epoxide, and acetate groups.



Clerodin (**2**), 15-methoxy-14,15-dihydroclerodin (**1226**), and 15-hydroxy-14,15-dihydroclerodin (**1227**) exhibited growth inhibitory activity against *Helicoverpa armigera* (cotton bollworm) with growth inhibition index (GI₅₀) values of 13, 21, and 11 ppm, respectively, compared to azadirachtin, the active ingredient of many pesticides, with a GI₅₀ value of 15 ppm.⁴²⁷ Clerodin (**2**), clerodendrin B (**849**), 3-epicaryoptin (**1228**), and 15-hydroxyepicaryoptin (**1229**) were effective antifeedants at 10 μg/cm³ of diet against *Earias vitella* and at 10 μg/cm² of leaf against *Spodoptera litura*.⁴²⁸ In addition, **2**, **122**, **849–850**, **1229**, and 2-acetoxyclerodendrin B (**1230**) showed good insect growth inhibitory activity, even at lower concentrations. In contrast, clerodendrin H (**851**), from *Clerodendron trichotomum*, distinctly stimulated feeding activity in adult turnip sawflies.³²⁵



Jodrellins A and B (**860–861**) and the reference compound clerodin (**2**) also reduced the growth of the plant pathogenic fungus *Fusarium oxysporum* f. sp. *Lycopersici* after 18 hr, and **861** and **2** maintained growth inhibition at 50 and 100 ppm after 66 hr. Compound **2** delayed germination of *Verticillium tricorpus* spores at 25, 50 and 100 ppm after 42 hr, and **861** had similar effects even at 66 hr. This study suggests that certain *neo*-clerodane diterpenoids may contribute to antifungal, as well as anti-insect, protection in plants.³²⁶ Clerod-14-ene-3 α ,4 β ,13 ζ -triol (**1231**) from *Viguiera tucumanensis* inhibited both germination and root growth of *Sorghum halapense* and *Chenopodium album* and also slightly inhibited *Ipomoea purpurea*.⁴²⁹ Allelopathic agents with phytogrowth inhibitory effects are attractive new leads for development of agrochemicals.




1231

3.1.2. Compilation of Structure–Activity Relationships of Clerodane Insect Antifeedants

To date, over 300 natural and semi-synthetic clerodanes have been examined in laboratory assays, yielding several compounds with potent antifeedant activity against various insect species, but it is not known whether this activity will be retained under field conditions. A comprehensive compilation of all test results on the insect antifeedant activity of clerodane diterpenes resulted in some interesting trends based on only the 10–

20% of the most active clerodanes per insect species.^{12,430}

- i. Active clerodanes generally have a *trans*-decalin *neo*-clerodane skeleton.
- ii. In the most potent clerodanes, the C-9 side chain fragment contains an oxygenated ring system. A furofuran-based structure appears to be most favorable for strong activity against many Lepidopteran insect species. Furan and butenolide side chains are also frequently found in the most potent clerodanes, and hydrogenation of these unsaturated moieties usually results in lower potency.
- iii. Structural elements from (i) and (ii) must be present simultaneously to produce high activity. However, a number of exceptions to this general observation are known. For example, while decalin **1233**, which has the more common 4 α -O epoxide, but no C-9 side chain, was inactive against *L. migratoria*, the decalin **1232** with a 4 β -O epoxide showed equal antifeedant activity under no-choice conditions as the clerodane derivative **1234**.¹²




* Synthetic and semisynthetic analogues

- iv. In addition to (iii), the key structural elements from (i) and (ii) must be able to adopt a certain spatial orientation for the compound to exert high activity. Indeed, the stereoelectronic factors are more important than the hydrophobic aspects as determinants of antifeedant activity. In addition, a furan ring in the side chain and a carbonyl α,β -unsaturated (or *spiro*-epoxide) group appear to be crucial. A conformational study indicated that the optimum interatomic distance between these

two moieties ranged from 9.5 to 10.5 Å.^{431,432}

For example, bacchotricuneatin A (**1235**), 7 α -hydroxybacchotricuneatin A (**1236**), **1237**, azadirachtin (**1238**), and the D-ring aromatic withanolide **1239** exhibited remarkable feedant-deterrent activity against *T. molitor* with PFI values of 22.62, 26.60, 25.03, 29.57, and 29.89, respectively.⁴³¹



- v. Both rings in the decalin fragment are often substituted with hydroxy, epoxy, or ester groups, but none of these moieties can be concluded to be essential for antifeedant activity. However, slight changes in the exact identities and orientations of such groups can affect the potency of the antifeedance effect.

The general observations in (i)–(v) represent a reasonable summary of the structural features involved in the overall antifeedant activity of clerodane diterpenes. However, the underlying mechanisms of insect antifeedant activity are certainly more complex than implied by this abridged picture.


3.2. Opioid Receptor Agonist

3.2.1. Salvinorin A as a Probe in Opioid Pharmacology and Other Salvinorin Analogues


The discovery of salvinorin A (**9**) as the first non-nitrogenous natural product with high affinity and efficacy at the κ -opioid receptors (KOR) led to a reevaluation of whether a basic nitrogen is necessary for opioid receptor affinity and efficacy. With

similar potency to LSD, compound **9** is one of the most potent naturally occurring hallucinogens, and appears to have distinctive properties at KOR, including ultra-high efficacy in particular transduction systems and a lower tendency to cause receptor desensitization.⁴³³⁻⁴⁴² In mice, it produces antinociception that can be blocked by KOR antagonists.^{443,444} It also produced an aversive response in the conditioned place preference assay,⁴⁴⁵ blocked the locomotor-stimulant effects of cocaine,⁴⁴⁶ and did not exert 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM)-like effects in nonhuman primates.⁴⁴⁷ Interestingly, compound **9** has low affinity for the μ -opioid receptor (MOR), although it does show allosteric MOR modulation.⁴⁴⁸ It exhibited deleterious effects on learning and memory, acting via a KOR mechanism.⁴⁴⁸⁻⁴⁵⁰

Phytochemical studies on *S. divinorum* led to the isolation of many clerodanes, including salvinorins C–J (**659–662**, **1240**, **663–665**), divinatorins A–F (**405–407**, **409–410**, **1241**), salvinicins A (**684**) and B (**685**), and salvidivins A–D (**686–687**, **587–588**).^{166,167,235,263-266,273,451} (The structures of **409–410**, **659**, **686**, **1240**, and **1241** are shown below, the remaining compounds can be found in the Structure Tables in Supplementary Material.) In a modification study of **9**, salvinorin C (**659**) had 250-fold lower KOR affinity compared with **9** ($K_i = 1022$ nM vs $K_i = 4$ nM).⁴⁵² Divinatorins D (**409**) and E (**410**) also had reduced KOR affinity compared with **9** ($K_i = 230$ nM and $K_i = 418$ nM, respectively, vs $K_i = 1.0$ nM).¹⁶⁷ Uniquely, salvidivin A (**686**) was identified as the first naturally occurring neoclerodane with KOR antagonist activity ($K_e = 440$ nM).⁴⁵³ Among dicarboxylic acid esters of **9**, the methyl malonyl derivative (**1242**) showed the highest binding affinity ($K_i = 2$ nM), although analogues **1243–1245** still exhibited significant KOR affinity ($K_i = 21$, 36, and 39 nM).⁴⁵⁴ 12-*epi*-Salvinorin A (**1246**), synthesized in four steps from **9**, was a selective partial KOR agonist. It partially activated signaling through G proteins, yet acted as a full agonist in the β -arrestin 2 DiscoverRx assay.^{455,456}



Of the derivatives of **9** reported to date, salvinorin B ethoxymethyl ether (**EOM-SB**) is the most potent. It exhibited ten-fold greater potency than **9** *in vitro* and in rodents, and had a longer duration of action in rodents.⁴⁵⁷⁻⁴⁶⁰ In addition, 22-thiocyanato- (**RB-64**) and 22-chloro-salvinorin A (**RB-48**) were both extremely potent and selective KOR agonists *in vitro* and *in vivo*.⁴⁶¹



3.2.2. Structure–Activity Relationships of Salvinorin A Analogues

The general SAR studies of **9** have been performed by semi-synthetic structure modifications, and have mainly focused on **9**'s high affinity and selectivity for the KOP receptor. Some of these analogues have interesting pharmacological profiles, from full KOR agonist to partial δ -opioid receptor (DOR) or μ -opioid receptor (MOR) agonists and antagonists.^{13,448,453,462-464} The SAR is summarized in **Figure 5**.^{13,457,465-471}





Fig. 5. General SAR for salvinorin A activity at KOP receptors.
[Adapted from Prisinzano TE and Rothman RB, Chem Rev., 2008, 108, 1732-1743.]

At the C-1 position, the reduction or removal of the carbonyl is tolerated, and introduction of a 1,10-alkene increases the possibility of antagonist activity.

At the C-2 position, (1) the size and electronegativity of the substituent at the C-2 position is critical for activity at opioid receptors. Bioisosteric replacements of the ester moiety are tolerated. (2) α -Substituents are preferred over the corresponding β -substituents. (3) In general, small alkyl esters favor binding to KORs. The compounds


with methoxymethyl (**1247**) and ethoxymethyl (**1248**) ethers at this position are among the most potent **9**-derived KOR agonists reported to date, while aromatic esters favor MOR binding.^{13,472} Different aromatic groups attached directly to the decalin core can be allowed by KOR.⁴⁷³



At the C-4 position, (1) small alkyl chains are preferential for KOR binding, while (2) hydrolysis or reduction of the carbomethoxy group leads to reduced KOR affinity at KOPs, and (3) conversion to an amide is generally not tolerated.^{13,472}

Furthermore, the furan ring at C-12 may be reduced or replaced, but KOR affinity is reduced. The reduction or removal of the carbonyl at C-17 and the introduction of an 8,17-alkene are tolerated.^{13,472}


Finally, degradation of the furan ring and/or replacement with other heterocycles is tolerated. Moreover, such a modification produced the first DOR selective ligand (**1249**) with the scaffold of **9**.^{13,472}




3.3. NGF-potentiating Activities

With EC₅₀ values of 20.2, 12.7, 4.0 and 2.4 $\mu\text{g/mL}$, balanspenes D–G (**13–16**), which have a 18,19-expoxy clerodane-type diterpene skeleton with an additional double bond at


C-3 and C-4, markedly increased the nerve growth factor NGF (20 ng/mL)-induced quantity of neurite-bearing cells.¹⁵ An equilibrium mixture of ptychonal (**380**) and ptychonal hemiacetal (**329**), 6 α ,7 α -dihydroxyannonene (**382**), and 7 α ,20-dihydroxyannonene (**383**), significantly enhanced NGF-mediated neurite outgrowth in PC12 cells at concentrations ranging from 0.1 to 50.0 μ M, 0.1 to 30.0 μ M, and 0.1 to 10.0 μ M, respectively.^{130,474} At 10, 30, and 100 μ mol, compounds **435** and **436** had no effect on neurite outgrowth from PC12D cells in the absence of NGF, but at 100 μ mol, decidedly increased the NGF (2 ng/mL)-induced proportion of neurite-bearing PC 12D cells by 49% and 53%, respectively.¹⁷⁴



Both crotopenes A and B (**764** and **765**) exhibited potentiating activities on NGF-mediated neurite outgrowth from PC12 cells.²⁹⁴ At a concentration of 10 μ M, degraded clerodane compounds **1064**, **1083**, and **1084** exhibited neurite outgrowth-promoting activity in NGF mediated PC12 cells.³⁸²




13-*epi*-15,16-Epoxy-15 α -methoxy-*ent*-clerod-3-en-18-oic acid (**1250**) and 15,16-epoxy-7 α ,18-dihydroxy-15-methoxy-*ent*-clerod-3-ene (**1251**) also markedly increased the NGF (2 ng/mL)-induced proportion of neurite-bearing cells by 49%, 53%, and 68%, respectively⁴⁷⁵



1250 R₁ = COOH R₂ = H
1251 R₁ = CH₂OH R₂ = OH


3.4. Antiulcer Activities⁴⁷⁶⁻⁴⁸²

Trans-dehydrocrotonin (**1076**), *trans*-crotonin (**1252**), cordatin (**1253**), and aparisthman (**1254**)⁴⁸¹ exhibited significant anti-ulcer activities, comparable with those of cimetidine. At a dose of 100 mg/kg (*p.o.*), the four compounds significantly reduced gastric injury induced by stress (67% or 72%), indomethacin/bethanechol (29%, 78%, 71%, 78%, respectively), ethanol (71% or 76%), pylorus ligation (30%, 35%, 59%, 50%, respectively), and hypothermic restraint (50% or 66%) in mice and rats. In the HCl/ethanol-induced gastric ulcer model, at 100 and 250 mg/kg (*p.o.*), gastric lesion formation was decreased by 48.1%, 52.3%; 50.8%, 55.8%; 70%, 59% and 77%, 66%, respectively, when compared to the control group. In the pylorus-ligation model, **1076** and **1252** (*p.o.*), like cimetidine, increased the volume of gastric fluid when compared to the control group, while **1253** and **1254** (*p.o.*) decreased the volume of gastric fluid. Compound **1076** exhibited low acute toxicity in mice (LD₅₀ 876 mg/kg) when administered orally, however, hepatotoxicity resulted from its long-term use.




3.5. Cytotoxic Activities

Casearupestrins A (**21**), B (**22**) and D (**24**) showed significant cytotoxicity against four cell lines (HL-60, HCT-8, MDA/MB-435, and SF-295), with IC_{50} values ranging from 0.10 to 1.3 μ M.¹⁷ Intrapetacins A (**38**) and B (**39**) displayed moderate cytotoxicity against KB cells, with IC_{50} values of 2.0 and 0.8 μ g/mL.²¹ In addition, compound **39** caused a significant (21 mm) zone of inhibition of fungal growth. Bioassay-guided fractionation of the EtOAc extracts of *Casearia membranacea* afforded caseamembrins A–E (**60–64**), M–O (**65–67**), and caseamembrols A (**119**) and B (**68**) as active principles.^{26–28} Compounds **60** and **62–64** exhibited cytotoxic activity against PC-3 and Hep 3B, with IC_{50} values below 3 μ M. Compounds **66** and **67** showed significant activity against KB, DLD-1, and Med tumor cell lines (1.94–8.94 μ g/mL). Compounds **119** and **68** were cytotoxic against PC-3 human prostate cancer cells with IC_{50} values of 2.45 and 5.66 μ M, respectively.²⁸




Laetiaprocerines A–D (**101–103**, **274**) were cytotoxic toward the MCF7 human tumor cell line.³⁶ The structurally similar zuleanin-type compound caseamembrin G (**1255**) was cytotoxic against KB, HeLa, and Hep59T/VGH carcinoma cell lines.⁴⁸³




Esculentin B (**95**) from *Casaria esculenta* and caseargrewiins A–H (**74**, **1256–1258**, **104–107**) from *C. grewiifolia* showed significant cytotoxicity against three cancer cell lines (KB, BC1, and NCI-H187) with IC₅₀ values ranging from 0.1 to 8.7 μg/mL.^{31,37} The most potent compounds were **104** and **106** against KB (IC₅₀ 0.66, 0.67 μg/mL), **1258**, **95**, **105**, and **107** against BC1 (IC₅₀ 0.1, 0.17, 0.20, 0.21 μg/mL), and **104** and **1257** against NCI-H187 (IC₅₀ 0.15, 0.3 μg/mL), respectively, similar values to those for the control

drug ellipticine. Bucidasins A–C (**133–135**) showed potent cytotoxicity against nine human tumor cell lines with IC_{50} values ranging from 0.5 to 1.9 μM .¹⁴




Compound **203** from Brazilian propolis reduced the incidence of skin tumors by inhibiting DNA synthesis via a de novo pathway, and suppressed the tumor growth by decreasing DNA synthesis via a salvage pathway.⁶⁹ Premnones A–C (**234–236**) exhibited cytotoxic activity when evaluated against three human cancer cell lines (Lu1, LNCaP, and MCF-7), and one normal cell line (HUVEC) in the range of ED_{50} of 0.7–7.0 $\mu\text{g}/\text{mL}$.⁸⁰ However, **234** was not active when evaluated in a follow-up *in vivo* hollow fiber assay at the highest dose tested (50 mg/kg), using LNCaP, Lu1, and MCF-7 cells.




Crispene E (**468**) inhibited STAT3 dimerization in a cell-free fluorescent polarization assay and displayed significant toxicity against the STAT3-dependent MDA-MB 231 breast cancer cell line with selective inhibition of the expression of STAT3 and STAT3 target genes cyclin D1, Fascin and bcl-2.¹⁹⁰ Ajugalide B (**507**) exhibited broad spectrum antiproliferative activity against A549, AGS, HepG2, and HT29 human cancer cell lines, with GI_{50} values ranging from 3.18 to 5.94 μM .⁴⁸⁴ Below


its cytotoxic concentration, **507** also reduced the tumorigenic and metastatic ability of A549 cancer cells by inhibiting anchorage-independent growth and cell migration; thus, **507** could be a lead for development of potential cancer chemotherapy.



Clerodermic acid (**548**) induced potent apoptosis against human leukemia HL60 cells.⁴⁸⁵ Compounds **590**, **609**, and **1260** from *Polyalthia barnesii* exhibited their highest potency against LNCaP and U373 cell lines, but generally showed broad spectrum cytotoxicity, with ED₅₀ values of less than 4 $\mu\text{g/mL}$ toward several cell lines.²³⁷ Scutebata L (**597**) exhibited moderate activity against several human cancer cell lines with IC₅₀ values ranging from 12.6 to 26.1 μM .²³¹ Calcicolins A (**598**) and C (**600**) showed significant cytotoxic effects against the D.mel-II and HepG2 cell lines with IC₅₀ values of 2.06, 2.10, and 9.04, 8.30 $\mu\text{g/mL}$, respectively.²⁴² Calcicolin B (**599**) also showed good toxicity against D.mel-II cells (IC₅₀ = 3.09 $\mu\text{g/mL}$) but was not as potent against HepG2 cells (IC₅₀ = 16.16 $\mu\text{g/mL}$).²⁴² Echinoclerodane A (**614**) exhibited moderate cytotoxicity against MOLT-4, HL-60, DLD-1 and LoVo tumor cells and inhibited superoxide anion generation and elastase release by human neutrophils.²⁴⁸ Tinosporin A (**643**) showed low cytotoxicity against HL-60 and MCF-7 cells, with IC₅₀ values of 18.63 and 23.58 μM , respectively.²⁵⁶ Crotonlide A (**713**) exhibited moderate cytotoxicity against HL-60 (IC₅₀ 9.42 μM) and P-388 (IC₅₀ 7.45 μM) tumor cell lines.¹⁶⁵



Many *neo-clerodane* diterpene alkaloids from *Scutellaria barbata* showed significant cytotoxic activity against three human cancer lines (HONE-1 nasopharyngeal, KB oral epidermoid carcinoma, and HT29 colorectal carcinoma cells) (IC_{50} 2.0–8.1 μ M) in various studies.^{230,232,233,367,370,371,378} Examples are shown below (**1001**, **1004**, **1027**, **1034**, **1052**) as well as in prior Section 2.9.1 (**998**, **1008**, **1009**, **1012**, **1030**, **1031**, **1036–1042**).



The rearranged clerodane polylongifoliaic A (**1156**) exhibited potent activity against SK-N-MC human neuroblastoma cells with an IC_{50} value of 1.64 μ M.²²⁰ 16-Oxo-cleroda-3,13(14)*E*-dien-15- oic acid (**1259**) and polyalthialdoic acid (**189**) showed antiproliferative activity against human leukemia HL-60 cells, with IC_{50} values

of 13.7 and 21.8 μM , respectively, compared with 5-fluorouracil's IC_{50} of 9.5 μM .^{60,487}




Table 34 lists cytotoxicity results found for casearins A–R (**1261–1278**) against V-79 cells.^{488,489} Three compounds without an oxygenated substituent at C-6, casearins G (**1267**), H (**1268**) and I (**1269**) showed the highest potency (IC_{50} 0.17–0.51 μM). Casearins J (**1270**) and K (**1271**) with a hydroxy moiety at C-6 exhibited similar or slightly weaker activity (IC_{50} 0.52 and 1.1 μM , respectively) than **1267–1269**. Casearins L (**1272**) and M (**1273**) have a hydroxy moiety at C-7 rather than C-6, and showed slightly reduced activity (IC_{50} 1.6 and 1.8 μM , respectively). Casearin C (**1263**), with an interesting decanoate at C-7 exhibited significant potency (IC_{50} 0.77 μM), while a related compound, casearin E (**1265**) with the same decanoate group but slightly different oxygenated substituents at C-6 and C-18 was much less potent (IC_{50} 4.7 μM). The authors postulated that the greater hydrophobicity of **1263** might increase its affinity for the V-79 cell membrane leading to significant activity. Furthermore, casearins A (**1261**) and D (**1264**) were converted to derivatives A_a (**1279**), A_b (**1280**), A_c (**1281**) with oxo, propionate, and butanoate groups, respectively, at C-6 and D_a (**1282** with oxo groups at both C-2 and C-6. Only compound **1279** retained cytotoxic potency (IC_{50} 0.55 μM); compounds **1280–1282** had greatly reduced activity (IC_{50} 17, 38, 19 μM , respectively). Thus, the bulkiness of the C-6 group could greatly influence the activity.^{489,490} In other studies, the structurally similar casearin X (**1283**) and caseargrewiin F (**105**), which do not have an oxygenated group at C-7, showed cytotoxic activity against MOLT-4, MDA-MB-435, HCT-8, and SF-295 human cell lines, with IC_{50} values from 0.22 to 0.97

and 0.09 to 0.17 μM , respectively. Their lower cytotoxicity against L-929 cells (IC_{50} 1.52 and 1.06 μM) perhaps indicated a more selective cytotoxic response to tumor cell lines.⁴⁹⁰ Other zuleanin-type clerodanes, casearvestrins A–C (**87–89**), had comparable IC_{50} values between 0.2 and 0.8 μM against a panel of tumor cell lines, including LX-1, HCT116, and A2780.³⁴




Table 34. Structures and cytotoxic data (V-79 cells) of casearins and their derivatives


Casearin	R ₁	R ₂	R ₃	R ₄	R ₅	IC ₅₀ ($\mu\text{mol/L}$)
A (1261)	OCH ₃	Ac	Ac	OH	OBu	1.0
B (1262)	OCH ₃	Ac	Ac	OAc	OBu	8.5
C (1263)	OH	Ac	Ac	OAc	ODc	0.77
D (1264)	OH	Bu	Ac	OH	OBu	1.8
E (1265)	OH	Et	Ac	OH	ODc	4.7
F (1266)	OH	Et	Ac	OH	OBu	29
G (1267)	OCH ₃	Ac	Ac	H	OBu	0.17
H (1268)	OH	Ac	Ac	H	OBu	0.37
I (1269)	OH	Ac	Bu	H	OBu	0.51
J (1270)	OCH ₃	Bu	Ac	OH	OBu	1.1
K (1271)	OAc	Ac	Ac	OH	OBu	0.52
L (1272)	OCH ₃	Bu	Ac	OAc	OH	1.6
M (1273)	OH	Bu	Bu	OAc	OH	1.8
N (1274)	OCH ₃	Ac	Bu	OAc	OBu	5.9
O (1275)	OCH ₃	Bu	Ac	OAc	OBu	6.0
P (1276)	OCH ₃	Ac	Ac	OAc	OAc	7.8
Q (1277)	OH	Ac	Ac	OAc	OBu	4.3
R (1278)	=O	Ac	Ac	OH	OBu	5.4
A _a (1279)	OCH ₃	Ac	Ac	=O	OBu	0.55
A _b (1280)	OCH ₃	Ac	Ac	OPr	OBu	17

A _c (1281)	OCH ₃	Ac	Ac	OBu	OBu	38
D _a (1282)	=O	Bu	Ac	=O	OBu	19
X (1283)	Bu	Bu	Ac	OH	H	

*Ac = acetate, Bu = butanoate, iBu = isobutanoate, Hx = hexanoate, Dc = decanoate

Mechanistic investigations showed that **1264** can protect DNA against different types of damage and act as an antioxidant by inducing detoxificant enzymes in HepG2 cells; these actions give rise to interesting chemopreventive characteristics in both HepG2 cells and the *Salmonella typhimurium* bacterial strain.⁴⁹¹ Finally, casearin X (**1283**) showed potent cytotoxic effects against CEM and HL-60 lines (IC₅₀ 0.4 μM) and PBMC cells (IC₅₀ 1.2 μM) and caused cell death via apoptotic pathways. These data further substantiated the promising antitumor-related properties of casearins.⁴⁹² In addition, **1283** exhibited chemopreventive activity against DNA damage induced by the particulates formed from burning sugarcane, which implied that **1283** can act by different mechanisms to protect DNA against damage, including repairable and non-repairable damages.⁴⁹³

Compounds **1284–1286** showed potent and selective cytotoxicity against P-388, A-549, HT-29, Mel-28 cell lines, with IC₅₀ values of 0.2–2.4 μM.⁴⁹⁴ (–)-Kolavenol (**1287**) increased lifespan (I.L.S.) in mice with IMC carcinoma, and was twice as effective (I.L.S. 98%, 41 mg/kg/day, 4 days) as 5-FU (46%, 30 mg/kg/day, 4 days).⁴⁹⁵ (+)-7β-Acetoxy-15,16-epoxycleroda-3,13(16),14-trien-18-oic acid (**1288**) strongly inhibited P-glycoprotein and likely has promise for development as an MDR-reversing agent.⁴⁹⁶ (5*R*,10*R*)-4*R*,8*R*-Dihydroxy-2*S*,3*R*:15,16-diepoxy-13(16),17,12*S*:18,1*S*-dilactone (**1289**) exhibited a preventive effect against chemically-induced hepatocellular carcinoma (HCC) in rats, and could be a potent chemopreventive drug for HCC.⁴⁹⁷




trans-Dehydrocrotonin (**1076**) and *trans*-crotonin (**1252**) (see structures in Section 3.4) were evaluated for their effects on the survival of mice bearing Sarcoma 180 and Ehrlich carcinoma ascitic tumors, as well as the proliferation of cultured Ehrlich cells and TNF α activity. When the mice were treated with 80 and 120 mg/kg of **1076** or 38 mg/kg of 5-FU, substantial antitumor activity was observed (%T/C 128–140). Both compounds showed a cytotoxic value of 16 μ M against Ehrlich carcinoma in 48 h cell culture. *In vitro* electrophoresis of DNA extracted from the treated tumor cells showed no apoptosis. But significant TNF α activity was detected in Ehrlich tumor-bearing mice treated with **1076**, likely due to enhanced immune function.⁴⁹⁸

3.6. Anti-inflammatory Activities

The hallucinogenic compound salvinorin A (**9**) (see structure in Section 3.2) is a potent KOR agonist. However, its multiple pharmacological effects are likely due to action on other targets, such as the cannabinoid CB1 receptor (CB1R). For instance, it exerted potent anti-inflammatory and antinociceptive effects, as mediated by KOR and CB1R,⁴⁹⁹ and thus, is an interesting new lead compound for the development of novel anti-inflammatory agents targeting KOR and CB1R. This observation also encourages


further studies on **9** leading to the development of novel peripherally restricted derivatives with similar potency and selectivity. Thus, **9**-related compounds may be useful future drugs, especially in patients with inflammatory bowel disease, in which pain is the most pronounced symptom during maintenance of remissions.⁵⁰⁰

Compound **485** inhibited LPS-induced NO production in BV-2 cells dose-dependently with an IC₅₀ value of 28.6±2.6 μM.¹⁹⁴ Tinospinosides B (**956**) and C (**957**) also showed inhibitory effects against NO production.³⁵⁵




E-Isolaridial (**1290**) and *E*-isolaridial methylketone (**1291**) inhibited human synovial sPLA₂ in a concentration-dependent manner with IC₅₀ values of 0.20 and 0.49 μM, respectively, similar to that of scalaridial, an anti-inflammatory marine natural product that selectively inhibits 14 kDa type II phospholipase A₂(PLA₂).⁵⁰¹ In addition, these compounds reduced cell-free 5-lipoxygenase activity and A23187-induced neutrophil LTB₄ biosynthesis, and significantly decreased receptor-mediated degranulation. 6-Oxocleroda-3,13(14)*E*-dien-15-oic acid methyl ester (**1292**) and 16-hydroxycleroda-3,13(14)*E*-dien-15-oic acid (**1293**), displayed significant activity against fMLP/CB induced superoxide generation by neutrophils with IC₅₀ values of 0.6 ± 0.09 and 1.49 ± 0.28 μg/mL, respectively.^{246,436} The suppressive effects of **1293** on human neutrophil respiratory burst and degranulation were due, at least partially, to inhibition of calcium, AKT, and p38 signaling pathways.^{457,502} 3β,4β:15,16-Diepoxy-13(16),14-clerodadiene (**1294**) and thysaspathone (**365**) inhibited

NO production in LPS-stimulated RAW 264.7 cells with IC_{50} values of 20.1 and 11.6 μM , respectively.^{143,438}




3.7. Antiparasitic/Antiprotozoal Activities

Caseargrewiins A–D (**74**, **1256–1258**, see structures in Section 3.5) were active *in vitro* against *Plasmodium falciparum in vitro*, with respective IC_{50} values of 2.9, 2.4, 3.0, and 3.3 $\mu\text{g/mL}$.³¹ Clerodane diterpenoids **227–230** also inhibited the growth of the chloroquine-resistant strain FeB1, with IC_{50} values between 4.3 and 14.6 $\mu\text{g/mL}$.⁷⁸ Penianthic acid (**1295**) and epicordatine (**1296**) exhibited weak activity against chloroquine-resistant strain K1.⁵⁰³ Casearlucine A (**1297**), caseamembrol A (**119**, see structure in Section 3.5), and laetiaprocerines A–D (**101–103**, **274**, see structures in Section 3.5) displayed activity against *P. falciparum* with IC_{50} values as low as 0.5 μM against FeB1 and F-32 strains.³⁶ In addition, compounds **119** and **1297** also showed activity against *Leishmania amazonensis* amastigote axenic stages and promastigote.³⁶ Ajujarin-1 (**1298**) showed moderate *in vivo* antiplasmodial activity, with an IC_{50} of $23.0 \pm 3.0 \mu\text{M}$, against FCA 20/GHA *P. falciparum*.^{504,505} At a dose of 200 mg/kg in mice, the clerodane diterpenoid gomphostenin-A (**1299**) exhibited an impressive 93% chemosuppression against *P. berghei*.⁵⁰⁶




Clerodane **182**, a diastereoisomer of kolavenol, exhibited trypanocidal activity (IC₅₀ 2.5 μg/mL) against *Trypanosoma brucei rhodesiense*, the parasitic cause of acute human African trypanosomiasis (sleeping sickness).⁵⁶ This compound was isolated from the root bark of *Entada abyssinica*, which is used by traditional healers in Uganda to treat sleeping sickness.

**182**

Infuscatin (**626**) and sepulturins A, C, D and E (**1300**, **1302–1304**) showed antiprotozoal activity against clinically isolated strains of *Entamoeba histolytica* and *Giardia lamblia* with similar potency to (+)-catechin and tyramine, but much less than metronidazole. Sepulturins A–F (**1300–1305**) were isolated from *Saliva shannoni* J.D. Smith, which is used as a traditional medicine in El Salvador against malaria.⁵⁰⁷ The structure of **626**²⁵¹ was also revised based on NOESY data and structural similarity to


1302. These new clerodane diterpenes contain a tertiary hydroxy group at C-8 or C-10 or both positions.




3.8. Antifungal and Antibacterial Activities

A fruit pulp extract of *Detarium microcarpum* inhibited the growth of the plant pathogenic fungus *Cladosporium cucumerinum* and of the enzyme acetylcholinesterase, which has been implicated in Alzheimer's disease. Fractionation of this extract led to the isolation of four new clerodane diterpenes, **197** (see Section 2.1.2.1), **266–267** (see Section 2.1.2.2), and **291** (see Section 2.1.3). Their structures were elucidated from spectroscopic data and X-ray crystallography of **197** and **266**. Compounds **197**, **267**, and **291** showed both antifungal activity and inhibition of acetylcholinesterase.⁶⁵

Caseanigrescen C (**39**) caused a significant (21 mm) zone of inhibition of fungal growth,²¹ and 16-oxo-cleroda-3,13(*E*)-diene-15-oic acid (**204**) also exhibited high antifungal activities, with MIC values of 25 to 50 μg , as compared with fungicide Dithane M-45.⁷⁰ Caseargrewiins A–D (**74**, **1256–1258**, see Section 3.5) exhibited moderate activity against *Mycobacterium tuberculosis*, with MIC values of 12.5, 12.5, 25.0, and 12.5 $\mu\text{g/mL}$, respectively.³¹




Compounds **205** and **206** were isolated as active antibacterial principles from *Haplopappus foliosus*.⁷¹ They were active against six gram-positive bacteria, but inactive against five gram-negative bacteria. 18-Acetoxy-cis-cleroda-3-en-15-oic acid (**226**) also showed antibacterial activity against five gram-positive bacteria.⁷⁷ 16 α -Hydroxy-cleroda-3,13(*Z*)-diene-15,16-olide (**551**) was highly active against gram-negative bacteria, including *Escherichia coli*, *Klebsiella aerogenes*, and *Pseudomonas* species, with MICs in the range 0.78–1.5 μg .⁷⁰ Among gram-positive bacteria, compound **551** was also highly active against *Bacillus* species with MIC of less than 2 μg . Interestingly, against gram-positive methicillin-resistant *Staphylococcus aureus*, compound **551** showed both *in vivo* efficacy in infected mice due to bacterial membrane disruption as well as synergistic activity with clinically used antibiotics, such as tetracycline, linezolid, and daptomycin.⁵⁰⁸



Furthermore, *neo*-clerodanes (5*R*,8*R*,9*S*,10*R*)-15,16-diol-15,16-dihydrohardwickiic acid (**1306**) and (2*S*,5*R*,8*R*,9*S*,10*R*)-2 β -hydroxy-16-oxo-15,16-dihydrohardwickiic acid (**1307**) from *Salvia adenophora* showed strain-dependent activity against gram-positive *Staph. epidermidis*.⁵⁰⁹ In contrast, lupulin A (**822**) showed clear activity against gram-negative *Ps. aeruginosa* and *E. coli* (inhibitory zone 3–5 mm),³¹⁵ and hativenes

A–C (**827–829**) showed potent activity against three gram-negative rods (*E. coli*, *Ps. aeruginosa* and *Salmonella typhimurium*).⁵¹⁰ Lupulin F (**794**) also showed antibacterial activity against *Ps. aeruginosa* and *E. coli*.³⁰⁰




3.9. Other Bioactivities

trans-Dehydrocrotonin (t-DCTN, **1076**, see structure in Section 3.4) exhibits multiple biological effects, including antitumor, antiulcerogenic, hypolipidaemic, antiatherogenic, antioestrogen, antigenotoxicity, anti-inflammatory, and insect growth inhibitory property activities.⁵¹¹⁻⁵¹⁸ The antihyperglycemic potential of this compound was supported by its reported hypoglycemic effect, which was almost comparable to that produced by glibenclamide (2 mg/kg), a clinically useful drug.⁵¹⁹ Compound **1076** can also be used as a potent analgesic agent in case of peripheral algnesia, without CNS effects.⁵²⁰ The hypotensive and bradycardia effects of **1076** are possibly related to some extent to the release of nitric oxide as well as direct effects on vascular smooth muscle, and cardiac pacemaker activity.⁵²¹

Casearinols A (**1308**) and B (**1309**) and casearinones A (**1310**) and B (**1311**),

inhibited the binding of T-cell leukocyte function antigen 1 to intercellular adhesion molecule 1, with an IC_{50} of $50 \mu\text{M}$.⁵²² This report is the first to link this diterpene class with immunomodulatory activity. Diterpene **1312**, an active principle of *Baccharis trimeta*, blocked vascular smooth muscle contractions induced by extracellular Ca^{2+} in KCl-depolarized preparations.⁵²³




Interestingly, 16α -hydroxycleroda-3,13Z-dien-15,16-olide (**551**, see structure in Section 3.8) is the first clerodane diterpene reported to have potential as a lipid lowering agent. It represents a new structural class of HMG-CoA reductase inhibitor.⁵²⁴

3.10. Toxicity

Some *neo*-clerodane diterpenoids, especially furan-containing diterpenoids, are highly hepatotoxic in mice, causing mid zonal hepatic necrosis. They have also been alleged to cause fulminant hepatitis, chronic hepatitis, or cirrhosis in humans.

Diosbulbin D (**1313**, DBD) was the first hepatotoxic furano norclerodane diterpenoid isolated from *Dioscorea bulbifera*.^{525,526} The effects of DBD on the growth of normal human liver L-02 cells may be due to its induction of cell apoptosis, which may also explain the toxicity observed with plants containing furano clerodane diterpenoids.⁵²⁷ Diosbulbin B (**1314**, DB) is another hepatotoxic compound found in high quantity in *D. bulbifera*.^{528,529} The hepatotoxic effects of the ornamental and medicinal germander plant (*Teucrium chamaedrys*) were attributed to the furano *neo*-clerodanes teucrin A (**1315**) and teuchamaedryn A (**1316**).⁵³⁰ Plants in the genus *Teucrium* have been used as

erroneously “safe” herbal hypoglycemic and slimming aids.⁵³⁰⁻⁵³² Other furanoclerodane diterpenoids have not been assayed for hepatotoxicity, with more attention put on other pharmacological properties. Determination of toxicity is an important criterium for both consumer safety and clinical candidacy. For instance, the possible development of 8-epidiosbulbin E acetate (**1317**) (with a δ -lactone *cis*-fused to the decalin system rather than *trans*-fused as in the hepatotoxic **1313**, DBD)⁵²⁶ as a potential plasmid-curing agent against multidrug-resistant bacteria, which pose a tremendous current health challenge.⁵³³



4. Conclusion

In this review, discoveries of clerodane diterpenes from 1990–2015 were categorized by their chemical structures. During the last 25 years, over 1,300 diterpenoids and *nor*-diterpenoids with the clerodane carbon skeleton have been isolated. These natural *neo*-clerodanes have been classified into seven different groups on the basis two fragments, the C-11–C-16 moiety and the decalin moiety. In addition, clerodane-type diterpene glycosides and clerodane derivatives, including *N*-containing derivatives, degraded derivatives, ring-*seco* derivatives, and rearranged derivatives reported in the literature were considered in this review. Although their insect antifeedant activity and opioid receptor agonist effects are generally considered most important, clerodane diterpenes exhibit many other pharmacological activities. The distribution, chemotaxonomic significance, biological activity, structure activity relationship correlations, and modes of action of active clerodanes have also been summarized.

The body of knowledge on the chemistry, biological activity, and pharmacology of clerodane diterpenes continues to grow rapidly. Despite such advances, continued investigations into the biological mechanisms involved in insect antifeedant activity, as well as extended research into the chemistry and pharmacology of opioid receptor ligands, such as salvinorin A (**9**) or other natural products, may provide the means to differentiate among different types of antifeedants and give better defined sets of clerodanes with a distinct mode of action from which more detailed structure-activity relationships can be deduced, and may yet yield the holy grail of opioids.

5. Acknowledgements

We are grateful for the financial support from Natural Science Foundation of China (21572082, 21262021) and the State Key Laboratory of Phytochemistry and Plant Resources in West China (No. P2015-KF01). This work was supported in part by National Cancer Institute Grant CA177584 awarded to K. H. Lee. We would like to thank Dr. Yan-Hong Li and Mr. Shi-Li Yan at Kunming University of Science and Technology for their contributions to the preparation and proofreading of the manuscript.

6. Supplementary Material Listing

Tables 2–32: Compound Structures arranged by Chemical Classifications
Structures of Clerodane Diterpenes arranged by Source

7. References

1. H. Kohno, M. Maeda, M. Tanino, Y. Tsukio, N. Ueda, K. Wada, S. Sugie, H. Mori and T. Tanaka, *Cancer Lett.*, 2002, **183**, 131-139.
2. J. O. Moody, V. A. Robert, J. D. Connolly and P. J. Houghton, *J. Ethnopharmacol.*, 2006, **104**, 87-91.
3. Q. Shi, M. Liang, W. Zhang, C. Zhang, R. Liu, Y. Shen, H. Li, X. Wang, X. Wang, Q. Pan and C. Chen, *Biomed. Chromatogr.*, 2007, **21**, 642-648.
4. J.-Y. Lallemand, Y. Six and L. Ricard, *Eur. J. Org. Chem.*, 2002, **3**, 503-513. Synthesis but OK
5. T. Tokoroyama, *Synthesis*, 2000, **5**, 611-633.
6. A. T. Merritt and S. V. Ley, *Nat. Prod. Rep.*, 1992, **9**, 243-287.
7. D. Rogers, G. G. Ünal, D. J. Williams, S. V. Ley, G. A. Sim and B. S. Joshi, *J. Chem. Soc.*

- Chem. Commun.*, 1979, **3**, 97-99.
8. (a) S. R. Wilson, L. A. Neubert and J. C. Huffman, *J. Am. Chem. Soc.*, 1976, **98**, 3669-3674. (b) R. J. Peters, *Nat. Prod. Rep.*, 2010, **27**, 1521-1530.
 9. A. K. Gayen, Ph.D. thesis, *University of Jadaupar*, 1984.
 10. A. Sato, M. Kurabayashi, H. Nagahori, A. Ogiso and H. Mishima, *Tetrahedron Lett.*, 1970, **13**, 1095-1098.
 11. J. P. Teresa, J. G. Urones, I. S. Marcos, F. Bermejo and P. Basabe, *Phytochemistry*, 1983, **22**, 2783-2785.
 12. E. A. Klein Gebbinck, B. J. M. Jansen and A. de Groot, *Phytochemistry*, 2002, **61**, 737-770.
 13. T. E. Prisinzano and R. B. Rothman, *Chem. Rev.*, 2008, **108**, 1732-1743.
 14. K. Hayashi, Y. Nakanishi, K. F. Bastow, G. Cragg, H. Nozaki and K. H. Lee, *Bioorg. Med. Chem. Lett.*, 2002, **12**, 345-348.
 15. J. Xu, Q. Zhang, M. Wang, Q. Ren, Y. Sun, D.-Q. Jin, C. Xie, H. Chen, Y. Ohizumi and Y. Guo, *J. Nat. Prod.*, 2014, **77**, 2182-2189.
 16. C. Calderón, C. De Ford, V. Castro, I. Merfort and R. Murillo, *J. Nat. Prod.*, 2014, **77**, 455-463.
 17. G. M. Vieira-Júnior, L. A. Dutra, P. M. Ferreira, M. O. de Moraes, L. V. Costa Lotufo, C. de Ó Pessoa, R. B. Torres, N. Boralle, V. da S. Bolzani and A. J. Cavalheiro, *J. Nat. Prod.*, 2011, **74**, 776-781.
 18. J. A. Beutler, K. L. McCall, K. Herbert, T. Johnson, R. H. Shoemaker and M. R. Boyd, *Phytochemistry*, 2000, **55**, 233-236.
 19. M. R. Khan, A. I. Gray, I. H. Sadler and P. G. Waterman, *Phytochemistry*, 1990, **29**, 3591-3595.
 20. N. H. Oberlies, J. P. Burgess, H. A. Navarro, R. E. Pinos, D. D. Soejarto, N. R. Farnsworth, A. D. Kinghorn, M. C. Wani and M. E. Wall, *J. Nat. Prod.*, 2001, **64**, 497-501.
 21. R. B. Williams, A. Norris, J. S. Miller, C. Birkinshaw, F. Ratovoson, R. Andriantsiferana, V. E. Rasamison and D. G. I. Kingston, *J. Nat. Prod.*, 2007, **70**, 206-209.
 22. E. L. Whitson, C. L. Thomas, C. J. Henrich, T. J. Sayers, J. B. McMahon and T. C. McKee, *J. Nat. Prod.*, 2010, **73**, 2013-2018.
 23. M. R. Khan, A. I. Gray and P. G. Waterman, *Phytochemistry*, 1990, **29**, 2939-2942.
 24. S. Gibbons, A. I. Gray and P. G. Waterman, *Phytochemistry*, 1996, **41**, 565-570.
 25. C. V. Sai Prakash, J. M. Hoch and D. G. I. Kingston, *J. Nat. Prod.*, 2002, **65**, 100-107.
 26. Y. C. Shen, C. H. Wang, Y. B. Cheng, L. T. Wang, J. H. Guh, C. T. Chien and A. T. Khalil, *J. Nat. Prod.*, 2004, **67**, 316-321.
 27. Y. C. Shen, Y. B. Cheng, A. F. Ahmed, C. L. Lee, S. Y. Chen, C. T. Chien, Y. H. Kuo and G. L. Tzeng, *J. Nat. Prod.*, 2005, **68**, 1665-1668.
 28. Y. C. Shen, L. T. Wang, C. H. Wang, A. T. Khalil and J. H. Guh, *Chem. Pharm. Bull.*, 2004, **52**, 108-110.
 29. M. A. Mosaddik, P. I. Forster, R. Booth and P. G. Waterman, *Nat. Prod. Commun.*, 2006, **1**, 441-448.
 30. M. A. Mosaddik, P. I. Forster, R. Booth and P. G. Waterman, *Biochem. Syst. Ecol.*, 2007, **35**, 631-633.
 31. S. Kanokmedhakul, K. Kanokmedhakul, T. Kanarsa and M. Buayairaksa, *J. Nat. Prod.*, 2005, **68**,

- 183-188.
32. E. K. S. Vijayakumar, S. Bal-Tembe, K. S. Joshi and V. B. Deore, *Indian J. Chem.*, 2002, **41B**, 2706-2708.
33. B. Wang, X. L. Wang, S. Q. Wang, T. Shen, Y. Q. Liu, H. Q. Yuan, H. X. Lou and X. N. Wang, *J. Nat. Prod.*, 2013, **76**, 1573-1579.
34. N. H. Oberlies, J. P. Burgess, H. N. A. Navarro, R. E. Pinos, C. R. Fairchild, R. W. Peterson, D. D. Soejarto, N. R. Farnsworth, A. D. Kinghorn, M. C. Wani and M. E. Wall, *J. Nat. Prod.*, 2002, **65**, 95-99.
35. J. A. Beutler, K. L. McCall, K. Herbert, D. L. Herald, G. R. Pettit, T. Johnson, R. H. Shoemaker and M. R. Boyd, *J. Nat. Prod.*, 2000, **63**, 657-661.
36. V. Jullian, C. Bonduelle, A. Valentin, L. Acebey, A.-G. Duigou, M.-F. Prévostb and Michel Sauvain, *Bioorg. Med. Chem. Lett.*, 2005, **15**, 5065-5070.
37. S. Kanokmedhakul, K. Kanokmedhakul and M. Buayairaksa, *J. Nat. Prod.*, 2007, **70**, 1122-1126.
38. M. R. Khan, A. I. Gray, I. H. Sadler, D. R. Reed and P. G. Waterman, *Phytochemistry*, 1990, **29**, 1609-1614.
39. G. M. Vieira Jr, T. de Oliveira Gonçalves, L. O. Regasini, P. M. Pinheiro Ferreira, C. do Ó Pessoa, L. V. Costa Lotufo, R. B. Torres, N. Boralle, V. da Silva Bolzani and A. J. Cavalheiro, *J. Nat. Prod.*, 2009, **72**, 1847-1850.
40. S. Gibbons, A. I. Gray and P. G. Waterman, *Phytochemistry*, 1996, **43**, 635-638.
41. C. Zdero, F. Bohlmann and R. M. King, *Phytochemistry*, 1992, **31**, 1703-1711.
42. K. He, G. Montenegro, J. J. Hoffmann and B. N. Timmermann, *Phytochemistry*, 1996, **41**, 1123-1127.
43. T. Dairi, Y. Hamano, T. Kuzuyama, N. Itoh, K. Furihata and H. Seto, *J. Bacteriol.*, 2001, **183**, 6085-6094.
44. F. Nagashima, S. Takaoka and Y. Asakawa, *Phytochemistry*, 1998, **49**, 601-608.
45. J. A. Chen, C. D. Huang and C. L. Wu, *J. Chin. Chem. Soc.*, 1992, **39**, 263-266.
46. K. Nabeta, T. Oohata, N. Izumi and K. Katoh, *Phytochemistry*, 1994, **37**, 1263-1268.
47. T. Hashimoto, I. Nakamura, M. Tori, S. Takaoka and Y. Asakawa, *Phytochemistry*, 1995, **38**, 119-127.
48. F. Nagashina, T. Sekiguchi, S. Takaoka and Y. Asakawa, *Chem. Pharm. Bull.*, 2004, **52**, 556-560.
49. A. Kijjoa, M. M. M. Pinto, P. M. M. Pinho and W. Herz, *Phytochemistry*, 1993, **34**, 457-460.
50. C. P. de Souza Moreira, D. M. de Oliveira, C. N. dos Santos, C. L. Zani and T. M. de Almeida Alves, *Tetrahedron Lett.*, 2014, **55**, 4898-4900.
51. F. Nagashima, M. Suzuki, S. Takaoka and Y. Asakawa, *Chem. Pharm. Bull.*, 2000, **48**, 1818-1821.
52. W. Tang, K. Harada, M. Kubo, H. Hioki and Y. Fukuyama, *Nat. Prod. Commun.*, 2011, **6**, 327-332.
53. H. Tazaki, T. Hayashida, T. Furuki and K. Nabeta, *Phytochemistry*, 1999, **52**, 1551-1553.
54. E. Tojoa, M. E. Rial, A. Urzua and L. Mendoza, *Phytochemistry*, 1999, **52**, 1531-1533.
55. M. Tori, A. Katto and M. Sono, *Phytochemistry*, 1999, **52**, 487-493.
56. F. Freiburghaus, A. Steck, H. Pfander and R. Brun, *J. Ethnopharmacol.*, 1998, **61**, 179-183.
57. C. Zdero, F. Bohlmann and R. M. King, *Phytochemistry*, 1992, **31**, 213-216.
58. A. Rustaiyan, Z. Habibi and C. Zdero, *Phytochemistry*, 1990, **29**, 985-987.

59. B. Jorge, M. Arlett, P. Samuel, L. L. A., M. Glauco, W. Oscar and B. Ivan, *Bol. Soc. Chil. Quim.*, 1995, **40**, 157-162.
60. G. Zhao, J. H. Jung, D. L. Smith, K. V. Wood and J. L. McLaughlin, *Planta Med.*, 1991, **57**, 380-383.
61. K. Nabeta, T. Oohata, S. Ohkubo, T. Sato and K. Katoh, *Phytochemistry*, 1996, **41**, 581-587.
62. A. Ohsaki, Y. Kasetani, Y. Asaka, K. Shibata, T. Tokoroyamat and T. Kubota, *Phytochemistry*, 1991, **30**, 4075-4077.
63. S. M. Yang, S. H. Wu, X. D. Qin, X. D. Luo and D. G. Wu, *Helv. Chim. Acta*, 2004, **87**, 1279-1286.
64. R. T. Nogueira, G. J. Shepherd, A. L. Jr., A. J. Marsaioli and P. M. Imamura, *Phytochemistry*, 2001, **58**, 1153-1157.
65. A. L. Cavin, A. E. Hay, A. Marston, H. Stoeckli-Evans, R. Scopelliti, D. Diallo and K. Hostettmann, *J. Nat. Prod.*, 2006, **69**, 768-773.
66. D. Avila and J. D. Medina, *Phytochemistry*, 1991, **30**, 3474-3475.
67. A. Ohsaki, Y. Asaka, T. Kubota, K. Shibata and T. Tokoroyama, *J. Nat. Prod.*, 1997, **60**, 912-914.
68. Z. X. Zeng, W. H. Ma, Y. L. Li, T. Han, C. J. Zheng and L. P. Qin, *Helv. Chim. Acta*, 2012, **95**, 1121-1125.
69. T. Mitamura, T. Matsuno, S. Sakamoto, M. Maemura, H. Kudo, S. Suzuki, K. Kuwa, S. Yoshimura and S. Sassa, *Anticancer Res.*, 1996, **16**, 2669-2672.
70. M. M. Murthy, M. Subramanyam, M. H. Bindu and J. Annapurna, *Fitoterapia*, 2005, **76**, 336-339.
71. A. Urzúa, R. Torres, L. Mendoza and F. Delle Monache, *Planta Med.*, 2003, **69**, 675-677.
72. M. Kuroyanagi, K. Uchida, A. Ueno, M. Satake and K. Shimomura, *Phytochemistry*, 1993, **34**, 1377-1384.
73. Y. Guo, Y. Li, J. Xu, N. Li, T. Yamakuni and Y. Ohizumi, *Chem Pharm Bull*, 2007, **55**, 1532-1534.
74. C. Zdero and F. Bohlmann, *Phytochemistry*, 1991, **30**, 607-609.
75. C. Zdero, J. Jakupovic and F. Bohlmann, *Phytochemistry*, 1990, **29**, 1231-1245.
76. G. G. Leitão, M. A. C. Kaplan and C. Galeffi, *Phytochemistry*, 1992, **31**, 3277-3279.
77. A. Urzua, F. Jara, E. Tojob, M. Wilkens, L. Mendoza and M. C. Rezende, *J. Ethnopharmacol.*, 2006, **103**, 297-301.
78. L. Mambu, P. Grellier, L. Florent, R. Joyeau, D. Ramanitrahasimbola, P. Rasoanaivo and F. Frappier, *Phytochemistry*, 2006, **67**, 444-451.
79. H. P. He, Y. M. Shen, G. Y. Zuo, X. S. Yang and X. J. Hao, *Helv. Chim. Acta.*, 2003, **86**, 3187-3193.
80. Y. W. Chin, W. P. Jones, Q. Mi, I. Rachman, S. Riswan, L. B. S. Kardono, H. B. Chai, N. R. Farnsworth, G. A. Cordell, S. M. Swanson, J. M. Cassady and A. D. Kinghorn, *Phytochemistry*, 2006, **67**, 1243-1248.
81. M. D. Bomm, J. Zukerman-Schpector and L. M. X. Lopes, *Phytochemistry*, 1999, **50**, 455-461.
82. C. Fazio, M. P. Paternostro, S. Passannanti and F. Piozzi, *Phytochemistry*, 1994, **37**, 501-503.
83. C. Fazio, S. Assannanti, M. P. Paternostro and F. Piozzi, *Phytochemistry*, 1992, **31**, 3147-3149.
84. B. Bläs, J. Zapp and H. Becker, *Phytochemistry*, 2004, **65**, 127-137.
85. M. Furlan, M. N. Lopes, J. B. Fernandes and J. R. Pirani, *Phytochemistry*, 1996, **41**, 1159-1161.

86. F. Nagashima, M. Suzuki, S. Takaoka and Y. Asakawa, *J. Nat. Prod.*, 2001, **64**, 1309-1317.
87. A. San Feliciano, M. Gordaliza, J. M. Miguel del Corral and M. L. de la Puente, *Phytochemistry*, 1993, **33**, 631-633.
88. T. Diyabalanage, K. B. Iken, J. B. McClintock, C. D. Amsler and B. J. Baker, *J. Nat. Prod.*, 2010, **73**, 416-421.
89. Y. Cai, Z. P. Chen and J. D. Phillipson, *Phytochemistry*, 1993, **32**, 755-760.
90. F. Nagashima, H. Tanaka, Y. Kan, S. Huneck and Y. Asakawa, *Phytochemistry*, 1995, **40**, 209-212.
91. D. Avila, J. D. Medina and A. J. Deeming, *J. Nat. Prod.*, 1992, **55**, 845-850.
92. I. Çalis and E. Bedir, *J. Nat. Prod.*, 1996, **59**, 457-460.
93. A. Fiorentino, B. D'Abrosca, S. Pacifico, A. Izzo, G. D'Angelo and P. Monaco, *Nat. Prod. Commun.*, 2010, **5**, 1539-1542.
94. D. Avila and J. D. Medina, *J. Nat. Prod.*, 1993, **56**, 1586-1589.
95. F. Nagashima, M. Tori and Y. Asakawa, *Phytochemistry*, 1991, **30**, 849-851.
96. Z.-K. Liu, D.-R. Wu, Y.-M. Shi, T. Zeng, S.-H. Liu, X. Dua, Y.-J. Dang, W.-L. Xiao and H.-D. Sun, *Chin. Chem. Lett.*, 2014, **25**, 677-679.
97. A. Faheem, A. Mohd and A. Prawez, *Nat. Prod. Res.*, 2010, **24**, 926-934.
98. J. Xu, L. J. Harrison, J. J. Vittal, Y.-J. Xu and S.-H. Goh, *J. Nat. Prod.*, 2000, **63**, 1062-1065.
99. T. H. Lee, M. J. Wang, P. Y. Chen, T. Y. Wu, W. C. Wen, F. Y. Tsai and C. K. Lee, *J. Nat. Prod.*, 2009, **72**, 1960-1963.
100. X. J. Hao, X. S. Yang, Z. Zhang and L. J. Shang, *Phytochemistry*, 1995, **39**, 447-448.
101. E. M. Kithsiri Wijerathne, L. B. Dd Silva, Y. Tezuka and T. Kikuchi, *Phytochemistry*, 1995, **39**, 443-445.
102. A. Ohsaki, M. Ogawa, Y. Imai, T. Shinzato, H. Shigemori and J. I. Kobayashi, *J. Nat. Prod.*, 2001, **64**, 804-805.
103. L. J. Harrison, J. D. Connolly and D. S. Rycroft, *Phytochemistry*, 1992, **31**, 1420-1421.
104. S. Ruiu, N. Anzani, A. Orru, C. Floris, P. Caboni, S. Alcaro, E. Maccioni, S. Distinto and F. Cottiglia, *J. Nat. Prod.*, 2015, **78**, 69-76.
105. H. Lv, J. Luo and L. Kong, *Nat. Prod. Res.*, 2014, **28**, 196-200.
106. C. M. Hasan, S. Khan, A. Jabbar and M. A. Rashid, *J. Nat. Prod.*, 2000, **63**, 410-411.
107. A. A. Sanchez, B. Esquivel, T. P. Ramamoorthy and L. Rodriguea-Hahn, *Phytochemistry*, 1995, **38**, 171-174.
108. A. Bisio, G. Damonte, D. Fraternali, E. Giacomelli, A. Salis, G. Romussi, S. Cafaggi, D. Ricci and N. D. Tommasi, *Phytochemistry*, 2011, **72**, 265-275.
109. G. Almanza, L. Balderrama, C. Labbé, C. Lavaud, G. Massiot, J.-M. Nuzillard, J. D. Connolly, L. J. Farrugia and D. S. Rycroft, *Tetrahedron*, 1997, **53**, 14719-14728.
110. L. M. West, A. P. T. N. A and B. A. C. N. Battershill, *Aust. J. Chem.*, 1998, **51**, 1097-1101.
111. G. Fontana, M. P. Paternostro, G. Savona, B. Rodríguez and M. C. de la Torre, *J. Nat. Prod.*, 1998, **61**, 1242-1247.
112. F. Fullas, R. A. Hussain, H.-B. Chai, J. M. Pezzuto, D. D. Soejarto and A. D. Kinghorn, *J. Nat. Prod.*, 1994, **57**, 801-807.
113. G. Xu, F. Zhao, X.-W. Yang, J. Zhou, L.-X. Yang, X.-L. Shen, Y.-J. Hu and Q.-S. Zhao, *Nat. Prod.*

- Bioprospect.*, 2011, **1**, 81-86.
114. S. Aravind, J. Balachandran, M. R. Ganesh and G. N. K. Kumari, *Nat. Prod. Res.*, 2010, **24**, 7-12.
115. C. Premprasert, S. Tewtrakul, A. Plubrukarn and J. Wungsintaweekul, *J. Nat. Med.*, 2013, **67**, 174-181.
116. M. J. S. Cuadrado, M. C. de la Torre, B. Rodríguez, M. Bruno, F. Piozzi and G. Savona, *Phytochemistry*, 1991, **30**, 4079-4082.
117. C. Y. Ragasa, M. C. Cruz, R. Gula and J. A. Rideout, *Org. Biomol. Chem.*, 2015, **13**, 3882-3886.
118. F. Nagashima and Y. Asakawa, *Phytochemistry*, 1990, **29**, 3229-3231.
119. H. Tazaki, J. Zapp and H. Becker, *Phytochemistry*, 1995, **39**, 859-868.
120. H. Tazaki, K. Nabeta and H. Becker, *Phytochemistry*, 1998, **48**, 681-685.
121. M. Blechschmidt and H. Becker, *J. Nat. Prod.*, 1992, **55**, 111-121.
122. A. M. Galstyan, A. S. Shashkov, G. B. Oganessian, V. A. Mnatsakanyan and E. P. Serebryakov, *Him. Prir. Soedin.*, 1992, **5**, 503-508.
123. J. Coll and Y. Tandrón, *Phytochemistry*, 2005, **66**, 2298-2303.
124. C. Moustapha, T. Hasen, M. Waleed and M. Sadaka, *Jordan J. Chem.*, 2011, **6**, 339-345.
125. M. A. M. Maciel, A. C. Pinto, S. N. Brabo and M. N. Da Silva, *Phytochemistry*, 1998, **49**, 823-828.
126. E. A. Sattar, J. S. Mossa, I. Muhammad and F. S. El-Feraly, *Phytochemistry*, 1995, **40**, 1737-1741.
127. P. Y. Malakov, G. Y. Papanov and I. M. Boneva, *Phytochemistry*, 1992, **31**, 4029-4030.
128. C. Zdero, F. Bohlmann and G. M. Mungai, *Phytochemistry*, 1990, **29**, 3233-3241.
129. R. Alcázar, M. C. de la Torre, R. B. Rodríguez, M. Bruno, F. Piozzi, G. Savona and N. A. Arnold, *Phytochemistry*, 1992, **31**, 3957-3960.
130. W. Tang, H. Hioki, K. Harada, M. Kubo and Y. Fukuyama, *J. Nat. Prod.*, 2008, **71**, 1760-1763.
131. A. Ortega, P. E. Garcia, J. Cárdenas, C. Mancera, S. Marquina, M. L. del Carmen Garduño and E. M. E., *Tetrahedron*, 2001, **57**, 2981-2989.
132. K. Graikou, N. Aligiannis, I. Chinou, A.-L. Skaltsounis, F. Tillequin and M. Litaudon, *Helv. Chim. Acta.*, 2005, **88**, 2654-2660.
133. M. A. Al-Yahya, I. Muhmmad, H. H. Mirza and F. S. El-Feraly, *J. Nat. Prod.*, 1993, **56**, 830-842.
134. M. A. Al-Yahya, F. S. El-Feraly, D. C. Dunbar and I. Muhmmad, *Phytochemistry*, 2002, **59**, 409-414.
135. R. B. Teponno, A. L. Tapondjou, D. Gatsing, J. D. Djoukeng, E. A. Mansour, R. Tabacchi, P. Tane, H. S. Evans and D. Lontsi, *Phytochemistry*, 2006, **67**, 1957-1963.
136. R. B. Teponno, A. Tapondjou, H. J. Jung, J. H. Nam, P. Tane and H. J. Park, *Helv. Chim. Acta*, 2007, **90**, 1599-1605.
137. W. Naengchomng, P. M. Pinho, A. Kijjoa, P. Sawangwong, M. J. Gonzalez, A. M. S. Silva, G. Eaton and W. Herz, *Phytochemistry*, 2006, **67**, 1029-1033.
138. D. X. Guo, R. X. Zhu, X. N. Wang, L. N. Wang, S. Q. Wang, Z. M. Lin and H. X. Lou, *Org. Lett.*, 2010, **12**, 4404-4407.
139. K. Katayama, K. Shimazaki, H. Tazaki, Y. Hasa, M. Miyoshi, H. Koshino, T. Furuki and K. Nabeta, *Biosci. Biotechnol. Biochem.*, 2007, **71**, 2751-2758.
140. R. J. Li, Y. Sun, B. Sun, X. N. Wang, S. S. Liu, J. C. Zhou, J. P. Ye, Y. Zhao, L. Liu, K. H. Lee and

- H.-X. Lou, *Phytochemistry*, 2014, **105**, 85-91.
141. I. Addae-Mensah, H. Achenbach, G. N. Thoithi, R. Waibel and J. W. Mwangi, *Phytochemistry*, 1992, **31**, 2055-2058.
142. E. Fattorusso, O. Taglialatela-Scafati, C. Campagnuolo, F. U. Santelia, G. Appendino and P. Spagliardi, *J. Agric. Food Chem.*, 2002, **50**, 5131-5138.
143. L. Harinantenaina, Y. Takahara, T. Nishizawa, C. Kohchi, G.-I. Soma and Y. Asakawa, *Chem. Pharm. Bull.*, 2006, **54**, 1046-1049.
144. M. Bruno, R. Alcazar, M. C. de la Torre, F. Piozzi, B. Rodriguez, G. Savona, A. Perales and N. A. Arnold, *Phytochemistry*, 1992, **31**, 3531-3534.
145. M. Bruno, G. Domínguez, A. Lourenço, F. Piozzi, B. Rodríguez, G. Savona, M. C. de la Torre and N. A. Arnold, *Phytochemistry*, 1991, **30**, 3693-3697.
146. M. C. de la Torre, M. Bruno, F. Piozzi, G. Savona, B. Rodríguez and A. A. Omar, *Phytochemistry*, 1991, **30**, 1603-1606.
147. J. Coll and Y. Tandrón, *Phytochemistry*, 2004, **65**, 387-392.
148. J. Hussain, R. Ullah, A. Khan, F. U. Khan, Z. Muhammad and M. R. Shah, *Nat. Prod. Commun.*, 2011, **6**, 171-173.
149. Z. Huang, M.-Y. Jiang, Z.-Y. Zhou, and D. Xu, *Z. Naturforsch. B*, 2010, **65**, 83-86.
150. S. S. Zaman, N. C. Barua and R. P. Sharma, *Indian J. Chem. B*, 1991, **30**, 1054-1055.
151. G. Appendino, F. Borrelli, R. Capasso, C. Campagnuolo, E. Fattorusso, F. Petrucci and O. Taglialatela-Scafati, *J. Agric. Food Chem.*, 2003, **51**, 6970-6974.
152. W. Tang, M. Kubo, K. Harada, H. Hioki, and Y. Fukuyama, *Bioorg. Med. Chem. Lett.*, 2009, **19**, 882-886.
153. H. Monti, N. Tiliacos and R. Faure, *Phytochemistry*, 1996, **42**, 1653-1656.
154. E. R. Silveira and J. D. McChesney, *Phytochemistry*, 1994, **36**, 1457-1463.
155. C. Zdero, F. Bohlmann and G. M. Mungal, *Phytochemistry* 1991, **30**, 575-581.
156. B. S. Simpson, D. J. Claudie, J. P. Gerber, S. M. Pyke, J. Wang, R. A. McKinnon and S. J. Semple, *J. Nat. Prod.*, 2011, **74**, 650-657.
157. M. T. L. P. Peres, M. G. Pizzolatti, R. A. Yunes and F. Delle Monache, *Phytochemistry*, 1998, **49**, 171-174.
158. H. Itokawa, Y. Ichihara, M. Shimizu, K. Takaya and M. Motidome, *Chem. Pharm. Bull.*, 1990, **38**, 701-705.
159. A. C. F. Amaral and R. A. Barnes, *Nat. Prod. Lett.*, 1998, **12**, 41-46.
160. G.-A. Zou, H.-W. Zhang, H. A. Aisa, J.-S. Yang, C.-Z. Peng and Z.-M. Zou, *J. Nat. Med.*, 2011, **65**, 391-394.
161. I. Anis, E. Anis, S. Ahmed, G. Mustafa, A. Malik, Z. Amtul and Atta-ur-Rahman, *Helv. Chim. Acta*, 2001, **84**, 649-655.
162. C.-M. Liu, R.-L. Zhu, R.-H. Liu, H.-L. Li, L. Shan, X.-K. Xu and W.-D. Zhang, *Planta Med.*, 2009, **75**, 1597-1601.
163. H. Heymann, Y. Tezuka, T. Kikuchi and S. Supriyatna, *Chem. Pharm. Bull.*, 1994, **42**, 1202-1207.
164. D.-X. Guo, X.-N. Wang, R.-X. Zhu, N. Liu, J.-C. Zhou, W.-T. Yu and H.-X. Lou, *Phytochem. Lett.*, 2012, **5**, 535-540.

165. C.-P. Liu, J.-B. Xu, J.-X. Zhao, C.-H. Xu, L. Dong, J. Ding and J.-M. Yue, *J. Nat. Prod.*, 2014, **77**, 1013-1020.
166. A. K. Bigham, T. A. Munro, M. A. Rizzacasa and R. M. Robins-Browne, *J. Nat. Prod.*, 2003, **66**, 1242-1244.
167. D. Y. W. Lee, Z. Ma, L.-Y. Liu-Chen, Y. Wang, Y. Chen, W. A. Carlezon Jr. and B. Cohen, *Bioorg. Med. Chem.*, 2005, **13**, 5635-5639.
168. M. T. Bayor, J. S. K. Ayim, G. Marston, R. M. Phillips, S. D. Shnyder, R. T. Wheelhouse and C. W. Wright, *Nat. Prod. Commun.*, 2008, **3**, 1875-1878.
169. D. F. Abega, D. W. F. G. Kapche, P. Y. Ango, R. Mapitse, S. O. Yeboah and B. T. Ngadjui, *Z. Naturforsch. C*, 2014, **69**, 181-185.
170. H. C. Krebs and H. Ramiarantsoa, *Phytochemistry*, 1997, **45**, 379-381.
171. H. C. Krebs and H. Ramiarantsoa, *Phytochemistry*, 1996, **41**, 561-563.
172. J. Hussain, N. Jamila, F. U. Khan, K. P. Devkota, M. R. Shah and S. Anwar, *Magn. Reson. Chem.*, 2009, **47**, 625-627.
173. J. Dai, R. Suttisri, E. Bordas, D. D. Soejarto and A. D. Kinghorn, *Phytochemistry*, 1993, **34**, 1087-1090.
174. Y. Guo, Y. Li, J. Xu, R. Watanabe, Y. Oshima, T. Yamakuni and Y. Ohizumi, *J. Nat. Prod.*, 2006, **69**, 274-276.
175. A. E. Mostafa, A. A. El-Hela, A.-E. I. Mohammad, M. Jacob, S. J. Cutler and S. A. Ross, *Phytochem. Lett.*, 2014, **8**, 10-15.
176. B. Rodriguez, M. C. de la Torre, B. Rodriguez, M. Bruno, F. Piozzi, G. Savona, M. S. J. Simmonds, W. M. Blaney and A. Perales, *Phytochemistry*, 1993, **33**, 309-315.
177. B. Rodríguez, M. C. de la Torre, B. Rodríguez and P. Gómez-Serranillos, *Phytochemistry*, 1996, **41**, 247-253.
178. A. San Feliciano, M. Gordaliza, J. M. Miguel de Corral, M. L. de la Puente, S. García-Granda and M. A. Salvado, *Tetrahedron*, 1993, **49**, 9067-9078.
179. M. Gordaliza, J. M. Miguel del Corral, M. M. Mahiques, A. C. Maria and A. San Feliciano, *Phytochemistry*, 1995, **40**, 1307-1309.
180. F. M. Harraz and R. W. Doskotch, *J. Nat. Prod.*, 1990, **53**, 1312-1326.
181. F. M. Harraz and R. W. Doskotch, *J. Nat. Prod.*, 1996, **59**, 463-468.
182. F. M. Harraz, M. J. Pcolinski and R. W. Doskotch, *J. Nat. Prod.*, 1996, **59**, 5-14.
183. C. M. Starks, R. B. Williams, M. G. Goering, M. O'Neil-Johnson, V. L. Norman, J.-F. Hu, ElianeGaro, G. W. Hough, S. M. Rice and G. R. Eldridge, *Phytochemistry*, 2010, **71**, 104-109.
184. L. K. Omosa, J. O. Midiwo, S. Derese, A. Yenesew, M. G. Peter and M. Heydenreich, *Phytochem. Lett.*, 2010, **3**, 217-220.
185. J. P. Cenal, O. S. Giordano, P. C. Rossomando and C. E. Tonn, *J. Nat. Prod.*, 1997, **60**, 490-492.
186. K.-I. Hayashi, T. Kanamori, A. Yamazoe, M. Yamada and H. Nozaki, *J. Nat. Prod.*, 2005, **68**, 1121-1124.
187. R.-J. Li, R.-X. Zhu, Y.-Y. Li, J.-C. Zhou, J.-Z. Zhang, S. Wang, J.-P. Ye, Y.-H. Wang, S. L. Morris-Natschke, K.-H. Lee and H.-X. Lou, *J. Nat. Prod.*, 2013, **76**, 1700-1708.
188. V. U. Ahmad, U. Farooq, A. Abbaskhan, J. Hussain, M. A. Abbasi, S. A. Nawaz and M. I.

- Choudhary, *Helv. Chim. Acta*, 2004, **87**, 682-689.
189. V. U. Ahmad, A. Khan, U. Farooq, F. Kousar, S. S. Khan, S. A. Nawaz, M. A. Abbasi and M. I. Choudhary, *Chem. Pharm. Bull.*, 2005, **53**, 378-381.
190. J. Mantaj, S. M. A. Rahman, B. Bokshi, C. M. Hasan, P. J. M. Jackson, R. B. Parsons and K. M. Rahman, *Org. Biomol. Chem.*, 2015, **13**, 3882-3886.
191. N. Liu, R. X. Zhu, S. Wang, J. Z. Zhang, Z. M. Lin, R. J. Li and H. X. Lou, *Chem. Biodivers.*, 2013, **10**, 1606-1612.
192. P. Y. Malakov and G. Y. Papanov, *Phytochemistry*, 1996, **43**, 173-178.
193. M. C. de la Torre, B. Rodriguez, M. Bruno, F. Piozzi, G. Savona, N. Vassallo and O. Servettaz, *Phytochemistry*, 1995, **38**, 181-187.
194. P. Guo, Y. Li, D.-Q. Jin, J. Xu, Y. He, L. Zhang and Y. Guo, *Phytochem. Lett.*, 2012, **5**, 563-566.
195. P. Y. Malakov and G. Y. Papanov, *Phytochemistry*, 1998, **49**, 2449-2452.
196. X. Shen, A. Isogai, K. Furihata, H. Sun and A. Suzuki, *Phytochemistry*, 1993, **34**, 1091-1094.
197. X. Shen, A. Isogai, K. Furihata, H. Sun and A. Suzuki, *Phytochemistry*, 1993, **33**, 887-889.
198. T. Amano, R. Nishida and Y. Kuwahara, *Biosci. Biotechnol. Biochem.*, 1997, **61**, 1518-1522.
199. Z. Liu, Z. Q. Li, C. X. Zhang, R. Y. Chen, Y. G. Zhang, Y. T. Qiu and S. H. Zhao, *Chin. Chem. Lett.*, 1995, **6**, 581-582.
200. Y. Miyaichi, H. Kizu, Y. Yamaguchi, Tomimori and Tsuyoshi, *Yakugaku Zasshi*, 1994, **114**, 264-271.
201. M. C. de la Torre, B. Rodriguez, M. Bruno, P. Y. Malakov, G. Y. Papanov, F. Piozzi and G. Savona, *Phytochemistry*, 1993, **34**, 1589-1594.
202. M. C. de la Torre, B. Rodríguez, M. Bruno, N. Vassallo, M. L. Bondí, F. Piozzi and O. Servettaz, *J. Nat. Prod.*, 1997, **60**, 1229-1235.
203. P. Y. Malakov, P. I. Bozov and G. Y. Papanov, *Phytochemistry* 1997, **46**, 587-589.
204. R. A. Raccuglia, G. Bellone, K. Loziene, F. Piozzi, S. Rosselli, A. Maggio, M. Bruno and M. S. J. Simmonds, *Phytochemistry*, 2010, **71**, 2087-2091.
205. Y. Y. Chan, *Chem. Pharm. Bull.*, 2005, **53**, 164-167.
206. Z.D. Min, M. Mizuno, S.Q. Wang, M. Iinuma and T. Tanaka, *Chem. Pharm. Bull.*, 1990, **38**, 3167-3168.
207. P. D. Bremner, M. S. J. Simmonds, W. M. Blaney and N. C. Veitch, *Phytochemistry*, 1998, **47**, 1227-1232.
208. H. Kizu, Y. Imoto, T. Tomimori, T. Kikuchi, S. Kadota and K. Tsubono, *Chem. Pharm. Bull.*, 1997, **45**, 152-160.
209. C. H. Li, Y. Liu, J. Hua, S. H. Luo and S. H. Li, *J. Integr. Plant Biol.*, 2014, **56**, 928-940.
210. L. Xu, D. Guo, J. Liu, J. Zheng, K. Koike, Z. Jia and T. Nikaido, *Heterocycles*, 1999, **51**, 605-609.
211. Z. Sun, Y. Li, D.-Q. Jin, P. Guo, H. Song, J. Xu, Y. Guo and L. Zhang, *Fitoterapia*, 2012, **83**, 1409-1414.
212. B. Rodriguez, M. C. de la Torre, M. Bruno, F. Piozzi, N. Vassallo, R. Ciriminna and O. Servettaz, *Phytochemistry*, 1997, **45**, 383-385.
213. K. Venkateswarlu, G. Satyalakshmi, K. Suneel, T. S. Reddy, T. V. Raju and B. Das, *Helv. Chim. Acta.*, 2008, **91**, 2081-2088.

214. R. T. Zhang, T. Feng, X. H. Cai and X. D. Luo, *Z. Naturforsch., B: J. Chem. Sci.*, 2009, **64**, 443-446.
215. A. T. Tchinda, S. R. Mouokeu, R. A. N. Ngono, M. R. E. Ebelle, A. L. K. Mokale, D. K. Nono and M. Frederich, *Nat. Prod. Res.*, 2015, **29**, 1990-1994.
216. V. Krishna and P. Singh, *Phytochemistry*, 1999, **52**, 1341-1343.
217. W. P. Jones, T. Lobo-Echeverri, Q. Mi, H.-B. Chai, D. D. Soejarto, G. A. Cordell, S. M. Swanson and D. Kinghorn, *J. Nat. Prod.*, 2007, **70**, 372-377.
218. W. Wang, Z. Ali, X. C. Li, T. A. Smillie, D. A. Guo and I. A. Khan, *Fitoterapia*, 2009, **80**, 404-407.
219. A. Kijjoa, M. M. M. Pinto, P. M. M. Pinho, B. Tantisewie and W. Herz, *Phytochemistry*, 1990, **29**, 653-655.
220. T. H. Wu, Y. Y. Cheng, J. R. Liou, T. D. Way, C. J. Chen, Y. H. Chen, S. C. Kuo, M. El-Shazly, F. R. Chang, Y. C. Wu and C. C. Liaw, *RSC Advances*, 2014, **4**, 23707-23712.
221. B. Achari, C. Chaudhuri, C. R. Saha, P. K. Dutta and S. C. Pakrashi, *Phytochemistry*, 1990, **29**, 3671-3673.
222. W. Geis, B. Buschauer. and H. Becker, *Phytochemistry*, 1999, **51**, 643-649.
223. M. Chakrabarty and A. C. Nath, *J. Nat. Prod.*, 1992, **55**, 256-258.
224. E. Maldonado and A. Ortega, *Phytochemistry*, 1997, **46**, 1249-1254.
225. L. M. Wang, S. J. Guo, Z. J. Jia and D. L. Cheng, *Chin. Chem. Lett.*, 1996, **7**, 619-620.
226. K. Iqbal, A. Malik, N. Mukhtar, I. Anis, S. N. Khan and M. I. Choudhary, *Chem. Pharm. Bull.*, 2004, **52**, 785-789.
227. A. C. Pinto, W. S. Garcez, P. P. S. Queiroz and N. G. Fiorani, *Phytochemistry*, 1994, **37**, 1115-1117.
228. F. Zhu, Y. T. Di, L. L. Liu, Q. Zhang, X. Fang, T. Q. Yang, X. J. Hao and H. P. He, *J. Nat. Prod.*, 2010, **73**, 233-236.
229. S. J. Dai, L. Shen and Y. Ren, *J. Integr. Plant Biol.*, 2008, **50**, 699-702.
230. S. J. Dai, G. W. Qu, Q. Y. Yu, D. W. Zhang and G. S. Li, *Fitoterapia*, 2010, **81**, 737-741.
231. F. Zhu, Y. T. Di, X. Y. Li, L. L. Liu, Q. Zhang, Y. Li, X. J. Hao and H. P. He, *Planta Med.*, 2011, **77**, 1536-1541.
232. S. J. Dai, J. Y. Tao, K. Liu, Y. T. Jiang and L. Shen, *Phytochemistry*, 2006, **67**, 1326-1330.
233. S. J. Dai, J. Y. Sun, Y. Ren, K. Liu and L. Shen, *Planta Med.*, 2007, **73**, 1217-1220.
234. G. W. Qu, X. D. Yue, G. S. Li, Q. Y. Yu and S. J. Dai, *J. Asian Nat. Prod. Res.*, 2010, **12**, 859-864.
235. O. Shiota, K. Nagamatsu and S. Sekita, *J. Nat. Prod.*, 2006, **69**, 1782-1786.
236. K. V. Sashidhara, S. P. Singh, J. Sarkar and S. Sinha, *Nat. Prod. Res.*, 2010, **24**, 1687-1694.
237. X. Ma, I. S. Lee, H. B. Chai, K. Zaw, N. R. Farnsworth, D. D. Soejarto, G. A. Cordell, J. M. Pezzuto and A. D. Kinghorn, *Phytochemistry* 1994, **37**, 1659-1662.
238. N. Hara, H. Asaki, Y. Fujimoto, Y. K. Gupta, A. K. Singh and M. Sahai, *Phytochemistry* 1995, **38**, 189-194.
239. C. M. Hasan, M. O. Islam and M. A. Rashid, *Pharmazie*, 1995, **50**, 227-228.
240. T. H. Wu, Y. Y. Cheng, C. J. Chen, L. T. Ng, L. C. Chou, L. J. Huang, Y. H. Chen, S.-C. Kuo, M. El-Shazly, Y. C. Wu, F. R. Chang and C. C. Liaw, *Molecules*, 2014, **19**, 2049-2060.

241. A. A. Hussein, M. C. de la Torre, M.-L. Jimeno, B. Rodríguez, M. Bruno, F. Piozzi and O. Servettaz, *Phytochemistry*, 1996, **43**, 835-837.
242. H. L. Rasikari, D. N. Leach, P. G. Waterman, R. N. Spooner-Hart, A. H. Basta, L. K. Banbury, K. M. Winter and P. I. Forster, *Phytochemistry*, 2005, **66**, 2844-2850.
243. P. Guo, Y. Li, J. Xu, Y. Guo, D. Q. Jin, J. Gao, W. Hou and T. Zhang, *Fitoterapia*, 2011, **82**, 1123-1127.
244. P. Guo, Y. Li, J. Xu, C. Liu, Y. Ma and Y. Guo, *J. Nat. Prod.*, 2011, **74**, 1575-1583.
245. Z. Sun, Y. Li, D. Q. Jin, P. Guo, J. Xu, Y. Guo and L. Zhang, *Planta Med.*, 2012, **78**, 1579-1583.
246. F. R. Chang, T. L. Hwang, Y. L. Yang, C. E. Li, C. C. Wu, H. H. Issa, W. B. Hsieh and Y. C. Wu, *Planta Med.*, 2006, **72**, 1344-1347.
247. K. Shimbo, M. Tsud, E. Fukushi, J. Kawabata and J. I. Kobayashi, *Tetrahedron* 2000, **56**, 7923-7926.
248. C. H. Cheng, H. M. Chung, T. L. Hwang, M. C. Lu, Z. H. Wen, Y. H. Kuo, W. H. Wang and P.-J. Sung, *Molecules*, 2012, **17**, 9443-9450.
249. E. Bautista, E. Maldonado and A. Ortega, *J. Nat. Prod.*, 2012, **75**, 951-958.
250. E. Bautista, R. N. A. Toscano and A. Ortega, *J. Nat. Prod.*, 2014, **77**, 1088-1092.
251. A. Ortega, E. Maldonado, C. K. Jankowski, M. R. V. Calsteren and E. Diaz, *Phytochem. Anal.*, 1994, **5**, 302-304.
252. B. Esquivel, O. Esquivel, J. Cardenas, A. A. Sanchez, T.P. Ramamoorthy, R. A. Toscano and L. Rodriguez-Hahn, *Phytochemistry*, 1991, **30**, 2335-2338.
253. E. Maldonado and A. Ortega, *Phytochemistry*, 2000, **53**, 103-109.
254. C. R. Su, Y. F. Ueng, N. X. Dung, M. V. B. Reddy and T. S. Wu, *J. Nat. Prod.*, 2007, **70**, 1930-1933.
255. C. Huang, W. Li, F. Ma, Q. Li, Y. Asada and K. Koike, *Chem. Pharm. Bull.*, 2012, **60**, 1324-1328.
256. N. B. Qin, A.-L. Wang, D. H. Li, K. B. Wang, B. Lin, Z. L. Li and H.-M. Hua, *Phytochem. Lett.*, 2015, **12**, 173-176.
257. H. Achenbach and H. Hemrich, *Phytochemistry*, 1991, **30**, 1957-1962.
258. C. R. Su, Y. F. Chen, M. J. Liou, H. Y. Tsai, W. S. Chang and T.-S. Wu, *Bioorg. Med. Chem.*, 2008, **16**, 9603-9609.
259. L. Rakotobe, L. Mambua, A. Deville, L. Dubost, V. Jeannoda, D. Rakoto and B. Bodo, *Phytochemistry*, 2010, **71**, 1007-1013.
260. R. B. Teponno, A. L. Tapondjou, E. Abou-Mansour, H. Stoeckli-Evans, P. Tane and L. Barboni, *Phytochemistry*, 2008, **69**, 2374-2379.
261. K. Pudhom and D. Sommit, *Phytochem. Lett.*, 2011, **4**, 147-150.
262. H.-L. Qin and Z.-H. Li, *Phytochemistry*, 2004, **65**, 2533-2537.
263. C. Zdero, F. Bohlmann and G. M. Mungai, *Phytochemistry*, 1990, **29**, 2247-2252.
264. L. J. Valdés, H. M. Chang, D. C. Visger and M. Koreeda, *Org. Lett.*, 2001, **3**, 3935-3937.
265. T. A. Munro and M. A. Rizzacasa, *J. Nat. Prod.*, 2003, **66**, 703-705.
266. L. M. Kutrzeba, D. Ferreira and J. K. Zjawiony, *J. Nat. Prod.*, 2009, **72**, 1361-1363.
267. D. S. B. Brasil, A. H. Müller, G. M. S. P. Guilhon, C. N. Alves, G. Peris, R. Llusar and V. Moliner, *J. Braz. Chem. Soc.*, 2010, **21**, 731-739.

268. C. Song and R. Xu, *Chin. Chem. Lett.*, 1992, **3**, 185-188.
269. A. Sivasubramanian, K. K. G. Narasimha, R. Rathnasamy and A. M. F. O. Campos, *Nat. Prod. Res.*, 2013, **27**, 1431-1436.
270. R. M. Murillo and J. Jakupovic, *Ingenieria Y Ciencia Quimica*, 2000, **19**, 68-73.
271. Z. Ma, G. Deng and D. Y. W. Lee, *Tetrahedron Lett.*, 2010, **51**, 5207-5209.
272. M. G. Pizzolatti, A. J. Bortoluzzi, I. M. C. Brighente, A. Zuchinalli, F. K. Carvalho, A. C. S. Candido and M. T. L. P. Peres, *J. Braz. Chem. Soc.*, 2013, **24**, 609-614.
273. W. W. Harding, K. Tidgewell, M. Schmidt, K. Shah, C. M. Dersch, J. Snyder, D. Parrish, J. R. Deschamps, R. B. Rothman and T. E. Prisinzano, *Org. Lett.*, 2005, **7**, 3017-3020.
274. T. B. Chen, D. L. Galinis and D. F. Wiemer, *J. Org. Chem.*, 1992, **57**, 862-866.
275. Y. Narukawa, M. Fukui, K. Hatano and T. Takeda, *J. Nat. Med.*, 2006, **60**, 58-63.
276. L. Rodríguez-Hahn, R. O'Reilly, B. Esquivel, E. Maldonado, A. Ortega, J. Cárdenas, R. A. Toscano and T.-M. Chan, *J. Org. Chem.*, 1990, **55**, 3522-3525.
277. A. Fiorentino, B. D'Abrosca, S. Pacifico, M. Scognamiglio, G. D'Angelo, M. Gallicchio, A. Chambery and P. Monaco, *Phytochemistry*, 2011, **72**, 2037-2044.
278. H. Lv, J. Luo, M. Zhu, S. Shan and L. Kong, *Chem. Pharm. Bull.*, 2014, **62**, 472-476.
279. N. Xie, Z. Min, S. Zhao, B. Wu, Q. Zheng and P. Zhang, *Phytochemistry*, 1991, **30**, 1963-1966.
280. M. Bruno, M. L. Bondi, S. Rosselli, F. Piozzi, M. R. Y. Al-Hillo, K. Lamara and S. Ladjel, *J. Nat. Prod.*, 2000, **63**, 1029-1031.
281. M. C. de la Torre, B. Rodríguez, M. Bruno, C. Fazio, K. H. C. Baser and H. Duman, *Phytochemistry*, 1997, **45**, 1653-1662.
282. M. Bruno, F. Piozzi, B. Rodriguez, G. Savona, M. C. de la Torre and O. Servettaz, *Phytochemistry*, 1992, **31**, 4366-4367.
283. M. C. de la Torre, M. Bruno, G. Savona, F. Piozzi, B. Rodriguez and O. Orietta, *Phytochemistry*, 1990, **29**, 988-989.
284. M. T. Davies-Coleman, J. R. Hanson and D. E. A. Rivett, *Phytochemistry*, 1994, **36**, 1549-1550.
285. S. Ladjel, K. Laamara, M. R. Y. Al-Hillo and M. Païs, *Phytochemistry*, 1994, **37**, 1663-1666.
286. O. V. Gallardo, C. E. Tonn, M. Nieto, G. B. Morales and O. S. Giordano, *Nat. Prod. Res.*, 1996, **8**, 189-197.
287. M. C. de la Torre, B. Rodríguez, F. Piozzia, G. Savonaa, M. Bruno and M. C. Carreirasa, *Phytochemistry*, 1990, **29**, 579-584.
288. B. Rodríguez, M. C. de la Torre, M. Bruno, F. Piozzi, N. Vassallo, R. Ciriminna and O. Serettaz, *Phytochemistry*, 1996, **43**, 435-438.
289. G. Topcu, C. Eris, C.-T. Che and A. Ulubelen, *Phytochemistry*, 1996, **42**, 775-778.
290. B. Rodriguez, M. C. de la Torre, M. L. Jimeno, M. Bruno, C. Fazio, F. Piozzi, G. Savoia and A. Perales, *Tetrahedron*, 1995, **51**, 837-848.
291. M. C. de la Torre, B. Rodríguez, M. Bruno, G. Savona, F. Piozzi, A. Perales, M. R. Torres and O. Servettaz, *Phytochemistry*, 1990, **29**, 2229-2233.
292. Y. Cai, Z. P. Chen and J. D. Phillipson, *Phytochemistry*, 1993, **34**, 265-268.
293. C. Zdero, F. Bohlmann and H. M. Niemeyer, *Phytochemistry*, 1990, **29**, 1227-1230.
294. Y. Sun, M. Wang, Q. Ren, S. Li, J. Xu, Y. Ohizumi, C. Xie, D.-Q. Jin and Y. Guo, *Fitoterapia*,

- 2014, **95**, 229-233.
295. L. Tchissambou, A. Chiaroni, C. Riche and F. Khuong-Huu, *Tetrahedron*, 1990, **46**, 5199-5202.
296. D. Sun and G. Li, *Phytochemistry*, 1993, **33**, 716-717.
297. E. Bedir, D. Tasdemir, I. Çalis, O. Zerbe and O. Sticher, *Phytochemistry*, 1999, **51**, 921-925.
298. A. Sivasubramanian, R. Rathnasamy and M. S. Muthuraman, *Der Pharmacia Lettre*, 2014, **6**, 295-298.
299. M. Ali, *Phytochemistry*, 1992, **31**, 2173-2175.
300. H. Chen, D. Q. Liu, X. Z. Li, Z. H. Xia, Y. Li, Z. L. Liu and R. X. Tan, *Indian J. Chem.*, 1999, **38B**, 743-745.
301. A. Castro, J. Coll and M. Arfan, *J. Nat. Prod.*, 2011, **74**, 1036-1041.
302. P. Y. Malakov and G. Y. Papanov, *Phytochemistry*, 1998, **49**, 2443-2447.
303. P. Y. Malakov, G. Y. Papanov, M. C. de la Torre and B. Rodríguez, *Phytochemistry*, 1991, **30**, 4083-4085.
304. M. C. de la Torre, B. Rodríguez, M. Bruno, F. Piozzi, N. Vassallo, M. L. Bondí and O. Servettaz, *Phytochemistry*, 1997, **45**, 121-123.
305. I. M. Boneva, P. Y. Malakov and G. Y. Papanov, *Phytochemistry*, 1998, **47**, 303-305.
306. M. D. Cole, J. C. Anderson, W. M. Blaney, L. E. Fellows, S. V. Ley, R. N. Sheppard and M. S. J. Simmonds, *Phytochemistry*, 1990, **29**, 1793-1796.
307. M. Bruno, M. C. de la Torre, F. Piozzi, B. Rodriguez, G. Savona and N. A. Arnold, *Phytochemistry*, 1993, **33**, 931-932.
308. M. C. de la Torre, M. Bruno, F. Piozzi, B. Rodriguez, G. Savona and O. Servetaz, *Phytochemistry*, 1992, **31**, 3639-3641.
309. M. Bruno, C. Fazio and N. A. Arnold, *Phytochemistry*, 1996, **42**, 555-557.
310. M. Bruno, M. L. Bondi, S. Rosselli, F. Piozzi and O. Servettaz, *J. Nat. Prod.*, 2000, **63**, 1032-1034.
311. A. Ohno, H. Kizu and T. Tomimori, *Chem. Pharm. Bull.*, 1996, **44**, 1540-1545.
312. M. Bruno, F. Piozzi, B. Rodríguez, M. C. de la Torre, N. Vassallo and O. Servettaz, *Phytochemistry*, 1996, **42**, 1059-1064.
313. P. Y. Malakov and G. Y. Papanov, *Phytochemistry*, 1997, **46**, 955-958.
314. P. Y. Malakov, G. Y. Papanov and V. B. Deltchev, *Phytochemistry*, 1998, **49**, 811-815.
315. H. Chen, R. X. Tan, Z. L. Liu and Y. Zhang, *J. Nat. Prod.*, 1996, **59**, 668-670.
316. P. I. Bozov, G. Y. Papanov, P. Y. Malakov, M. C. de la Torre and B. Rodriguez, *Phytochemistry*, 1993, **34**, 1173-1175.
317. H. Ben Jannet, F. Harzallah-Skhiri, Z. Mighri, M. S. J. Simmonds and W. M. Blaney, *Fitoterapia*, 2000, **71**, 105-112.
318. B. Achari, C. Giri, C. R. Saha, P. K. Dutta and S. C. Pakrashi, *Phytochemistry*, 1992, **31**, 338-340.
319. R. Pandey, R. K. Verma and M. M. Gupta, *Phytochemistry*, 2005, **66**, 643-648.
320. M. Bruno, M. Cruciata, M. L. Bondi, F. Piozzi, M. C. de la Torre, B. Rodríguez and O. Servettaz, *Phytochemistry*, 1998, **48**, 687-691.
321. F. Zhu, L. Liu, Y. Di, X. Hao and H. He, *Yunnan Zhiwu Yanjiu*, 2009, **31**, 474-476.
322. B. Rodríguez, M. C. de la Torre, M.-L. Jimeno, M. Bruno, N. Vassallo, M. Bondí, F. Piozzi and O.

- Servettaz, *J. Nat. Prod.*, 1997, **60**, 348-355.
323. I. M. Boneva, B. P. Mikhova, P. Y. Malakov, G. Y. Papanov, H. Duddeck and S. L. Spassov, *Phytochemistry*, 1990, **29**, 2931-2933.
324. L. J. M. Rao, J. Pereira and K. N. Gurudutt, *Phytochemistry*, 1993, **34**, 572-574.
325. K. Kawai, T. Amano, R. Nishida, Y. Kuwahara and H. Fukami, *Phytochemistry*, 1998, **49**, 1975-1980.
326. M. D. Cole, P. D. Bridge, J. E. Dellar, L. E. Fellows, M. C. Cornish and J. C. Anderson, *Phytochemistry*, 1991, **30**, 1125-1127.
327. A. Ohno, H. Kizu and T. Tomimori, *Chem. Pharm. Bull.*, 1997, **45**, 1097-1100.
328. K. Kawai, R. Nishida and H. Fukami, *Biosci. Biotechnol. Biochem.*, 1999, **63**, 1795-1797.
329. P. Y. Malakov, G. Y. Papanov and S. L. Spassov, *Phytochemistry*, 1997, **44**, 121-124.
330. D. M. Muñoz, M. C. de la Torre, B. Rodríguez, M. S. J. Simmonds and W. M. Blaney, *Phytochemistry*, 1997, **44**, 593-597.
331. P. I. Bozov, P. Y. Malakov, G. Y. Papanov, M. C. de la Torre, B. Rodriguez and A. Perales, *Phytochemistry*, 1993, **34**, 453-456.
332. P. I. Bozov, G. Y. Papanov and P. Y. Malakov, *Phytochemistry*, 1994, **35**, 1285-1288.
333. H. Lee and S. H. Shim, *Helv. Chim. Acta.*, 2011, **94**, 643-649.
334. S. H. Shim, *Chem. Nat. Compds.*, 2014, **50**, 256-257.
335. B. Esquivel, J. S. Calderón and E. Flores, *Phytochemistry*, 1998, **47**, 135-137.
336. N. Ezer, Y. Akcos and B. Rodríguez, *Phytochemistry*, 1998, **49**, 1825-1827.
337. B. Esquivel, R. M. Dominguez, M. A. Martinez and G. Espinosa-Pérez, *Heterocycles*, 1997, **45**, 2247-2252.
338. H. Lee, Y. Kim, I. Choi, B. S. Min and S. H. Shim, *Bioorg. Med. Chem. Lett.*, 2010, **20**, 288-290.
339. H. L. Siddiqui, K. Munesada and T. Suga, *Chem. Lett.*, 1991, **4**, 701-704.
340. T. Aoki, T. Ohro, Y. Hirage, T. Suga, M. Uno and S. Ohta, *Phytochemistry*, 1997, **46**, 839-844.
341. X. H. Meng, C. Z. Zou, X. J. Jin, G. D. Huang, Y. J. Yang, X. Y. Zou, X. J. Yao and Y. Zhu, *Fitoterapia*, 2014, **93**, 39-46.
342. X. L. Li, L. M. Yang, Y. Zhao, R. R. Wang, G. Xu, Y. T. Zheng, L. Tu, L. Y. Peng, X. Cheng and Q. S. Zhao, *J. Nat. Prod.*, 2007, **70**, 265-268.
343. L. R. R. Harinantenaina, R. Kasai and K. Yamasaki, *Phytochemistry*, 2002, **60**, 339-343.
344. N. Kawahara, T. Tamura, M. Inoue, T. Hosoe, K.-I. Kawai, S. Sekita, M. Satake and Y. Goda, *Phytochemistry*, 2004, **65**, 2577-2581.
345. H. Hu, H. Cao, Y. F. Jian, X. D. Zheng and J. X. Liu, *Indian J. Chem.*, 2008, **47B**, 166-170.
346. E. Maldonado, J. Cárdenas, H. Bojórquze, E. M. Escamilla and A. Ortega, *Phytochemistry*, 1996, **42**, 1105-1108.
347. N. Fukuda, M. Yonemitsu and T. Kimura, *Liebigs Ann. Chem.*, 1993, 491-495.
348. T. S. Martin, K. Ohtani, R. Kasai and K. Yamasaki, *Phytochemistry*, 1996, **42**, 153-158.
349. D. A. Cifuentes, E. J. Borkowski, M. E. Sosa, J. C. Gianello, O. S. Giordano and C. E. Tonn, *Phytochemistry*, 2002, **61**, 899-905.
350. Z. Y. Jiang, W. J. Li, L. X. Jiao, J. M. Guo, K. Tian, C. T. Yang and X. Z. Huang, *Planta Med.*, 2014, **80**, 419-425.

351. T. S. Martin, K. Ohtani, R. Kasai and K. Yamasaki, *Phytochemistry*, 1995, **40**, 1729-1736.
352. L. Pan, C. Terrazas, C. M. Lezama-Davila, N. Rege, J. C. Gallucci, A. R. Satoskar and A. D. Kinghorn, *Org. Lett.*, 2012, **14**, 2118-2121.
353. M. I. Choudhary, M. Ismail, K. Shaari, A. Abbaskhan, S. A. Sattar, N. H. Lajis and Atta-ur-Rahman, *J. Nat. Prod.*, 2010, **73**, 541-547.
354. V. Wazir, R. Maurya and R. S. Kapil, *Phytochemistry*, 1995, **38**, 447-449.
355. W. Li, C. Huang, S. Li, F. Ma, Q. Li, Y. Asada and K. Koike, *Planta Med.*, 2012, **78**, 82-85.
356. P. V. Kiem, C. V. Minh, N. T. Dat, L. V. Kinh, D. T. Hang, N. H. Nam, N. X. Cuong, H. T. Huong and T. V. Lau, *Fitoterapia*, 2010, **81**, 485-489.
357. W. Li, K. Wei, H. Fu and K. Koike, *J. Nat. Prod.*, 2007, **70**, 1971-1976.
358. A. Fiorentino, B. D'Abrosca, A. Ricci, S. Pacifico, S. Piccolella and P. Monaco, *Magn. Reson. Chem.*, 2009, **47**, 1007-1012.
359. P. Y. Malakov, G. Y. Papanov, I. M. Boneva, M. C. de la Torre and B. Rodriguez, *Phytochemistry*, 1993, **34**, 1095-1098.
360. M. Gavagnin, M. Carbone, P. Amodeo, E. Mollo, R. M. Vitale, V. Roussis and G. Cimino, *J. Org. Chem.*, 2007, **72**, 5625-5630.
361. M. Carbone, M. Gavagnin, E. Mollo, M. Bidello, V. Roussis and G. Cimino, *Tetrahedron*, 2008, **64**, 191-196.
362. K. Annan, E. Ekuadzi, C. Asare, K. Sarpong, D. Pistorius, L. Oberer, B. A. Gyan and M. Ofori, *Phytochem. Lett.*, 2015, **11**, 28-31.
363. J. Appenzeller, G. Mihci, M. T. Martin, J. F. Gallard, J. L. Menou, N. B. Esnault, J. Hooper, S. Petek, S. Chevalley, A. Valentin, A. Zaparucha, A. A. Mourabit and C. Debitus, *J. Nat. Prod.*, 2008, **71**, 1451-1454.
364. G. R. Pettit, Y. Tang, Q. Zhang, G. T. Bourne, C. A. Arm, J. E. Leet, J. C. Knight, R. K. Pettit, J.-C. Chapuis, D. L. Doubek, F. J. Ward, C. Weber and J. N. A. Hooper, *J. Nat. Prod.*, 2013, **76**, 420-424.
365. T. Kubota, T. Iwai, A. Takahashi-Nakaguchi, J. Fromont, T. Gonoï and J. I. Kobayashi, *Tetrahedron*, 2012, **68**, 9738-9744.
366. F. Wang, F. C. Ren, Y.-J. Li and J. K. Liu, *Chem. Pharm. Bull.*, 2010, **58**, 1267-1270.
367. S. J. Dai, W. B. Peng, D. W. Zhang, L. Shen, W. Y. Wang and Y. Ren, *J. Nat. Prod.*, 2009, **72**, 1793-1797.
368. X. P. Nie, G. W. Qu, X. D. Yue, G. S. Li and S. J. Dai, *Phytochem. Lett.*, 2010, **3**, 190-193.
369. Z. Q. Wang, F. M. Xu, X. Z. Yan and Y. Zhu, *Chin. Chem. Lett.*, 1996, **7**, 333-334.
370. S. J. Dai, D. D. Liang, Y. Ren, K. Liu and L. Shen, *Chem. Pharm. Bull.*, 2008, **56**, 207-209.
371. S. J. Dai, M. Chen, K. Liu, Y. T. Jiang and L. Shen, *Chem. Pharm. Bull.*, 2006, **54**, 869-872.
372. S. J. Dai, W. B. Peng, L. Shen, D. W. Zhang and Y. Ren, *J. Asian Nat. Prod. Res.*, 2009, **11**, 451-456.
373. J. I. Kobayashi, M. Sekiguchi, S. Shimamoto, H. Shigemori and A. Ohsaki, *J. Nat. Prod.*, 2000, **63**, 1576-1579.
374. J. I. Kobayashi, M. Sekiguchi, H. Shigemori and A. Ohsaki, *Tetrahedron Lett.*, 2000, **41**, 2939-2943.

375. Y. Y. Cheng, S. F. Li, Y. Zhang, G. H. Tang, Y. T. Di, X. J. Hao, S. L. Li and H.-P. He, *Fitoterapia*, 2012, **83**, 1100-1104.
376. N. Xie, Z. D. Min, S.-X. Zhao, Y. Lu, Q. T. Zheng, C. Wang, M. Mizuno, M. Iinuma and T. Tanaka, *Chem. Pharm. Bull.*, 1992, **40**, 2193-2195.
377. M. Bruno, C. Fazio, F. Piozzi, G. Sovona, B. Rodríguez and M. C. de la Torre, *Phytochemistry*, 1995, **40**, 505-507.
378. S. J. Dai, G. F. Wang, M. Chen, K. Liu and L. Shen, *Chem. Pharm. Bull.*, 2007, **55**, 1218-1221.
379. V. H. Nguyen, V. C. Pham, T. T. H. Nguyen, V. H. Tran and T. M. H. Doan, *Eur. J. Org. Chem.*, 2009, 5810-5815.
380. X. Z. Huang, C. M. C. Dai, G. M. Fu, J. M. Guo, Y. Yin and H. Liang, *Molecules*, 2010, **15**, 8360-8365.
381. P. Tane, H. K. Wabo, J. F. Ayafor and O. Sterner, *Phytochemistry*, 1997, **46**, 165-167.
382. Z. Pan, D. Ning, X. Wu, S. Huang, D. Li and S. Lv, *Bioorg. Med. Chem. Lett.*, 2015, **25**, 1329-1332.
383. K. Kidyu, H. Thaisuchat, P. Meepowpan, S. Sukdee, N. Nuntasaeen, S. Punyanitya and W. Pompimon, *Nat. Prod. Commun.*, 2011, **6**, 1069-1072.
384. H. M. Zakaria, F. Kenne, C. C. Musa, C. K. Modest, J. M. Joseph, M. M. Mainen, L. Filip, G. Kees, F. Jan, P. René, V. Arnold, A. Sandra and P. Luc, *Planta Med.*, 2009, **75**, 262-267.
385. G. C. Wang, J. G. Li, G. Q. Li, J. J. Xu, X. Wu, W. C. Ye and Y. L. Li, *J. Nat. Prod.*, 2012, **75**, 2188-2192.
386. Z.-D. Min, N. Xie, P. Zhang, S.-X. Zhao, C.-S. Wang and Q.-T. Zheng, *Phytochemistry*, 1991, **30**, 4175-4177.
387. W.-H. Huang, G. Q. Li, J. G. Li, X. Wu, W. Ge, H. Y. Chung, W. C. Ye, Y. L. Li and G.-C. Wang, *Heterocycles*, 2014, **89**, 1585-1593.
388. Y. Ichihara, K. Takey, Y. Hitotsuyanai, H. Morita, S. Okuyama, M. Sukanuma, H. Fujiki, M. Motidome and H. Itokawa, *Planta Med.*, 1992, **58**, 549-551.
389. B. A. Soares, C. L. Firme, M. A. M. Maciel, C. R. Kaiser, E. Schilling and A. J. Bortoluzzi, *J. Braz. Chem. Soc.*, 2014, **25**, 629-638.
390. M. Bruno, C. Fazio, F. Piozzi, B. Rodríguez and M. C. de la Torre, *Phytochemistry*, 1995, **40**, 1481-1483.
391. S. Kabir, M. S. Rahman, A. M. S. Chowdhury, C. M. Hasan and M. A. Rashid, *Nat. Prod. Commun.*, 2010, **5**, 1543-1546.
392. M. Toyota, I. Omatsu, F. Sakata, J. Braggins and Y. Asakawa, *Nat. Prod. Commun.*, 2010, **5**, 999-1003.
393. H. Tazaki, H. Becker and K. Nabeta, *Phytochemistry*, 1999, **51**, 743-750.
394. U. M. Hertewich, J. Zapp and H. Becker, *Phytochemistry*, 2003, **63**, 227-233.
395. A. Ortega, J. Cárdenas, A. Toscano, E. Maldonado, A. Aumelas, M. R. V. Calsteren and C. Jankowskq, *Phytochemistry*, 1991, **30**, 3357-3360.
396. R. A. Toscano, E. Maldonado and A. Ortega, *J. Chem. Crystallogr.*, 1996, **26**, 239-242.
397. F. Ahmad, M. Ali and P. Alam, *Nat. Prod. Res.*, 2010, **24**, 926-9354.
398. M. del Carmen Fernández, B. Esquivel, J. Cárdenas, A. A. Sánchez, R. A. Toscano and L.

- Rodríguez-Hahn, *Tetrahedron*, 1991, **47**, 7199-7208.
399. H. P. He, Y. M. Shen, X. Hong, Y. B. Zhao, J. Zhou and X. J. Hao, *J. Nat. Prod.*, 2002, **65**, 392-394.
400. A. Ohsaki, Y. Kasetani, Y. Asaka, K. Shibata, T. Tokoroyama and T. Kubota, *Phytochemistry*, 1995, **40**, 205-207.
401. H. M. Niu, D. Q. Zeng, C. L. Long, Y. H. Peng, Y. H. Wang, J. F. Luo, H. S. Wang, Y. N. Shi, G. H. Tang and F. W. Zhao, *J. Asian. Nat. Prod. Res.*, 2010, **12**, 7-14.
402. Y. Narukawa, K. Hatano and T. Takeda, *J. Nat. Med.*, 2006, **60**, 206-209.
403. B. Esquivel, R. M. Domínguez, S. H. Ortega, R. A. Toscano and L. R. Hahn, *Tetrahedron*, 1994, **50**, 11593-11600.
404. G. Xu, L. Peng, X. Niu, Q. Zhao, R. Li and H. Sun, *Helv. Chim. Acta*, 2004, **87**, 949-955.
405. M. Á. Jaime-Vasconcelos, B. A. Frontana-Uribe, M.-S. José Antonio, M. Salmón and J. Cárdenas, *Molecules*, 2011, **16**, 9109-9115.
406. A. Bisio, N. Fontana, G. Romussi, G. Ciarallo, N. D. Tommasi, C. Pizza and A. Mugnoli, *Phytochemistry*, 1999, **52**, 1535-1540.
407. B. Esquivel, R. Tello and A. A. Sánchez, *J. Nat. Prod.*, 2005, **68**, 787-790.
408. P. Tuntiwachwuttikul, J. B. B. Nicha Boonrasria and W. C. Taylor, *Phytochemistry*, 1999, **52**, 1335-1340.
409. P. Tuntiwachwuttikul and W. C. Taylor, *Chem. Pharm. Bull.*, 2001, **49**, 854-857.
410. E. Bautista, R. A. Toscano and A. Ortega, *Org. Lett.*, 2013, **15**, 3210-3213.
411. H. Gaspar, F. M. S. B. Palma, M. C. de la Torre, B. Rodríguez and A. Perales, *Tetrahedron*, 1995, **51**, 2363-2368.
412. H. Tazaki, M. Blechschmidt, V. Huch, M. Veith and H. Becker, *Phytochemistry*, 1994, **37**, 491-494.
413. G. Topcu, C. Eris, A. Ulubelen, M. Krawiec and W. H. Watson, *Tetrahedron*, 1995, **51**, 11793-11800.
414. G. Topcu and C. Eris, *J. Nat. Prod.*, 1997, **60**, 1045-1047.
415. J. Cárdenas, T. Pavón, B. Esquivel, A. Toscano and L. Rodríguez-Hahn, *Tetrahedron Lett.*, 1992, **33**, 581-584.
416. I. Kubo and K. Nakanishi, *Adv. Pestic. Sci., Plenary Lect. Symp. Pap. Int. Congr. Pestic. Chem., 4th*, 1979, **2**, 284-294.
417. I. Kubo, J. A. Klocke, I. Miura and Y. Fukuyama, *J. Chem. Soc., Chem. Commun.*, 1982, **11**, 618-619.
418. J. Pereira and K. N. Gurudutt, *J. Chem. Ecol.*, 1990, **16**, 2297-2306.
419. I. Kubo, Y. Asaka and K. Shibata, *Phytochemistry*, 1991, **30**, 2545-2546.
420. L. Rodríguez-Hahn, B. Esquivel and J. Cardenas, *Prog. Chem. Org. Nat. Prod.*, 1994, **63**, 107-196.
421. F. Piozzi, *Heterocycles*, 1994, **37**, 603-626.
422. F. Piozzi, M. Bruno and S. Rosselli, *Heterocycles*, 1998, **48**, 2185-2203.
423. J. C. Anderson, W. M. Blaney, M. D. Cole, L. L. Fellows, S. V. Ley, R. N. Sheppard and M. S. J. Simmonds, *Tetrahedron Lett.*, 1989, **30**, 4737-4740.

424. M. Bruno, N. Vassallo and M. S. J. Simmonds, *Phytochemistry*, 1999, **50**, 973-976.
425. M. Bruno, R. Ciriminna, F. Piozzi, S. Rosselli and M. S. J. Simmonds, *Phytochemistry*, 1999, **52**, 1055-1058.
426. M. Bruno, F. Piozzi and S. Rosselli, *Nat. Prod. Rep.*, 2002, **19**, 357-378.
427. G. Abbaszadeh, C. Srivastava and S. Walia, *Natl. Acad. Sci. Lett.*, 2012, **35**, 457-464.
428. G. N. K. Kumari, J. Balachandran, S. Aravind and M. R. Ganesh, *J. Agric. Food Chem.*, 2003, **51**, 1555-1559.
429. C. E. Vaccarin, S. M. Palacios, K. M. Meragelman and V. E. Sosa, *Phytochemistry*, 1999, **50**, 227-230.
430. A. Gonzalez-Coloma, C. Gutierrez, J. M. Miguel del Corral, M. Gordaliza, M. L. de la Puente and A. San Feliciano, *J. Agric. Food Chem.*, 2000, **48**, 3677-3681.
431. R. D. Enriz, H. A. Baldoni, M. A. Zamora, E. A. Jauregui, M. E. Sosa, C. E. Tonn, J. M. Luco and M. Gordaliza, *J. Agric. Food Chem.*, 2000, **48**, 1384-1392.
432. R. D. Enriz, H. A. Baldoni, E. A. Jauregui, M. E. Sosa, C. E. Tonn and O. S. Giordano, *J. Agric. Food Chem.*, 1994, **42**, 2958-2963.
433. A. Ortega, J. F. Blount and P. S. Manchand, *J. Chem. Soc. Perkin Trans. I*, 1982, **10**, 2505-2508.
434. I. Leander J. Valdes, W. M. Butler, G. M. Hatfield, A. G. Paul and M. Koreeda, *J. Org. Chem.*, 1984, **49**, 4716-4720.
435. B. L. Roth, K. Baner, R. Westkaemper, D. Siebert, K. C. Rice, S. Steinberg, P. Ernsberger and R. B. Rothman, *Proc. Natl. Acad. Sci. USA*, 2002, **99**, 11934-11939.
436. D. J. Siebert, *J. Ethnopharmacol.*, 1994, **43**, 53-56.
437. D. J. Sheffler and B. L. Roth, *Trends Pharmacol. Sci.*, 2003, **24**, 107-109.
438. D. C. Rees and J. C. Hunter, in J.C. Emmett (Ed.), *Comprehensive Medicinal Chemistry*, **3**, Pergamon, Oxford, 1990, pp. 805-846.
439. C. W. Cunningham, R. B. Rothman and T. E. Prisinzano, *Pharmacol. Rev.*, 2011, **63**, 316-347.
440. C. Chavkin, S. Sud, W. Jin, J. Stewart, J. K. Zjawiony, D. J. Siebert, B. A. Toth, S. J. Hufeisen and B. L. Roth, *J. Pharmacol. Exp. Ther.*, 2004, **308**, 1197-1203.
441. Y. Wang, K. Tang, S. Inan, D. Siebert, U. Holzgrabe, D. Y. W. Lee, P. Huang, J.-G. Li, A. Cowan and L.-Y. Liu-Chen, *J. Pharmacol. Exp. Ther.*, 2005, **312**, 220-230.
442. D. M. Walentiny, R. E. Vann, J. A. Warner, L. S. King, H. H. Seltzman, H. A. Navarro, C. E. T. Jr., B. F. Thomas, A. F. Gilliam, B. P. Gilmour, F. I. Carroll and J. L. Wiley, *Psychopharmacology*, 2010, **210**, 275-284.
443. T. F. John, L. G. French and J. S. Erlichman, *Eur. J. Pharmacol.*, 2006, **545**, 129-133.
444. C. R. McCurdy, K. J. Sufka, G. H. Smith, J. E. Warnick and M. J. Nieto, *Pharmacol. Biochem. Behav.*, 2006, **83**, 109-113.
445. Y. Zhang, E. R. Butelman, S. D. Schlussman, A. Ho and M. J. Kreek, *Psychopharmacology*, 2005, **179**, 551-558.
446. E. H. Chartoff, D. Potter, D. Damez-Werno, B. M. Cohen and W. A. C. Jr, *Neuropsychopharmacology*, 2008, **33**, 2676-2687.
447. J. X. Li, K. C. Rice and C. P. France, *J. Pharmacol. Exp. Ther.*, 2008, **324**, 827-833.
448. R. B. Rothman, D. L. Murphy, H. Xu, J. A. Godin, C. M. Dersch, J. S. Partilla, K. Tidgewell, M.

- Schmidt and T. E. Prisinzano, *J. Pharmacol. Exp. Ther.*, 2007, **320**, 801-810.
449. M. Waldhoer, S. E. Bartlett and J. L. Whistler, *Annu. Rev. Biochem.*, 2004, **73**, 953-990.
450. D. Braida, A. Donzelli, R. Martucci, V. Capurro and M. Sala, *Int. J. Toxicol.*, 2011, **30**, 650-661.
451. Z. Ma and D. Y. W. Lee, *Tetrahedron Lett.*, 2007, **48**, 5461-5464.
452. T. A. Munro, M. A. Rizzacasa, B. L. Roth, B. A. Toth and F. Yan, *J. Med. Chem.*, 2005, **48**, 345-348.
453. D. S. Simpson, P. L. Katavic, A. Lozama, W. W. Harding, D. Parrish, J. R. Deschamps, C. M. Dersch, J. S. Partilla, R. B. Rothman, H. Navarro and T. E. Prisinzano, *J. Med. Chem.*, 2007, **50**, 3596-3603.
454. P. R. Polepally, K. White, E. Vardy, B. L. Roth, D. Ferreira and J. K. Zjawiony, *Bioorg. Med. Chem. Lett.*, 2013, **23**, 2860-2862.
455. C. Béguin, J. Potuzak, W. Xu, L.-Y. Liu-Chen, J. M. Streicher, C. E. Groer, L. M. Bohn, W. A. C. Jr. and B. M. Cohen, *Bioorg. Med. Chem. Lett.*, 2012, **22**, 1023-1026.
456. C. Béguin, K. K. Duncan, T. A. Munro, D. M. Ho, W. Xu, L.-Y. Liu-Chen, W. A. C. Jr. and B. M. Cohen, *Bioorg. Med. Chem.*, 2009, **17**, 1370-1380.
457. T. A. Munro, K. K. Duncan, W. Xu, Y. Wang, L.-Y. Liu-Chen, W. A. Carlezon Jr., B. M. Cohen and C. Béguin, *Bioorg. Med. Chem.*, 2008, **16**, 1279-1286.
458. J. M. Hooker, T. A. Munro, C. Béguin, D. Alexoff, C. Shea, Y. Xu and B. M. Cohen, *Neuropharmacology*, 2009, **57**, 386-391.
459. L. E. Baker, J. J. Panos, B. A. Killinger, M. M. Peet, L. M. Bell, L. A. Haliw and S. L. Walker, *Psychopharmacology*, 2009, **203**, 203-211.
460. Y. Wang, Y. Chen, W. Xu, D. Y. W. Lee, Z. Ma, S. M. Rawls, A. Cowan and L.-Y. Liu-Chen, *J. Pharmacol. Exp. Ther.*, 2008, **324**, 1073-1083.
461. F. Yan, R. V. Bikbulatov, V. Mocanu, N. Dicheva, C. E. Parker, W. C. Wetsel, P. D. Mosier, R. B. Westkaemper, J. A. Allen, J. K. Zjawiony and B. L. Roth, *Biochemistry*, 2009, **48**, 6898-6908.
462. W. W. Harding, K. Tidgewell, N. Byrd, H. Cobb, C. M. Dersch, E. R. Butelman, R. B. Rothman and T. E. Prisinzano, *J. Med. Chem.*, 2005, **48**, 4765-4771.
463. W. W. Harding, M. Schmidt, K. Tidgewell, P. Kannan, K. G. Holden, C. M. Dersch, R. B. Rothman and T. E. Prisinzano, *Bioorg. Med. Chem. Lett.*, 2006, **16**, 3170-3174.
464. C. E. Groer, K. Tidgewell, R. A. Moyer, W. W. Harding, R. B. Rothman, T. E. Prisinzano and L. M. Bohn, *Mol. Pharmacol.*, 2007, **71**, 549-557.
465. J. Fichna, K. Lewellyn, F. Yan, B. L. Roth and J. K. Zjawiony, *Med. Chem. Lett.*, 2011, **21**, 160-163.
466. D. Y. W. Lee, V. V. R. Karnati, M. He, L.-Y. Liu-Chen, L. Kondaveti, Z. Ma, Y. Wang, Y. Chen, C. Béguin, J. William A. Carlezon and B. Cohen, *Bioorg. Med. Chem. Lett.*, 2005, **15**, 3744-3747.
467. C. Béguin, M. R. Richards, Y. Wang, Y. Chen, L.-Y. Liu-Chen, Z. Ma, D. Y. W. Lee, W. A. Carlezon and B. M. Cohen, *Bioorg. Med. Chem. Lett.*, 2005, **15**, 2761-2765.
468. C. Béguin, M. R. Richards, J.-G. Li, Y. Wang, W. Xu, L.-Y. Liu-Chen, W. A. Carlezon and B. M. Cohen, *Bioorg. Med. Chem. Lett.*, 2006, **16**, 4679-4685.
469. K. Tidgewell, W. W. Harding, A. Lozama, H. Cobb, K. Shah, P. Kannan, C. M. Dersch, D. Parrish, J. R. Deschamps, R. B. Rothman and T. E. Prisinzano, *J. Nat. Prod.*, 2006, **69**, 914-918.

470. D. J. Stewart, H. Fahmy, B. L. Roth, F. Yan and J. K. Zjawiony, *Arzneimittel Forschung*, 2006, **56**, 269-275.
471. D. Y. W. Lee, L. Yang, W. Xu, G. Deng, L. Guo and L.-Y. Liu-Chen, *Bioorg. Med. Chem. Lett.*, 2010, **20**, 5749-5752.
472. K. M. Lovell, K. M. Prevatt-Smith, A. Lozama and T. E. Prisinzano, *Top. Curr. Chem.*, 2011, **299**, 141-185.
473. K. M. Lovell, T. Vasiljevik, J. J. Araya, A. Lozama, K. M. Prevatt-Smith, V. W. Day, C. M. Dersch, R. B. Rothman, E. R. Butelman, M. J. Kreek and T. E. Prisinzano, *Bioorg. Med. Chem.*, 2012, **20**, 3100-3110.
474. W. Tang, M. Kubo, K. Harada, H. Hioki and Y. Fukuyama, *Bioorg. Med. Chem. Lett.*, 2009, **19**, 882-886.
475. Y. Guo, Y. Li, J. Xu, N. Li, T. Yamakuni and Y. Ohizumi, *Chem. Pharm. Bull.*, 2007, **55**, 1532-1534.
476. A. R. M. Souza Brito, J. A. Rodriguez, C. A. Hiruma-Lima, M. Haun and D. S. Nunes, *Planta Med.*, 1998, **64**, 126-129.
477. C. A. Hiruma-Lima, R. C. Spadari-Bratfisch, D. M. G. Kassisse and A. R. M. Souza Brito, *Planta Med.*, 1999, **65**, 325-330.
478. J. A. Rodriguez, C. A. Hiruma-Lima and A. R. Souza Brito, *Hum. Exp. Toxicol.*, 2004, **23**, 455-461.
479. C. A. Hiruma-Lima, W. Toma, J. D. S. Gracioso, A. B. A. D. Almeida, L. M. Batista, L. Magri, A. C. B. D. Paula, F. R. Soares, D. S. Nunes and A. R. M. Souza Brito, *Biol. Pharm. Bull.*, 2002, **25**, 452-456.
480. C. A. Hiruma-Lima, J. D. S. Gracioso, W. Toma, A. C. B. D. Paula, A. B. A. D. Almeida, D. D. S. B. Brasil, A. H. Muller and A. R. M. Souza Brito, *Biol. Pharm. Bull.*, 2000, **23**, 1465-1469.
481. C. A. Hiruma-Lima, J. S. Gracioso, W. Toma, A. B. Almeida, A. C. Paula, D. S. B. Brasil, A. H. Muller and A. R. M. Souza Brito, *Phytomedicine*, 2001, **8**, 94-100.
482. D. S. B. Brasil, R. Y. O. Moreira, A. H. Muller and C. N. Alves, *Int. J. Quantum Chem.*, 2006, **106**, 2706-2713.
483. Y. C. Shen, C. L. Lee, A. T. Khalil, Y. B. Cheng, C. T. Chien and Y. H. Kuo, *Helv. Chim. Acta*, 2005, **88**, 68-77.
484. C.-T. Chiou, Y.-H. Kuo, Y.-Y. Chan, S.-H. Juang, H.-H. Chan and T.-S. Wue, *Phytochemistry*, 2012, **80**, 64-69.
485. M. Efdi, T. Itoh, Y. Akao, Y. Nozawa, M. Koketsu and H. Ishihara, *Bioorg. Med. Chem.*, 2007, **15**, 3667-3671.
486. A. P. Phadnis, S. A. Patwarshan, N. N. Dhaneshwar, S. S. Tavale and T. N. G. Row, *Phytochemistry*, 1988, **27**, 2899-2901.
487. T. Akihisa, T. Kikuchi, H. Nagai, K. Ishii, K. Tabata and T. Suzuki, *J. Oleo Sci.*, 2011, **60**, 71-77.
488. H. Itokawa, N. Totsuka, H. Morita, K. Takeya, Y. Itaka, E. P. Schenkel and M. Motidome, *Chem. Pharm. Bull.*, 1990, **38**, 3384-3388.
489. H. Morita, M. Nakayama, H. Kojima, K. Takeya, H. Itokawa, E. P. Schenkel and M. Motidome, *Chem. Pharm. Bull.*, 1991, **39**, 693-697

490. A. G. dos Santos, P. M. P. Ferreira, G. M. Vieira Júnior, C. C. Perez, A. G. Tininis, G. H. Silva, V. da Silva Bolzani, L. V. Costa-Lotufo, C. do Ó Pessoa and A. J. Cavalheiro, *Chem. Biodivers.*, 2010, **7**, 205-215.
491. A. M. Prieto, A. G. dos Santos, A. P. S. Oliveira, A. J. Cavalheiro, D. H. S. Silva, V. S. Bolzani, E. A. Varanda and C. P. Soares, *Food Chem. Toxicol.*, 2013, **53**, 153-159.
492. P. M. P. Ferreira, A. G. Santos, A. G. Tininis, P. M. Costa, A. J. Cavalheiro, V. S. Bolzani, M. O. Moraes, L. V. Costa-Lotufo, R. C. Montenegro and C. Pessoa, *Chem-Biol. Interact.*, 2010, **188**, 497-504.
493. A. M. Prieto, A. G. Santos, A. R. Csipak, C. M. Caliri, I. C. Silva, M. A. Arbex, F. S. Silva, M. R. R. Marchi, A. J. Cavalheiro, D. H. S. Silva, V. S. Bolzani and C. P. Soares, *Toxicol. Appl. Pharm.*, 2012, **265**, 368-372.
494. M. Gordaliza, J. M. Miguel del Corral, M. L. de la Puente, M. D. Garcia-Grávalos and A. San Feliciano, *Bioorg. Med. Chem. Lett.*, 1997, **7**, 1649-1654.
495. A. Ohsaki, L. T. Yan, S. Ito, H. Edatsugi, D. Iwata and Y. Komoda, *Bioorg. Med. Chem. Lett.*, 1994, **4**, 2889-2892.
496. H. J. Jung, S. Y. Chung, J.-W. Nam, S. W. Chae, Y.-J. Lee, E.-K. Seo and H. J. Lee, *Chem. Biodivers*, 2010, **7**, 2095-2101.
497. M. Dhanasekaran, A.-A. Baskar, S. Ignacimuthu, P. Agastian and V. Durairandiyan, *Invest New Drugs*, 2009, **27**, 347-355.
498. N. F. Grynberg, A. Echevarria, J. E. Lima, S. S. R. Pamplona, A. C. Pinto and M. A. M. Maciel, *Planta Med.*, 1999, **65**, 687-689.
499. G. Aviello, F. Borrelli, F. Guida, B. Romano, K. Lewellyn, M. D. Chiaro, L. Luongo, J. K. Zjawiony, S. Maione, A. A. Izzo and R. Capasso, *J. Mol. Med.*, 2011, **89**, 891-902.
500. J. Fichna, M. Dickey, K. Lewellyn, A. Janecka, J. K. Zjawiony, W. K. MacNaughton and M. A. Storr, *Inflamm. Bowel Dis.*, 2012, **18**, 1137-1145.
501. R. Benrezzouk, M. C. Terencio, M. L. Ferrándiz, A. San Feliciano, M. Gordaliza, J. M. Miguel del Corral, M. L. de la Puente, and M. J. Alcaraz, *Life Sci.*, 1999, **64**, 205-11.
502. H. L. Chang, F. R. Chang, J. S. Chen, H. P. Wang, Y. H. Wu, C. C. Wang, Y. C. Wu and T. L. Hwang, *Eur. J. Pharmacol.*, 2008, **586**, 332-339.
503. L. Mambu, V. Ramanandraibe, M. T. Martin, A. Blond, P. Grellier and F. Frappier, *Planta Med.*, 2002, **68**, 377-379.
504. K. A. M. Kuria, H. Chepkwony, C. Govaerts, E. Roets, R. Busson, P. d. Witte, I. Zupko, G. Hoornaert, L. Quiryneen, L. Maes, L. Janssens, J. Hoogmartens and G. Laekeman, *J. Nat. Prod.*, 2002, **65**, 789-793.
505. J. Coll and Y. A. Tandrón, *Phytochem. Rev.*, 2008, **7**, 25-49.
506. M. Sathe, R. Ghorpade, A.K. Srivastava and M.P. Kaushik, *J. Ethnopharmacol.*, 2010, **130**, 171-174.
507. E. Bautista, A. Toscano, F. Calzada, E. Díaz, L. Yépez-Mulia and A. Ortega, *J. Nat. Prod.*, 2013, **76**, 1970-1975.
508. V. K. Gupta, S. Verma, A. Pal, S.K. Srivastava, P.K. Srivastava and M.P. Darokar, *Appl. Microbiol Biotechnol.*, 2013, **97**, 9121-9131.

509. A. Bisio, A.M. Schito, S.N. Ebrahimi, M. Hamburger, G. Mele, G. Piatti, G. Romussi, F. Dal Piaz and N. De Tommasi, *Phytochemistry*, 2015, **110**, 120-132.
510. H. Ben Jannet, A. Chaari, Z. Mighri, M. T. Martin, and A. Loukaci, *Phytochemistry*, 1999, **52**, 1541-1545.
511. M. A. M. Maciel, A. C. Pinto, A. C. Arruda, S. G. S. R. Pamplona, F. A. Vanderlinde, A. J. Lapa, A. Echevarria, N. F. Grynberg, I. M. S. Colus, R. A. F. Farias, A. M. L. Costa and V. S. N. Rao, *Ethnopharmacol.*, 2000, **70**, 41-55.
512. M. A. M. Maciel, T. N. C. Dantas, A. C. Pinto, V. F. Veiga, N. F. Grynberg and A. Echevarria, *Curr. Top. Phytochem.*, 2005, **7**, 73-88.
513. M. A. M. Maciel, T. N. C. Dantas, J. K. P. Câmara, A. C. Pinto, V. F. Veiga, C. R. Kaiser, N. A. Pereira, C. M. T. S. Carneiro, F. A. Vanderlinde, A. J. Lapa, A. R. Agner, I. M. S. Cólus, J. Echevarria-Lima, N. F. Grynberg, A. Esteves-Souza, K. Pissinate and A. Echevarria, *Advances in Phytomedicine*, 2006, **2**, 225-253.
514. M. A. M. Maciel, J. K. P. C. Cortez and F. E. S. Gomes, *Revista Fitos*, 2006, **2**, 54-73.
515. M. P. d. Costa, N. S. S. Magalhães, F. E. S. Gomes and M. A. M. Maciel, *Rev. Bras. Farmacogn.*, 2007, **17**, 275-286.
516. I. Kubo, J. A. Klocke and S. Asano, *J. Insect Physiol.*, 1983, **29**, 307-316.
517. A. M. L. Costa, J. C. R. Silva, A. R. Campos, V. S. N. Rao, M. A. M. Maciel and A. C. Pinto, *Phytother. Res.*, 1999, **13**, 689-691.
518. J. T. Carvalho, M. F. C. Silva, M. A. M. Maciel, A. C. Pinto, D. S. Nunes, R. M. Lima, J. K. Bastos and S. J. Sarti, *Planta Med.*, 1996, **62**, 402-404.
519. R. A. F. Farias, V. S. N. Rao, G. S. B. Viana, E. R. Silveira, M. A. M. Maciel and A. C. Pinto, *Planta Med.*, 1997, **63**, 558-560.
520. M. T. H. Khan, A. Ather, A. C. Pinto and M. A. M. Maciel, *Rev. Bras. Farmacogn.*, 2009, **19**, 7-13.
521. R. M. Silva, F. A. Oliveira, K. M. A. Cunha, J. L. Maia, M. A. M. Maciel, A. C. Pinto, N. R. F. Nascimento, F. A. Santos and V. S. N. Rao, *Vascular Pharmacology*, 2005, **43**, 11-18.
522. M. S. Hunter, D. G. Corley, C. P. Carron, E. Rowold, B. F. Kilpatrick and R. C. Durley, *J. Nat. Prod.*, 1997, **60**, 894-899.
523. L. M. B. Torres, M. T. Gamberini, N. F. Roque, M. T. Lima-Landman, C. Souccar and A. J. Lapa, *Phytochemistry*, 2000, **55**, 617-619.
524. K. V. Sashidhara, S. P. Singh, A. Srivastava, A. Puri, Y. S. Chhonker, R. S. Bhatta, P. Shah and M. I. Siddiqi, *Eur. J. Med. Chem.*, 2011, **46**, 5206-5211.
525. T. Kawasaki, T. Komori and S. Setoguchi, *Chem. Pharm. Bull.*, 1968, **16**, 2430-2435.
526. R. D. H. Murray, Z. D. Jorge, N. H. Khan, M. Shahjahan and M. Quaisuddin, *Phytochemistry*, 1984, **23**, 623-625.
527. M. Ma, Z. Jiang, J. Ruan, X. Tan, J. Liu, C. Wang, X. M. Zha and L. Zhang, *Exp. Toxicol. Pathol.*, 2012, **64**, 611-618.
528. J. Wang, Q. Liang, L. Ji, H. Liu, C. Wang and Z. Wang, *Hum. Exp. Toxicol.*, 2010, **30**, 1333-1341.
529. Y. Ma, C. Niu, J. Wang, L. Ji and Z. Wang, *Hum. Exp. Toxicol.*, 2014, **33**, 729-736.
530. L. Gori, P. Galluzzi, V. Mascherini, E. Gallo, F. Lapi, F. Menniti-Ippolito, R. Raschetti, A. Mugelli, A. Vannacci and F. Firenzuoli, *Basic Clin. Pharmacol. Toxicol.*, 2011, **109**, 521-526.

531. I. Starakis, D. Siagris, L. Leonidou, E. Mazokopakis, A. Tsamadas, and C. Karatza, *Eur. J. Gastroenterol. Hepatol.*, 2006, **18**, 681-6823.
532. S. Chitturi and G. C. Farrell, *J. Gastroenterol. Hepatol.*, 2008, **23**, 366-373.
533. V. Shriram, S. Jahagirdar, C. Latha, V. Kumar, V. Puranik, S. Rojatkar, P. K. Dhakephalkar and M. G. Shitole, *Int. J. Antimicrob. Agents*, 2008, **32**, 405-410.